In silico methods in prediction of drug metabolism, mass fragmentation, and chromatographic behavior : Application to toxicological drug screening by liquid chromatography/time-of-flight mass spectrometry by Tyrkkö, Elli
Hjelt Institute 
Department of Forensic Medicine 
University of Helsinki 
Finland
IN SILICO METHODS IN PREDICTION OF DRUG 
METABOLISM, MASS FRAGMENTATION, AND 
CHROMATOGRAPHIC BEHAVIOR 
APPLICATION TO TOXICOLOGICAL DRUG SCREENING BY LIQUID 
CHROMATOGRAPHY/TIME-OF-FLIGHT MASS SPECTROMETRY 
Elli Tyrkkö 
ACADEMIC DISSERTATION 
 
To be publicly discussed, with the permission of the Medical Faculty of  
the University of Helsinki, in the auditorium of Department of Forensic Medicine 
on April 25th 2014, at 12 noon. 
 
Helsinki 2014 
SUPERVISORS
Professor Ilkka Ojanperä
Hjelt Institute
Department of Forensic Medicine
University of Helsinki, Finland
Dr. Anna Pelander
Hjelt Institute
Department of Forensic Medicine
University of Helsinki, Finland
REVIEWERS
Docent Tuulia Hyötyläinen
VTT, Technical Research Centre of Finland
Helsinki, Finland
Docent Ari Tolonen
Admescope
Oulu, Finland
OPPONENT
Dr. Frank T. Peters
Forensic and Clinical Toxicology
Institute of Forensic Medicine
University of Jena, Germany
ISBN 978-952-10-9574-0 (paperback)
ISBN 978-952-10-9575-7 (PDF)
http://ethesis.helsinki.fi
Unigrafia
Helsinki 2014
Any fool can know.
The point is to understand.
Albert Einstein
CONTENTS
CONTENTS ............................................................................................................................4
ABBREVIATIONS ..................................................................................................................6
LIST OF ORIGINAL PUBLICATIONS ................................................................................. 7
ABSTRACT ............................................................................................................................ 8
1 INTRODUCTION ....................................................................................................... 10
2 REVIEW OF THE LITERATURE ............................................................................. 12
2.1 Drug metabolism .............................................................................................. 12
2.1.1 Conventional drug metabolism studies ....................................................... 12
2.1.2 Drug metabolism in silico............................................................................. 13
2.2 Software tools in compound identification .................................................... 16
2.2.1 Mass spectral data processing ...................................................................... 16
2.2.2 Liquid chromatographic retention prediction ............................................ 19
2.3 Accurate mass-based mass spectrometry ....................................................... 19
2.3.1 Accurate mass-based toxicological drug screening .................................... 21
2.3.2 Compound identification without primary reference standards .............. 22
3 AIMS OF THE STUDY .............................................................................................. 24
4 MATERIALS AND METHODS .................................................................................25
4.1 Materials ...........................................................................................................25
4.1.1 Chemicals and reagents ................................................................................25
4.1.2 Urine samples ................................................................................................25
4.2 Sample preparation ..........................................................................................25
4.2.1 Urine samples ................................................................................................25
4.2.2 In vitro incubations ......................................................................................25
4.3 Liquid chromatography/mass spectrometry ..................................................25
4.4 Software ........................................................................................................... 26
4.4.1 Data analysis................................................................................................. 26
4.4.2 Metabolism ................................................................................................... 26
4.4.3 Mass fragmentation ...................................................................................... 27
4.4.4 Chromatographic retention .......................................................................... 27
5 RESULTS AND DISCUSSION ................................................................................. 28
5.1 Metabolite prediction ...................................................................................... 28
5.1.1 Quetiapine metabolism................................................................................ 28
5.1.2 Designer drug metabolism .......................................................................... 29
5.2 Mass fragmentation in silico .......................................................................... 32
5.2.1 Differentiation of structural isomers .......................................................... 32
5.2.2 Metabolite structure identification ............................................................. 34
5.3 Liquid chromatographic retention prediction................................................35
5.4 Software tools applied to accurate mass data................................................ 36
5.5 Preliminary compound identification ............................................................. 37
6 GENERAL DISCUSSION .......................................................................................... 40
7 CONCLUSIONS ......................................................................................................... 46
ACKNOWLEDGEMENTS ...................................................................................................47
REFERENCES ..................................................................................................................... 49
6ABBREVIATIONS
2C-H 2,5-dimethoxyphenethylamine
2-DPMP 2-desoxypipradrol
3,4-DMMC 3,4-dimethylmethcathinone
bbCID broadband collision-induced dissociation
CNS central nervous system
CYP cytochrome P450
DMPEA 3,4-dimethoxyphenethylamine
EI electron impact
FWHM full width half maximum
FT-ICR/MS Fourier-transform ion-cyclotron resonance mass spectrometry
GC gas chromatography
HHMA 3,4-dihydroxymethamphetamine
HLM(s) human liver microsome(s)
HMA 4-hydroxy-3-methoxyamphetamine
HRMS high-resolution mass spectrometry
ISCID in-source collision-induced dissociation
LC liquid chromatography
M(1-12) metabolite (numbering 1-12)
[M+H]+ protonated molecule
mDa millidalton
MPA methiopropamine
MS mass spectrometry
MS/MS tandem mass spectrometry
m/z mass to charge ratio
NMR nuclear magnetic resonance
NPS(s) new psychoactive substance(s)
ppm parts per million
PRS(s) primary reference standard(s)
Į-PVP Į-pyrrolidinovalerophenone
Q quadrupole
QSAR quantitative structure-activity relationship
QSRR quantitative structure-retention relationship
QTOFMS quadrupole-time-of-flight mass spectrometry
QTP quetiapine
RP resolving power
RS resolution
tR retention time
TOFMS time-of-flight mass spectrometry
UHPLC ultra-high performance liquid chromatography
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8ABSTRACT
Analysis of drugs in forensic and clinical toxicology has conventionally relied on the use of
primary reference standards (PRSs). However, the availability of PRSs for novel
pharmaceuticals, new psychoactive substances (NPSs), and their metabolites is often limited.
Full metabolite data on new pharmaceutical drugs might be unpublished, and in the case of
emerging NPSs, the metabolism is often unknown. Knowledge of the metabolism of these
substances is important not only for toxicological risk assessment, but also in terms of analytical
method development and forensic or clinical interpretation. Mass spectrometry (MS) techniques
with accurate mass measurement capability allow determination of the compound’s elemental
composition, which facilitates structural elucidation. Computer systems, i.e. simulation in silico,
are available to speed up and assist with the interpretation of analytical data.
In the present thesis, current in silico systems were evaluated for their usefulness within
accurate mass-based toxicological drug screening. Different software tools were employed to
predict drug metabolism, mass fragmentation and chromatographic retention. The aim was to
produce supportive information for tentative compound identification without the necessity of
possessing PRSs.
Human phase I metabolism of the antipsychotic drug quetiapine (QTP) and four NPSs, 2-
desoxypipradrol (2-DPMP), 3,4-dimethylmethcathinone (3,4-DMMC), Į-pyrrolidino-
valerophenone (Į-PVP), and methiopropamine (MPA), was studied using the metabolism
prediction software Meteor (Lhasa Limited). Two software tools for in silico fragmentation -
ACD/MS Fragmenter (ACD/Labs) and SmartFormula3D (Bruker Daltonik) - were used for the
identification of compound-characteristic fragments in order to differentiate structural isomers
and aid in the structural elucidation of metabolites. The retention time prediction software
ACD/ChromGenius (ACD/Labs) was used to calculate chromatographic retention times for a
large set of compounds included in a target database for toxicological drug screening.
The in vivo metabolites of the compounds studied were identified in human urine samples.
The metabolism of the four NPSs was also studied using human liver microsomes (HLMs), in
order test the ability of the in vitro experiments to generate the main human urinary
metabolites. The metabolites predicted in silico were screened from the in vivo and in vitro
samples, and the results were compared with the published metabolic reactions of either the
compounds studied or their structural analogs.
Liquid chromatography coupled with time-of-flight MS (LC/TOFMS) or quadrupole-time-of-
flight MS (LC/QTOFMS) were the analytical methods employed in this thesis. Fragmentation of
the compounds was performed using either in-source collision-induced dissociation (ISCID) or
a data-dependent acquisition method. Identification of the compounds was accomplished from
full-scan MS data by accurate mass and isotopic pattern match comparison (SigmaFit), and
structural elucidation of the analytes was carried out by identifying the characteristic product
ion structures. In these experiments, high mass accuracy was obtained: the mean mass accuracy
and the mean isotopic pattern match value of the analyses were below 1 mDa and 30 mSigma,
respectively.
9Meteor software assigned most of the main human urinary phase I metabolites of QTP, 2-
DPMP, 3,4-DMMC, Į-PVP, and MPA. In silico metabolite prediction aided in the identification
of eleven previously unreported metabolites for the NPSs studied. The in vitro experiments
produced the majority of the most abundant NPS metabolites detected in vivo.
Fragment assignment by ACD/MS Fragmenter and SmartFormula3D assisted in the
differentiation of structural isomers and in elucidation of the metabolite structures. Together
with accurate mass data, these software tools greatly facilitated the determination of fragment
structure. In silico fragment prediction allowed the structural identification of drug metabolites
without PRSs. The retention time prediction software ACD/ChromGenius, although not
sufficiently accurate to be used in compound identification alone, was useful when calculating
the correct compound retention order and thus to support the differentiation of structural
isomers.
The software systems employed in this thesis were useful in analytical toxicology procedures,
especially when applied to accurate mass data. In silico metabolite prediction provided a rapid
technique for generating a list of possible metabolites which can readily be screened from
biological samples by their accurate masses to identify the true positive metabolites. In vitro
studies allow experimentation with biological material for metabolism studies of toxicologically
relevant substances when an authentic urine sample cannot be obtained. The fragment
prediction software facilitated the structural elucidation of unknown compounds without the
use of PRSs. The software also aided in the differentiation of structural isomers, which cannot
be accomplished by accurate molecular mass alone. Computer aided retention time calculation
can offer additional information to be used with accurate mass data and information from other
software systems. The in silico methodologies assist preliminary compound identification in
cases where no corresponding PRS is obtainable. The present thesis demonstrates an integrated
approach, in which the data generated in silico can be applied to toxicological LC/TOFMS drug
screening in support of compound identification from authentic urine samples.
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1 INTRODUCTION
Drug testing serves many authorities of modern society, including pharmaceutical, food, and
environment regulatory agencies, health care, and crime investigation. Forensic toxicology looks
for chemical proof for legal investigations mainly in the areas of post-mortem toxicology, driving
under the influence of alcohol or drugs, drug-facilitated or drug-related crime, and workplace
drug testing. Clinical toxicology focuses on the diagnosis and treatment of patients. Doping
control laboratories analyze prohibited substances in sports, which are listed by the World Anti-
Doping Agency. Laboratories performing drug testing employ similar analytical techniques and
methods. An increasingly common and important technique is liquid chromatography (LC)
combined with electrospray ionization mass spectrometry (MS) at atmospheric pressure [1].
LC/MS enables analysis of polar and non-volatile compounds over a wide range of molecular
sizes.
Established drugs of abuse such as amphetamine, cocaine and heroin have been joined on
the illicit drug market by new psychoactive substances (NPSs). Also known as designer drugs or
legal highs, NPSs are intended to mimic the effects of controlled drugs. The penalties from drugs
of abuse crimes are avoided by slightly modifying the chemical structure of these compounds, as
the new structure leaves them outside the regulations. The number of NPSs has increased
rapidly during the last few years: notifications on 237 compounds were made through the
European Union’s early-warning system between 2005 and 2012 [2,3]. This sets demands on
laboratories testing for these compounds, as they need to develop and maintain their analytical
methods to keep up with the growing variety of molecules.
The identification of drug compounds is traditionally based on comparison with reference
data, such as retention time (tR) and/or spectral data, obtained using primary reference
standards (PRSs). The availability of reference material for designer drugs, novel prescription
drugs and their metabolites is often limited, which hinders method development and
identification. Understanding the metabolism of new drug compounds is essential for
toxicological risk assessment as well as for analytical method development, as the detection of
metabolites together with the parent drug compound clearly improves the reliability of the
identification. Drug metabolism studies on NPSs in humans are not possible for obvious ethical
reasons. Computer software tools that can predict possible metabolic routes in silico based on
the molecular structure of a compound are widely used by the pharmaceutical industry in drug
development.
Hyphenated LC/MS techniques allow fast and sensitive generation of detailed and
information-rich analytical data on the compounds studied. These techniques can provide a
useful way of compensating for the difficulties related to the availability of PRSs. Accurate
molecular mass measurement of a substance allows the determination of its elemental
composition, which facilitates the structure identification. High-resolution MS (HRMS)
instruments with high resolving power improve separation of peaks with adjacent m/z values.
Further detailed structural information about the substances studied can be produced using
tandem mass spectrometry (MS/MS) to fragment the compound to its product ions. Advanced
computational methods are necessary for effective data processing. In silico tools  may help in
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predicting possible product ion structures or even in calculating the compound’s tR in the
chromatographic system used.
This thesis focuses on the employment of published software tools to predict drug
metabolism, mass fragmentation, and chromatographic behavior in silico in order to tentatively
identify compounds of toxicological interest without the immediate necessity of PRSs. The
results are evaluated in the context of toxicological urine drug screening based on accurate mass
measurement using LC/time-of-flight (TOF) MS techniques.
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2 REVIEW OF THE LITERATURE
2.1 Drug metabolism
Metabolism is the major elimination pathway of xenobiotics from the human body. Drug
metabolizing enzymes are present in all tissues, but mainly in the liver and intestine [4]. Drug
metabolizing reactions transform lipophilic compounds to more hydrophilic form and facilitate
their excretion from the body.  The reactions are divided into phase I and phase II reactions [5].
Phase I reactions (functionalization reactions), such as oxidation, hydrolysis and reduction,
produce or uncover a chemically reactive functional group. The most important enzymes
catalyzing phase I drug metabolism reactions are cytochrome P450 (CYP) enzymes [6]. In phase
II reactions (conjugative reactions) a highly polar endogenous compound, such as glucuronic
acid, is attached to the parent drug or to a metabolite from phase I reactions. Phase II reactions
usually result in inactive and excreted products.
Understanding drug metabolism is essential in drug discovery and development. Metabolic
reactions can potentially lead to drug-drug interactions [7] or to formation of pharmacologically
more active and toxic species [8]. Toxicity, which is often related to metabolism, is a significant
factor in the rejection of a lead molecule during drug development and the withdrawal of new
drugs [9,10]. Determination of a drug’s metabolic stability, as well as identification of its major
metabolites and their structural characterization, is central during the early discovery phase.
Elucidation of the main metabolism steps of drugs is also of great interest in forensic and
clinical toxicology [11,12]. Numerous NPSs emerge on the illicit drug market annually [2,3]. The
metabolites of these compounds may cause toxic effects, or they can have interactions with other
pharmaceutical substances. Information about the chemical structure of metabolites is also
crucial in the development of toxicological screening methodologies.
2.1.1 Conventional drug metabolism studies
Prior to the introduction of in vivo studies on animals and humans, the metabolic fate of drugs
was effectively studied using simple in vitro systems. The in vitro models  help to  identify  the
main metabolites and the primary enzymes involved in the metabolic reactions [13-15]. There
are several enzyme sources available for in vitro metabolism studies, including subcellular
fractions such as human liver microsomes (HLMs), cytosol, and S9 fraction; complementary
DNA-expressed recombinant isozymes; as well as hepatocytes and liver slices. HLMs afford the
most convenient way to study CYP metabolism [16,17]. In vitro studies employing HLMs or
complementary DNA-expressed CYP enzymes can predict clinical drug-drug interactions due to
inhibition or induction, as well as genetic polymorphism [14,15]. Whole cell systems, i.e.
hepatocytes and liver slices, give the most complete picture for hepatic metabolism, as they
comprise all the metabolizing enzymes and cofactors [18,19]. Thus, they offer a more reliable in
vivo/in vitro correlation than subcellular fractions. Although, the current in vitro models are
sophisticated and well established, they cannot replace the in vivo metabolism studies
completely [16,20]. After comprehensive metabolism studies in vitro, the pharmacokinetic
profile and toxicity of the drug are determined in suitable animal models (rodents and non-
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rodents) [14]. The metabolic profile of the drug is further recorded in vivo in clinical studies
[21].
Identification of all the possible metabolites is the initial step in metabolite profiling,
followed by structural characterization and quantitation [22,23]. The detection of metabolites is
often a challenging task, as they are present only at trace levels in complex biological matrixes.
Metabolism studies therefore require highly specific, sensitive and reliable analytical methods.
Several analytical techniques have been applied to studies on drugs and their metabolites,
among them gas chromatography (GC), LC, ultraviolet or fluorescence detection, and MS. A
commonly employed method is radioactive labeling (14C, 3H) of the parent drugs and detection
of the metabolites using radioactivity detection [24-26]. The method enables detection and
quantitation of the parent drug and metabolites without PRSs. However, due to the laborious
synthesis of the radiolabeled drugs and the high costs, this approach is mainly used in drug
development. Currently, the most popular and widely used technique in drug metabolite
identification and structure characterization is LC/MS, which offers excellent sensitivity,
specificity, and high sample throughput [22,27-33]. LC/MS also allows quantitative bioanalysis
of metabolites at low concentrations. Structural information on the metabolites can be obtained
using MS/MS techniques. MS techniques providing accurate mass measurement and high
resolving power (RP) enable effective characterization and structural elucidation of drug
metabolites in complex biological matrixes [31,33]. The use of ultra-high performance LC
(UHPLC) improves chromatographic resolution and decreases analysis time [34,35]. Nuclear
magnetic resonance (NMR) spectroscopy coupled with LC and MS (LC/NMR/MS) provides
reliable confirmation of metabolite structures [36,37].  However, NMR analysis requires a
relatively large amount of sample compared to LC/MS methods. The lack of sensitivity impairs
the applicability of NMR in structural characterization of minor metabolites.
Metabolism studies are mandatory for new drugs before their submission to drug regulatory
authorities with a view to approval. In contrast, NPSs are distributed on the black market
without pharmacology or safety testing. Hence, forensic and clinical toxicology authorities need
to examine the toxic effects and pharmacokinetics, including metabolism, of NPSs. In vitro
experiments [38] and in vivo animal models [11,12] are commonly used to study the metabolism
of these compounds. Different MS methodologies have served in metabolite identification and
characterization of NPSs. While NMR techniques are too expensive and complicated for
analytical toxicology practice, accurate mass and HRMS techniques provide valuable
information to aid in proposing structures for potential metabolites [31].
2.1.2 Drug metabolism in silico
Experimental drug metabolism studies are time-consuming and resource intensive. Computer
modeling systems for prediction of drug metabolism pathways in silico are therefore of
considerable interest. The in silico tools for drug metabolism prediction have advanced
considerably in the recent years [39]. Modern in silico approaches aim to identify the metabolic
liability in a molecule, predict the metabolites’ chemical structures, and explain the effects of
drugs on metabolizing enzymes, focusing on detection of potential inhibition and/or induction
[39]. In silico techniques that predict xenobiotic metabolism can be categorized into global
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(comprehensive) and local (specific) systems [20]. Table 1 lists some examples of currently
available in silico tools for predicting and studying drug metabolism.
Global methods, or so-called expert systems, aim to predict the sites and the products of
metabolism using known metabolic reactions [40,41]. Predictive expert systems identify
functional groups in a molecule liable towards metabolism, and involve them in a suitable
metabolic reaction from their knowledge-base. Examples of the expert systems META,
MetabolExpert and Meteor, and their main features are listed in Table 1.
Meteor and MetabolExpert have shown relatively high prediction sensitivity. In a diverse test
set of 22 compounds, Meteor predicted ~70% of the experimentally observed metabolites [42].
MetabolExpert showed similar accuracy (82%) in a study with 21 drug molecules [43]. The most
criticized feature of these expert systems is that they tend to overpredict; in other words they
form an enormously long list of possible metabolites [40,42,44]. Another drawback is that some
expert systems combine metabolic rules from different mammalian species, and the results may
not describe metabolism in the specific species studied [39]. Despite the rather low prediction
precision [42], these software tools can provide suggestions for unexpected metabolites [45].
Local methods examine particular enzymes or metabolic reactions, and they can be divided
into ligand-based and structure-based approaches [20,39,46]. In the ligand-based methods,
such as quantitative structure-activity relationships (QSAR) and pharmacophore modeling, the
focus is on the drug compound’s structure. They attempt to identify the sites of metabolism and
the structures of the metabolites. Ligand-based methods do not require prior knowledge about
the target protein structure. In QSAR analysis, the chemical structures of the compounds are
related to the molecular properties [47]. QSAR studies seek quantitative relationships between
the drug compound and its activity. Pharmacophore models provide indirect information about
the protein’s active site based on the structural and electronic properties of its substrates [48].
Pharmacophore models give an estimate of whether a query compound is a substrate of the
enzyme being studied.
Structure-based methods study the properties of the metabolizing enzyme, its interactions
with xenobiotics, and the reaction mechanism [46]. Structure-based drug metabolism
prediction requires experimentally determined three-dimensional structures of drug-
metabolizing enzymes and ligands. These in silico methods employ molecular and quantum
mechanics to predict drug metabolism and drug-drug interactions.
Compared with structure-based methods, the ligand-based methods provide less certain
estimate of the binding site of the metabolizing enzyme [39]. Structure-based methods suffer
from the difficulty of calculating the quantum mechanics variables of the ligand-enzyme
interaction [49]. Therefore, a combination of global and local approaches would be the most
promising system, and would provide a greater understanding of the metabolic transformations
[48]. Software systems that employ a combined approach are MetaSite [50,51], SMARTCyp
[52,53] and StarDrop [54], see Table 1. In a critical evaluation of Meteor, MetaSite and
StarDrop, the last two were found more precise in predicting the metabolites observed in vivo
than the expert system, as they did not suggest as many false negative metabolites [42]. Meteor
software, however, showed better prediction sensitivity in being able to assign most of the
metabolites detected in vivo. Nevertheless, despite advances in computational drug metabolism
prediction methods, it is unlikely that in silico tools will completely replace in vitro and in vivo
studies in the near future [39,46].
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Table 1 In silico tools for drug metabolism studies.
Comprehensive databases specializing in metabolism information are available. They can aid
in metabolite prediction of a novel molecule using knowledge of structurally similar compounds
in the database [66]. Accelrys Metabolite database [67] includes metabolic schemes from in vivo
and in vitro studies compiled from the literature. Software employing data from the Accelrys
Metabolite database are the Metabolite module of ADMET Predictor [61] and MetaPrint2D
[64,65] (Table 1). Other large metabolite databases are DrugBank [68], Human Metabolome
Database [69,70] and METLIN [71,72]. Metabolism databases have mostly been applied to
metabolomics [73-75] to cover the whole metabolic process, rather than to predict certain
metabolite structures.
Software packages from MS manufacturers such as MetaboLynx [76], MetWorks [77]
MetabolitePilot [78] and MetaboliteTools [79] are able to predict simple metabolic reactions
based on a selection of common biotransformations. They create a list of expected metabolites
to be screened from the analysis data. The role of these software packages lies mostly in
metabolite identification, which is discussed in Chapter 2.2.1.
Global Name Features Ref.
Expert
systems
META
Uses a selected dictionary to create metabolic paths for query
molecules.
[55,56]
MetabolExpert
Predicts likely metabolite structures. The knowledge base includes
metabolic pathways for humans, animals or plants.
[57,58]
Meteor
Metabolite predictions based on rules that account for physicochemical
and structural properties. Includes two algorithms for prediction
likelihood evaluation. It can be integrated with SMARTCyp, and it is
compatible with certain MS instruments.
[59,60]
Local Name Features Ref.
ADMET Predictor
Metabolite module
Calculates likelihood scores for metabolic oxidation reactions to take
place at specific atomic sites. Identifies substrates for nine CYP
isoforms.
[61]
MetaDrug
Combination of QSAR modeling and metabolic rules for metabolite
prediction. Estimates metabolite primarity.
[62,63]
MetaPrint2D and
MetaPrint2D-React
Predicts sites of metabolism, metabolic transformations and
metabolites using a data-mining approach. Assigns a confidence score
to the predictions.
[64,65]
MetaSite
Predicts CYP-mediated metabolic transformations, estimates the
primary site of metabolism, and provides the structure of the
metabolites.
[50,51]
SMARTCyp
Ligand structure-based method to predict site-specific metabolic
reactivity of five major CYP enzymes.
[52,53]
StarDrop
Predicts the relative proportion of metabolite formation at different
sites on a molecule. Employs quantum mechanical approach to identify
potential sites liable for CYP-mediated metabolism.
[54]
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In silico metabolism prediction systems have helped to identify the biotransformation
products of pharmaceuticals [42,80,81]. However, prior to the present thesis, drug metabolism
prediction using commercial or self-coded software has not been exploited for NPSs or other
toxicologically relevant compounds.
2.2 Software tools in compound identification
LC/MS is a standard technique for detecting and identifying small molecules in complicated
biological samples. Modern LC/MS instruments provide high-throughput and information-rich
MS spectra with high sensitivity. Structural elucidation of compounds requires sophisticated
software tools for MS data evaluation and interpretation [82-84]. In addition to MS data
managing systems, the prediction of the retention behavior of a compound plays a key role for
the systematic identification process [83].
2.2.1 Mass spectral data processing
Computational MS provides solutions for automated analysis of MS data [82]. There are
numerous tools for interpretation of MS data obtained by different instruments, and over a
range of molecular sizes. The most relevant in silico tools currently available for small molecule
HR and accurate mass spectral interpretation are discussed here and listed in Table 2. Their
applications for compound identification are further discussed in section 2.3.2. The
computational methods dealing with compound identification concentrate on molecular
formula assignment, in silico fragmentation, and mass spectral library searches.
The most basic but highly important step in identification of a compound is the
determination of its molecular formula, which serves as a basis of further structural elucidation.
To reduce the number of possible candidates, accurate mass measurement with adequate mass
resolution is required [85]. The simplest approaches compute the elemental composition using a
set of potential elements [86,87]. Combining experimental and theoretical isotopic pattern
comparison with determination of the elemental composition significantly cuts down the
number of possible combinations [88]. Algorithms that calculate theoretical isotopic
abundances have been applied to MS since its introduction [89]. There are several approaches
available, e.g. BRAIN [90], Emass [91] and IsoDalton [92], implementing different algorithms
in the isotopic pattern calculations. Seven Golden Rules is a set of heuristic rules, including the
Senior and Lewis rules, isotopic abundance matching filter, and element ratio rule, for elemental
composition calculations [93].
Software tools that simulate mass fragmentation can be classified either as rule-based or
combinatorial [82]. Rule-based systems include a knowledge base with fragmentation rules
extracted from the literature. ACD/MS Fragmenter [94] and MassFrontier [95] attempt to
predict possible fragments of a compound based on its molecular structure. The state-of-the-art
rule-based predictor MassFrontier evaluates the accuracy and probability of the proposed
fragments and assigns structures for the product ions detected in the MS/MS spectra. The
software is widely used in several fields of research, such as metabolomics [96,97] and
environmental analysis [98]. It has also served for structural elucidation of designer drug
metabolites [99] and for determination of fragmentation pathways of doping agents [100].
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Table 2 Computational tools for MS/MS mass spectral interpretation.
Molecular formula
assignment
Name Features Ref.
Isotopic pattern
match scoring
Seven Golden Rules
Set of heuristic rules for elemental composition
calculations.
[93]
In silico
fragmentation
Name Features Ref.
Rule based fragment
prediction
ACD/MS Fragmenter
Predicts product ions based on common MS
fragmentation rules from the literature.
[94]
MassFrontier
General reactions for fragment prediction.
>30,900 fragmentation schemes; >129,000
fragmentation reactions; >151,000 chemical
structures.
[95]
Combinatorial
fragmentation
Fragment iDentificator
(FiD)
Calculates optimal bond energies to predict the
most stable fragments. Scoring function to rank
competing fragmentation pathways.
[101]
MetFrag
Compares and scores in silico mass spectra
obtained using the bond disconnection approach
with experimental spectra.
[102]
SIRIUS2
Isotopic pattern analysis to determine the
molecular formula, and computed fragmentation
tree explaining the product ion peaks.
[103,104]
MS library search Name Features Ref.
MS/MS spectral
libraries
MassBank
Open access database with ~40,000 spectra
acquired on diverse types of MS instruments.
[105,106]
METLIN
Open access database with >57,000 MS/MS
spectra of >11,000 metabolites.
[71,72]
NIST/EPA/NIH MS/MS
Mass Spectral Library 2012
>9,900 ion trap spectra of >4,600 compounds;
>91,000 collision-cell spectra of >3,700
compounds; NIST MS Search algorithm.
[107]
Wiley Registry of Tandem
Mass Spectral Data,
MSforID
>12,000 spectra of >1,200 compounds, MSforID
search algorithm.
[108]
Software for spectral
library search
SmileMS
Universal spectral library search algorithm for
targeted and non-targeted screening.
[109]
Instead of general fragmentation rules, combinatorial fragmenters use molecular structures
and experimental MS/MS spectra to predict structure-characteristic fragmentation trees
[102,110-112]. The benefit of the fragment tree approach is that it can automatically identify
unknown compounds by comparing experimental MS/MS spectra with the fragment trees of
reference compounds. Fragmentation pattern similarities are strongly correlated with the
structural analogy of molecules. Combinatorial fragmentation systems such as MetFrag [102],
SIRIUS2 [103,104] and FiD [101] were developed by non-commercial authorities and are freely
available. The performances of MetFrag [102] and FiD [101] were also compared with
MassFrontier, and both combinatorial methods achieved more accurate results than the rule-
based system.
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Traditionally, spectral library search has been the primary approach for identification of
small molecules [82,83]. There are large spectral libraries available for GC/EI mass spectra
matching, e.g. Wiley Registry 10th Edition/NIST 2012 (>870,000 mass spectra) [113].  MS/MS
spectral libraries for internal laboratory use have been created [114,115]; however, the rather
poor reproducibility of electrospray ionization MS/MS spectra between different instruments
has hindered the development of comprehensive reference spectral libraries for LC/MS data
[116]. A platform-independent MS/MS spectral library with a peak-matching search algorithm
MSforID was introduced by Oberacher et al. [117,118]. The library was developed on a
quadrupole (Q) -TOFMS instrument using 10 different collision energies. The approach is today
part of the Wiley Registry of Tandem Mass Spectral Data, which includes over 12,000 accurate
mass MS/MS spectra [108]. The NIST LC/MS/MS 2012 [107] included in the Wiley/NIST 2012
library [113] covers small organic compounds and peptides, the spectra being acquired on
different types of mass spectrometers. MassBank [105,106] and METLIN [71,72] are public
spectral databases that allow web-based MS/MS spectra searches or comparisons. Despite the
effort put into universal MS/MS spectral libraries and their search algorithms, their reliability,
robustness, and transferability are still doubtful, especially for the identification of unknown
compounds [119].
SmileMS software allows targeted and non-targeted screening via a spectral library search
approach for LC/MS/MS data [109]. It is compatible with data acquired with most LC/MS/MS
instruments (unit resolution and HR), and both commercial and in-house spectral libraries can
be utilized. SmileMS can detect unknown compounds automatically with group-specific
structures stored in the fragment library [120,121].
Metabolites are commonly identified by comparing and contrasting the test sample with the
blank sample (negative control) [22]. However, finding traces of metabolites in complex
biological matrixes is often challenging, as the metabolite ions can be masked by background
noise or matrix components [29]. Methodologies for post-acquisition data mining of accurate
mass and HRMS data have been developed. Mass defect filtering removes biological background
ions whose m/z decimal  portion  is  dissimilar  (typically  ±50  mDa)  to  that  of  the  parent
compound being studied [122,123]. An accurate mass-based isotope pattern filtering algorithm
is applicable for matrix ion removal, and the method helps identification of metabolites with
stable-labeled isotopes, or compounds containing natural isotopes such as those of chlorine or
bromine [124]. The background subtraction approach removes interfering matrix ion signals
detected in the control samples within a specified time window and mass error tolerance from
the test samples [125-127]. This system does not require knowledge of the metabolite structures
or fragmentation pathways. Some of the above-mentioned data processing tools have been
integrated into sophisticated metabolite identification software from MS manufacturers,
examples being MetaboLynx [76], MetWorks [77] and MetabolitePilot [78].
In the present thesis, in silico fragment prediction was applied to structural characterization
of toxicologically relevant compounds and their metabolites. Fragment identification was used
to resolve a previously criticized limitation related to full-scan accurate mass measurement
techniques, namely differentiation between structural isomers.
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2.2.2 Liquid chromatographic retention prediction
Prediction of chromatographic separation using in silico tools has benefited analytical method
development, optimization and validation [128]. Commercial software tools that predict liquid
chromatographic retention parameters include DryLab [129] and ChromSwordAuto [130].
These tools base their calculations on experimental data, and have predicted tR for  a  small
number of compounds in rather simple isocratic or linear gradient systems [128,131]. Their
main purpose of use is thus in method development.
Quantitative structure-retention relationship (QSRR) models can give more comprehensive
information about retention phenomena [132-134]. QSRR models aim at finding the relation
between calculated molecular descriptors and retention. They seek to identify the most useful
structural descriptors of a compound, calculate the physicochemical properties of the analytes,
describe the molecular retention mechanism of a structure, and compare the separation
mechanism of different chromatography columns. QSRR systems can also estimate the
biological activity of drug candidates and other xenobiotics [135]. Drug compound tR prediction
in an LC system using QSRR models has been applied to retention behavior determination
[136,137]. In terms of compound identification, they have been applied to proteomics [138,139]
and metabolomics [140].
A critical phase in the QSRR analysis is the selection of the most representative molecular
descriptors from a large collection of possibilities [132]. The models also require careful
evaluation and validation with a large set of test compounds [134]. In addition, QSRR models
without a commercial or open software implementation are thought to be too complicated for
the majority of analysts [83].
The prediction and investigation of the retention behavior of a compound are key for
structural elucidation by MS coupled with chromatographic separation techniques [83]. The
calculated retention index or tR can be used as an orthogonal filter for determination of the
correct molecular formula and structure. GC retention index prediction was included in the
Seven Golden Rules approach [93] (see Chapter 2.2.1, and Table 2), which showed a substantial
reduction  in  possible  structures  (from  36,623  to  105).  Kern  et  al.  [98]  used  a  simple  LC tR
prediction as part of a pesticide transformation product screening, which reduced the number of
possible structures by 30%. No universal retention index database is available for LC systems,
and thus tR prediction is not as straightforward as for GC [83]. This thesis demonstrates an
original approach for identification of drug compounds included in a toxicology database using
tR prediction.
2.3 Accurate mass-based mass spectrometry
The principle of calculating the elemental composition of a molecule from the mass of an ion,
provided it is measured with sufficient accuracy, was introduced in the 1950s [141]. Mass
accuracy is the difference between the theoretical and measured mass of an ion, and high mass
accuracy refers to mass measurements below 5 ppm [142]. Resolution (RS) is the degree of
separation of two mass spectral peaks, and RP is the capacity of a mass spectrometer to
distinguish ions with close m/z values  [85].  RP is  dependent  on the m/z value and the charge
state of the ion measured, and for evaluation between different mass analyzers the m/z value of
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the reported RP should be specified. Two different definitions are used to describe RS and these
are explained in detail in Table 3. The 10% valley definition is used with magnetic sector
instruments, and the peak full width at half maximum (FWHM) definition is employed with
quadrupole, ion trap, TOF, and Fourier-transform ion-cyclotron resonance (FT-ICR) techniques
[143]. A high RP in MS is essential to separate adjacent mass peaks, which is often required in
the analysis of complex biological matrixes. Mass analyzers capable of a routine broadband RP
of  20,000 are  classified as  HRMS [142].  HRMS produces  narrower mass  peaks,  and reduces
the ambiguity related to the determination of elemental composition. Modern HRMS
instruments provide a mass accuracy of <5 ppm routinely, and even a mass accuracy of <1 ppm
has become common [85]. However, accurate mass measurement is attainable without high RP
[144], and accurate mass measurement techniques and HRMS are presented here in parallel.
Table 3 lists the key terms related to these methodologies.
Table 3 Terms related to HR and accurate mass MS [145].
Term Definition
Accurate mass The experimentally determined mass of an ion.
Exact mass Summation of the masses of the most abundant isotope of each element (monoisotopic mass).
Mass accuracy The difference between the measured and theoretical value of the mass of an ion.
Resolution (RS)
Measure of separation between two mass spectral peaks, expressed as (m/z)/Ʃ(m/z), where the
observed (m/z) value is divided by the smallest difference Ʃ(m/z) for two ions that can be
separated.
? 10% valley A value for two peaks of equal height in a mass spectrum that are separated by a valley of nomore than 10% of the peak height.
? FWHM A value for a single peak, Ʃm/z is the peak full width at half maximum.
Resolving power
(RP)
The ability of a mass spectrometer to provide a certain value of mass resolution.
HRMS is an increasingly popular analytical technique in studies of small molecules in
biological samples [31,146-149] and in the environmental sciences [150,151]. It is a central
technique in pharmaceutical drug development [33,152] and metabolism studies [29-31,33], and
has been applied in clinical and forensic toxicology [146,148] and doping control [153].
Combined with LC, HRMS instruments provide fast and sensitive detection of compounds with
a large diversity in molecular size [85]. HRMS instruments are commonly coupled with a Q or
ion trap [154-157] to perform MS/MS analysis and attain detailed structural information. The
key factors in achieving good mass accuracy are ion abundance, peak shape, RP, and mass scale
calibration [158,159]. Accurate mass measurement, high RP and the isotopic pattern fit of an ion
increase certainty when calculating a compound’s elemental composition [88,93,160,161].
HRMS and accurate mass instruments that are compatible with LC and used for biochemical
analyses are TOFMS, orbital trapping instruments (orbitrap), and FT-ICR/MS [85].
In a TOF mass analysis, the ions are accelerated with an electrostatic field and follow a given
flight path to the detector [162]. The mass of the ion is determined by the flight time, the length
of the flight path and its kinetic energy. TOF instruments are capable of fast and sensitive full-
scan data acquisition, and the RP has been shown to be independent of the acquisition rate
[163]. Standard TOF instruments with an orthogonal ion accelerator have a high RP (~20,000
at m/z ~900  for  TOFMS,  and  ~40,000  at m/z ~900 for QTOFMS instruments) and mass
accuracy (<5 ppm for TOFMS, and <2 ppm for QTOFMS) [164]. Co-eluting isobaric compounds
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with a mass difference below the instrument’s RP will therefore form a sum peak, which leads to
large mass errors and false molecular formula assignment [161]. This increases the risk of false
negative results when complex biological matrixes are analyzed [163]. Modern TOFMS
instruments provide an even higher RP of >40,000 and a mass accuracy below 1 ppm [35,164].
Orbitraps operate on the basis of harmonic ion oscillations in an electrostatic field with a
frequency characteristic of their m/z values [165]. Orbitraps can operate with an RP up to
240,000 (m/z 400)  and  <1  ppm  mass  accuracy  [164].  However,  the  RP  of  orbitraps  depends
crucially on the acquisition rate, and 1 Hz data collection time is needed for maximum RP
[35,161]. This is too slow for modern UHPLC instruments with a column particle size of <2 μm
which are capable of producing narrow (2-4 s) chromatographic peaks [35].
In FT-ICR/MS the charged ions in a magnetic field move in a circular oscillation at an m/z-
specific cyclotron frequency, and this signal can be converted to a mass spectrum [166]. In terms
of RP and mass accuracy, FT-ICR/MS instruments are the most powerful available. An FT-
ICR/MS instrument can operate at an RP of 2,500,000 (m/z 400) and a mass accuracy <1 ppm
[164]; however, when coupled with LC an RP of 50,000-100,000 is achieved [167]. In terms of
routine analytical toxicology practice, FT-ICR/MS instruments are very expensive and
complicated [146], although they are widely used in metabolomics [167] and proteomics [168].
2.3.1 Accurate mass-based toxicological drug screening
In analytical toxicology, numerous toxicologically significant compounds need to be detected
and identified routinely within a limited turnaround time and with high reliability.
Traditionally, systematic toxicological screening analyses are based on GC/MS, with compound
identification relying on a comparison with reference data [146,149,153,169,170]. Since the
introduction of accurate mass-based drug screening by LC/TOFMS in toxicology [144,171-173]
more than a decade ago, the technique has successfully been adopted by laboratories in the
fields of clinical and forensic toxicology, as well as doping control [146,149,153,169,170]. The
technique is suitable for a broad variety of specimens, including urine [144], blood [174] and
vitreous humor [175]. In toxicological drug screening, the methods exploiting HRMS and
accurate mass measurement techniques are based on TOFMS and orbitrap instruments. The
TOFMS databases cover several hundreds or even thousands of drug compounds and their
metabolites [114,176,177], while databases for orbitraps include a maximum of 320 compounds
[178].
Target screening methods for qualitative analysis by accurate mass and HRMS most
commonly rely on full-scan data acquisition followed by a search through an in-house database
of exact monoisotopic masses and tR [144,172-174,179-181]. Comparison of theoretical and
measured isotopic patterns provides additional information. To support compound
identification, the respective formulae of known metabolites are included in the database
[144,173]. Collision-induced dissociation (CID), either in the ion source (in-source collision-
induced  dissociation,  ISCID)  [176],  or  in  the  collision  cell  (broadband,  bbCID)  [182],  can  be
used to generate structural information on the target compounds. In data-independent
acquisition mode all ions are fragmented in every second scan with the same collision energy.
Diagnostic product ion data can be added to the database to support parent compound
identification [100,176,182-184].
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Another compound detection and identification approach for toxicological drug screening by
accurate mass and HRMS is spectral library search [114,185,186]. MS/MS spectra are produced
using data-dependent acquisition, where fragmentation is performed for targeted compounds or
for ions exceeding an abundance threshold. Broecker et al. [114] introduced a library search
method including CID mass spectra of >2,500 toxicological compounds and metabolites,
measured with an LC/QTOFMS instrument. An advanced search algorithm included in the
Wiley Registry of Tandem Mass Spectral Data, MSforID [108] strives for platform independence
and instrument universality [185-187]. The library includes about 10,000 spectra for 1,200
substances, and has been found to be both robust and sensitive in identification of
toxicologically relevant compounds in human body fluids [186]. Nevertheless, identification of
compounds not included in the library is not possible. However, despite promising
developments in sophisticated search algorithms, LC/MS spectral libraries cannot perform with
the same universality and robustness as those of GC/MS [188].
Polettini et al.  [177] introduced a method for toxicological drug screening by LC/TOFMS in
which the reference database of approximately 50,500 toxicologically relevant substances was a
subset derived from the PubChem Compound Database. The latter database includes
pharmaceutical and illicit drugs, as well as other poisons, and contains around 6,000 phase I
metabolites. Due to the size of the database, the number of possible candidates with identical
molecular formulae ranged from 1 to 39, precluding explicit compound identification. The
number of hits was reduced by half using the “metabolomics” approach, in which the isomers
were differentiated by identifying their metabolites [189]. This approach presumably works well
for unusual toxicological cases, where the answer needs to be sought outside the repertoire of
conventional drug screening methods [146]. The use of very large databases in daily analytical
toxicology may be impractical because of the excessive number of false-positive findings.
2.3.2 Compound identification without primary reference standards
The poor availability of PRSs delays the analysis of drugs, for which identification is
traditionally based on comparison of chromatographic retention and spectra between the
analyte and the standard [190]. This problem especially relates to rare and new drug substances
and to drug metabolites [191].
NPSs, or so-called designer drugs, comprise a variety of compounds that are intended to
mimic the effects of existing controlled drugs [2,192]. These substances are of special interest
among drug users, as they are not controlled under international drug laws. The main groups of
NPSs that are followed by the EU early-warning system are phenethylamines, cathinones,
piperazines, tryptamines, synthetic cannabinoids, as well as a large group of plant-derived and
synthetic compounds outside the above-mentioned categories [2]. The pharmacological and
toxic effects and pharmacokinetics, including metabolism, of NPSs in humans is often
incomplete or even unknown [11]. Data on the metabolism of designer drugs is required, as it is
a prerequisite for development of toxicological urine drug screening procedures, as well as for
toxicological risk assessment [191,193]. The lack of PRSs hinders not only the detection of NPSs,
but also the identification of metabolites of pharmaceuticals, as detailed information about the
human urinary metabolites is not always available [194]. Knowledge of the biotransformation
products of toxicologically relevant compounds is essential, as the detection of the metabolites
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in conjunction with the parent drug confirms the identification [120,144]. Numerous drugs are
excreted mainly as their metabolites [195], and for some drugs detection of the metabolites
proves illicit drug use [196].
One of the major advantages of accurate mass and HRMS-based screening is the complete
collection of full-scan data, which allows retrospective data-mining of formerly unknown
compounds [146,153,169,170,184]. Accurate mass MS is a powerful tool for elucidating the
structure of small molecules (<2,000 Da) [83]. However, even a very high mass accuracy (<1
ppm) alone is not enough to restrict the molecular formulae to a single possibility, when the size
and complexity of the molecule increase [88]. Large public web-based compound databases, for
example PubChem and ChemSpider, or the specific drug and metabolism databases HMDB and
DrugBank, make it possible to search for exact masses or molecular formulae. Even so, the
database search is likely to result in several structural isomers for a molecular formula [84].
Orthogonal filters, such as isotopic pattern filter [88], heuristic rules for elemental composition
calculation [93] and tR and mass fragmentation prediction [84], are applied to narrow down the
number of compound candidates. Nevertheless, the assignment of the most likely structure to a
molecular formula is the most challenging phase in the identification procedure [84].
The compound database and MS/MS spectra database search approaches allow the
identification of the compounds included in the datasets; however, this limits the detection of
unknown compounds and metabolites. This restriction can be overcome using fragmentation
trees and automated fragmentation pattern similarity comparison [102,110-112]. This method
enables deduction of the compound class of an unknown, and identification of substances not
included in any databases. Thus, fragmentation tree systems are of special interest within
metabolomics. Wolf et al. [102] exported fragment tree data for reference compounds from large
public databases. However, unambiguous compound identification could not be achieved,
because with a large dataset the result list contains many structurally similar compounds.
Rasche et al. [110] used a fragment tree system with a relatively small database, and reliably
identified the molecular formulae of 35% of the unknown metabolites. The system was less
successful for compounds lacking similar molecules in the database and substances with poor
MS/MS spectral data.
In forensic and clinical toxicology practice the focus is on a limited number of relevant
compounds. The large database search approaches are rarely used in this context, as the number
of false-positive findings increases with the size of the target database [146]. Wissenbach et al.
[120] successfully used the SmileMS software for non-targeted screening of drugs-of-abuse
metabolites. The identification of unknown compounds was based on detection of group-specific
structures from unit resolution multiple stage MS2 and  MS3 data. Accurate mass MS/MS
analysis enables determination of the product ion’s elemental composition. In silico fragment
prediction to assign product ion structures facilitates the structural elucidation of the parent
compound. Fragment structure prediction combined with accurate mass data has helped in
metabolite structure characterization [28,197,198]. The employment of in silico tools with
accurate mass and moderate RP TOFMS data for compound identification and structural
characterization in a forensic toxicology context has been studied and is further discussed in this
thesis.
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3 AIMS OF THE STUDY
The aims of the study were:
? To evaluate the ability of metabolite prediction software to predict the human phase I
metabolism of toxicologically relevant compounds (I, IV).
? To employ two software tools for mass fragmentation in silico in order to identify
characteristic fragments of compounds for structural determination of drug metabolites
and differentiation of structural isomers (I, II, IV).
? To assess the capacity of liquid chromatography retention time prediction software to
calculate retention times for compounds included in a large target database for
toxicological drug screening (III).
? To obtain additional information by in silico predictions for tentative compound
identification without primary reference standards (I-IV).
? To demonstrate the benefits of different in silico methods when applied to toxicological
drug screening by liquid chromatography/time-of-flight mass spectrometry (I-IV).
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4 MATERIALS AND METHODS
4.1 Materials
4.1.1 Chemicals and reagents
All solvents and reagents were of analytical, LC or LC/MS grade. Pharmaceutical purity
standards were obtained from several different suppliers. 2-Desoxypipradrol (2-DPMP), 3,4-
dimethylmethcathinone (3,4-DMMC), and methiopropamine (MPA) were seized material
obtained from the Finnish National Bureau of Investigation or from the Finnish Customs (IV).
HLMs and NADPH regenerating systems A and B were provided by BD Biosciences (Woburn,
MA, USA) (IV).
4.1.2 Urine samples
Urine samples were either collected at autopsies (I, IV) or they were clinical toxicology cases
investigated at our laboratory (IV). The urine samples examined were tested positive for the
compounds studied in our routine drug screening by LC/TOFMS [144,176]. Drug-free urine was
used in metabolism studies (I) as a pseudo-reference sample.
4.2 Sample preparation
4.2.1 Urine samples
Urine samples (1 mL) were hydrolyzed with ǃ-glucuronidase, and mixed-mode solid phase
extraction was used for sample preparation (I, IV).
4.2.2 In vitro incubations
Phase I metabolism in vitro of 2-DPMP, 3,4-DMMC, Į-PVP, and MPA was studied using HLMs
(IV). The reaction mixture consisted of NADPH regenerating systems A and B in 100 mM
phosphate  buffer  at  pH  7.4  as  described  in  the  general  assay  of  BD  Biosciences.  The  drug
concentration was 100 μM, and the protein concentration was 2.0 mg/mL. The incubation time
was 4 hours at 37°C. A blank sample without the drug, a biological control sample without either
HLMs or coenzymes, and a chemical control sample without HLMs and coenzymes were
prepared in addition to the test samples.
4.3 Liquid chromatography/mass spectrometry
The LC/MS instrumentations, including the columns and mobile phase components used in the
study are listed in Table 4. The LC instruments included a vacuum degasser, a binary pump, an
autosampler and a column oven. LC separations were performed in stepwise gradient mode at
40°C.
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Table 4 LC/MS instrumentation used in studies I-IV.
aAgilent Technologies (Santa Clara, CA, USA), bBruker Daltonik (Bremen, Germany), cWaters (Milford,
MA, USA), dPhenomenex (Torrance, CA, USA)
ACN acetonitrile, FA formic acid, MeOH methanol, NH4OAc ammonium acetate
The TOF instruments were coupled with an orthogonal electrospray ionization source. The
nominal resolution of the instruments was 10,000 FWHM (at m/z 922). The instruments were
operated in positive ion mode with an m/z range of 50-800. External instrument calibration was
performed with sodium formate solution using ten cluster ions (Na(NaCOOH)1-10) with exact
masses between 90.9766 and 702.8635, and the same ions were used for post-run internal mass
calibration for each sample. Mass fragmentation was carried out using ISCID (I), or either an
unselective (II) or a selected precursor (IV) AutoMS(n) method.
4.4 Software
4.4.1 Data analysis
DataAnalysis software (Bruker Daltonik, Bremen, Germany) was used for processing of the
sample analysis data (I-III:  version  4.0; IV: version 4.1). MetaboliteDetect 2.0 (Bruker
Daltonik, Bremen, Germany) was employed in finding quetiapine (QTP) metabolites in human
urine (I) with a relative intensity threshold of 30%. The software subtracts the blank sample
data from the test sample data, and then lists the molecular formulae calculated for all peaks
detected. Thus, information on both predicted and unexpected metabolites is obtained. An
automatic reverse database search [173] for assigning designer drug metabolites in human urine
and HLM incubation samples was carried out with TargetAnalysis 1.2 (Bruker Daltonik,
Bremen, Germany) (IV). The selected metabolite identification criteria were: peak area counts
of  2,000,  mass  tolerance  of  ±3  mDa,  and  isotopic  pattern  match  value,  mSigma  threshold  of
200. The SigmaFit (Bruker Daltonik, Bremen, Germany) algorithm compares the theoretical
[199] and measured isotopic patterns, and calculates a match factor based on the deviations of
the signal intensities [200]. The better the isotopic match, the lower the SigmaFit value.
4.4.2 Metabolism
The  metabolism  of  QTP  (I)  and  the  NPSs,  2-DPMP,  3,4-DMMC,  Į-PVP  and  MPA  (IV), was
predicted using Meteor software (versions 10.0.2 (I)  and  14.0.0  (IV), Lhasa Limited, Leeds,
UK). Meteor is a rule-based expert system which predicts the metabolism of a compound by
comparing the substructures to structure-metabolism rules included in its knowledge base. The
Paper LC MS Column Mobile phase MS/MS
I 1100a micrOTOFb
Luna C18d
100×2 mm (3 μm)
5 mM NH4OAc, 0.1% FA +
ACN (1)
ISCID
II 1200a micrOTOF-Qb
Luna PFPd
100×2 mm (3 μm)
2 mM NH4OAc, 0.1% FA +
MeOH (2)
AutoMS(n),
unselective
III 1200a micrOTOF-Qb C18 and PFP (1) and (2) none
IV UPLCc micrOTOF-Qb PFP (2)
AutoMS(n),
precursor
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possibility of the metabolic reactions is evaluated, and more improbable metabolites are
rejected. The prediction parameters used for Meteor in this study (I, IV) included phase I
reactions in mammals, while the maximum number of metabolic steps was set at four, and the
reaction likelihood level was either plausible or equivocal. The predicted metabolic reactions
were compared with the published reactions of the drugs (I, IV) or their structural analogs (IV).
4.4.3 Mass fragmentation
ACD/MS Fragmenter software (Advanced Chemistry Development, Toronto, Canada) was
employed to predict mass fragmentation (I, II: version 11.01; IV: 12.01). This software
generates fragments for a molecule using fragmentation rules known in the literature. ACD/MS
Fragmenter provides possible fragment structures with calculated exact masses and detailed
fragmentation routes. Positive mode atmospheric pressure ionization, as well as fragment
reactions including heterolytic and homolytic cleavages, neutral losses, and hydrogen
rearrangements, were the fragmentation parameters selected in this study. Experimental
spectra of the compounds studied were compared with the predicted fragments to identify the
characteristic fragment structures.
SmartFormula3D is a mass spectra interpretation tool included in DataAnalysis (Bruker
Daltonik, Bremen, Germany). The software was used to differentiate structural isomers (II), and
to obtain additional structural information on designer drug metabolites (IV). SmartFormula3D
calculates molecular formulae for possible fragments and precursor ions from experimental
accurate mass and isotopic pattern match results. It includes an algorithm that calculates
whether or not a product ion formula is a subset of the precursor ion. Product ions that cannot
be fragmented from the precursor ion, and precursor ions that cannot be comprised of the
product ions observed, are excluded.
4.4.4 Chromatographic retention
ACD/ChromGenius 12.00 software (Advanced Chemistry Development, Toronto, Canada) was
used to calculate tR for compounds included in a database for toxicological urine drug screening
(III). Two tR knowledge bases, PFP and C-18, were created from the LC/QTOFMS in-house
toxicology databases of approximately 500 compounds. ACD/ChromGenius software used
chemical structures and calculated physicochemical properties to predict tR for compounds.
Each compound is compared to the 30 most similar structures in the knowledge base to search
for the physical properties that correlate with tR. The predicted tR of the compounds in the PFP
and C18 knowledge bases, as well as the calculated retention order of the 118 structural isomers
in the PFP knowledge base, were compared with the experimental values.
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5 RESULTS AND DISCUSSION
5.1 Metabolite prediction
Table 5 presents the generalized phase I metabolic reactions employed by the Meteor software
for metabolite prediction of QTP (I)  and the four  NPSs studied:  2-DPMP, 3,4-DMMC, Į-PVP,
and MPA (IV). The total number of metabolites generated in silico and the prediction likelihood
levels of Meteor for each reaction are also presented. The metabolism of 2-DPMP, 3,4-DMMC,
Į-PVP, and MPA was also predicted from the published reactions of their structural analogs.
Studies of the metabolism of 2-DPMP had not previously been reported. Its metabolites were
concluded from the metabolism of phencyclidine-structured designer drugs [12]. 3,4-DMMC
metabolites [201] were completed by comparison with the metabolism of ǃ-keto-structured
cathinones [12,202]. Į-PVP metabolites identified in rats [203] were supplemented with
metabolic information on other pyrrolidinophenone-derived drugs [11,12]. In addition to the
normetabolite of MPA [204], its metabolism was predicted by using methamphetamine [205]
and thiophene-structured compounds [206] as model compounds. The main metabolic
pathways of QTP are sulfoxidation, hydroxylation, oxidation to the corresponding carboxylic
acid, N-dealkylation, and O-dealkylation [207]. Meteor software did not predict hydroxy
metabolites, which were therefore added manually to the list of metabolites and applied to the
MetaboliteDetect software.
Table 5 Metabolic reactions employed in metabolite prediction by Meteor software and based on the
analogous reactions found in the literature (*) (I, IV).
*Published analogous reactions, **Not predicted by Meteor
aProbable likelihood level, bPlausible likelihood level, cEquivocal likelihood level
Total number of predicted metabolites are in brackets. Identified metabolic reactions are in italics.
5.1.1 Quetiapine metabolism
Twelve phase I metabolites were detected and identified for QTP in ten autopsy urine samples
by LC/TOFMS using MetaboliteDetect software and manual inspection (I). The metabolites
identified were N-desalkyl-QTP (M1), O-desalkyl-QTP (M2), QTP-sulfoxide (M3), OH-QTP
(M4), QTP-acid (M5), N-desalkyl-OH-QTP (M6), O-desalkyl-OH-QTP (M7), O-desalkyl-QTP-
QTP
(n=14 / *11)
2-DPMP
(n=42 / *14)
3,4-DMMC
(n=69 / *11)
?-PVP
(n=15 / *23)
MPA
(n=21 / *13)
*Dealkylationa *Dealkylationb *Dealkylationa *Dealkylationa *Dealkylationb
*Oxidationa Deaminationc *Hydroxylationa,b *Dehydrogenationb Deaminationb
Sulfonationa Decarboxylationc *Oxidationb *Hydroxylationb Decarboxylationc
*Sulfoxidationa *Dehydrogenationb *Reductiona *Oxidationb *Hydroxylationb,c
Hydrolysisc Reductionb Oxidationb
*Hydroxylationb,c Reductionb
*Oxidationa,b
*Hydroxylation** Reductionb *Sulfoxidation**
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sulfoxide (M8), O-desalkyl-QTP-acid (M9), QTP-sulfoxide acid (M10), OH-QTP-sulfoxide (M11)
and N-desalkyl-OH-QTP-sulfoxide (M12). Contrary to what was reported in the original
publication I, QTP did not metabolize by N-dealkylation and sulfoxidation. This structure was
later  found  to  be  an  ISCID  fragment  of  the O-dealkyl-sulfoxy metabolite (M8). Eleven
metabolites for QTP have been described in the literature [207-210]. However, no detailed
structural information about QTP metabolites is available. The metabolic reactions participating
in formation of metabolites the M1-M12 are listed in Table 6. The metabolites identified here
were formed via the known metabolic reactions [207]. Figure 1 shows the positions at which the
metabolic reactions took place in the QTP molecule.
Figure 1 Main metabolic steps for QTP in human (I)
Meteor predicted 14 metabolites for QTP, and seven were detected in the urine samples. The
five metabolites identified, but not predicted by Meteor under the chosen reasoning constraints,
were hydroxylated species. Aromatic hydroxylation is one of the main metabolic routes of QTP,
and the OH- and N-desalkyl-OH- metabolites are pharmacologically active [207]. Therefore,
missing an important metabolic route was considered a significant drawback in the performance
of the Meteor software.
5.1.2 Designer drug metabolism
The human urinary phase I metabolic reactions identified for 2-DPMP, 3,4-DMMC, Į-PVP, and
MPA are listed in Table 6 (IV). The metabolic reactions that took place in the in vitro
experiments by HLMs are also presented.
2-DPMP was metabolized extensively by oxidative metabolic reactions. From the ten 2-
DPMP urine samples studied, six phase I metabolites were identified: OH-DPMP (M1 and M2),
oxo-DPMP (M3), OH-oxo-DPMP (M4), di-OH-oxo-DPMP (M5) and di-OH-carboxy-DPMP
(M6). These were formed via aromatic and aliphatic hydroxylation and dehydrogenation
reactions, as well as oxidation after opening of the piperidine ring structure. The proposed in
vivo human phase I metabolism of 2-DPMP is presented in Figure 2. The aromatic and aliphatic
hydroxy metabolites (M1 and M2) were present in relatively high abundance in the urine
samples studied, indicating that hydroxylation is the main phase I metabolic route for 2-DPMP.
N
N
S
N
O
OH
Quetiapine
N-dealkylation
O-dealkylation
Sulfoxidation
Hydroxylation
Oxidation
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The in vitro experiments produced aliphatic OH-DPMP (M2) and oxo-DPMP (M3), and the
aromatic OH-DPMP (M1) was detected at trace levels.
Table 6 Phase I metabolic reactions of QTP, 2-DPMP, 3,4-DMMC, Į-PVP and MPA identified in vivo in
human urine (I, IV).
Metabolites predicted by Meteor are presented in bold
*Metabolites found in vitro
arom. aromatic, ali. aliphatic, dealkyl. dealkylation, demethyl. demethylation, dehydrogen.
dehydrogenation, hydrox. hydroxylation
Meteor software predicted two of the six metabolites identified (Table 6). The reason for this
relatively poor prediction accuracy was that Meteor did not suggest an aliphatic hydroxylation
reaction, which was involved in the formation of OH-DPMP (M2), OH-oxo-DPMP (M4), and di-
OH-oxo-DPMP (M5). Meteor predictions at equivocal likelihood level proposed hydroxylation at
carbon atoms in the piperidine ring only as a reaction intermediate in the lactam structure (oxo-
2-DPMP; M3) formation. The software predicted correctly the oxidative N-dealkylation,
resulting in piperidine ring opening, and the subsequent oxidation of the primary alcohol to the
corresponding carboxylic acid. However, it failed to predict the final structure of the aromatic
di-OH-carboxy-DPMP (M6), as sequential hydroxylation reactions in the aromatic rings were
not predicted at equivocal likelihood level.
QTP 2-DPMP 3,4-DMMC ?-PVP MPA
M1 N-dealkylat. Hydrox. (arom.) *N-demethyl. *Reduction *N-demethyl.
M2 O-dealkylat. *Hydrox. (ali.) *Reduction *Hydrox.
M3 Sulfoxidation
*Hydrox. (ali.)
Dehydrogen.
N-demethyl.
Reduction
*Hydrox.
Dehydrogen.
M4 Hydrox.
2 × Hydrox. (ali.)
1 × Dehydrogen.
*Hydrox.
*Reduction
Hydrox.
Dehydrogen.
M5 Oxidation
3 × Hydrox. (ali. & arom.)
1 × Dehydrogen.
N-demethyl.
Hydrox.
*Degradation of
pyrrolidine ring
M6
N-dealkylat.
Hydrox.
2 × Hydrox. (arom.)
Ring opening
Oxidation
*Reduction
Hydrox.
Oxidation
*Hydrox.
Dehydrogen.
Ring opening
Oxidation
M7
O-dealkylat.
Hydrox.
Hydrox.
Oxidation
M8
O-dealkylat.
Sulfoxidation
M9
O-dealkylat.
Oxidation
M10
Sulfoxidation
Oxidation
M11
Hydrox.
Sulfoxidation
M12
N-dealkylat.
Hydrox.
Sulfoxidation
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Three 3,4-DMMC-positive autopsy urine cases were studied, and six phase I metabolites
(Table 6) were identified: dimethylcathinone (DMC; M1), ǃ-OH-DMMC (M2), ǃ-OH-DMC (M3),
OH-methyl-DMMC (M4), OH-methyl-DMC (M5) and ǃ-OH-carboxy-DMMC (M6). Meteor
software predicted all the identified metabolites, and the main in vivo metabolic events were
detected in vitro as well. Figure 2 shows the suggested main metabolic routes for 3,4-DMMC.
DMC (M1), ǃ-OH-DMMC (M2), and ǃ-OH-DMC (M3), which were formed via N-demethylation
and reduction, and their combination, were consistent with the metabolites reported for 3,4-
DMMC [201]. Here, OH-methyl-DMMC (M4) and ǃ-OH-carboxy-DMMC (M6) were identified,
metabolites that had previously been published as putative [201]. N-demethylation and
hydroxylation produced the novel metabolite OH-methyl-DMC (M5). An MS/MS spectrum of
M5 could not be generated, and an accurate mass and isotopic pattern match solely determined
identification of this compound.
Figure 2 Main metabolic steps for 2-DPMP, 3,4-DMMC, Į-PVP, and MPA in human (IV)
Į-PVP was extensively metabolized in man, and seven phase I metabolites:  ǃ-OH-Į-PVP
(M1), OH-propyl-Į-PVP (M2), oxo-Į-PVP (M3), ǃ-OH-oxo-Į-PVP (M4), N,N-bisdealkyl-Į-PVP
(M5), Į-PVP-N-butylic acid (M6), and Į-PVP-propanoic acid (M7), were identified in the eight
urine samples studied. Figure 2 and Table 6 show the metabolic reactions involved in the
metabolism of Į-PVP. Reduction of the ǃ-ketone to the corresponding alcohol formed ǃ-OH-Į-
PVP (M1), which was the most abundant metabolite of Į-PVP both in vivo and in vitro. OH-
O
NH
3,4-DMMC
N-demethylation
Reduction
Hydroxylation
+ oxidation
Hydroxylation
NH
2-DPMP
Hydroxylation
Dehydrogenation
Ring opening +
oxidation
Hydroxylation
O
N
??-PVP
Reduction
Hydroxylation
Dehydrogenation
Ring opening +
oxidation
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pyrrolidine ring
Hydroxylation
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NHS N-demethylation
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propyl-Į-PVP (M2), oxo-Į-PVP (M3), and N,N-bisdealkyl-Į-PVP (M5) had earlier been
identified in rat urine [203].  Oxo-Į-PVP (M3) was further metabolized by reduction as well as
pyrrolidinone ring opening and oxidation to produce the respective metabolites ǃ-OH-oxo-Į-
PVP (M4) and Į-PVP-N-butylic acid (M6). Reduction of the ǃ-ketone (ǃ-OH-Į-PVP, M1; and ǃ-
OH-oxo-Į-PVP, M4), and oxidation of the propyl side chain (Į-PVP-propanoic acid, M7) were
previously unreported metabolic routes for Į-PVP. Four novel phase I metabolites: M1, M4, M6,
and M7, were identified. The main metabolic reactions of Į-PVP identified in vivo also took
place in the in vitro experiments. Meteor software predicted correctly five of the seven
metabolites identified for Į-PVP, and, most important, it helped in identification of a new main
metabolic route: reduction of the ǃ-ketone.
MPA  is  known  to  be  metabolized  to  a  minor  extent  in  humans  [204],  which  supports  the
identification of only one metabolite, the N-desmethyl metabolite (M1), for MPA (Table 6, and
Figure 2). In addition to nor-MPA, traces of hydroxy metabolites could be seen in vitro, which,
however, were not detected in human urine samples. Meteor predicted the N-demethylation
reaction as well.
5.2 Mass fragmentation in silico
Fragment identification in silico was employed in structural elucidation of the metabolites of
QTP, 2-DPMP, 3,4-DMMC, Į-PVP and MPA (I, IV), and in differentiation of their isomeric
metabolites, such as the hydroxy and sulfoxy metabolites of QTP and aromatic and aliphatic
OH-DPMP (I, IV). In silico fragment assignment was also used to differentiate between the
structural isomers found in a large target database for toxicological drug screening (II).
ACD/MS Fragmenter predicted approximately 30 to 250 fragments per compound,
depending on size and structure (II). The software listed several possible fragment structures
with calculated monoisotopic masses under the respective nominal mass. SmartFormula3D
suggested 1-4 formulae as a precursor ion and 2-15 formulae for the respective product ion. The
software provides a sum formula for the product ions identified, and thus the results do not
enable fragment structure determination alone. Neither of the software tools estimated
differences in ion abundances, and thus these were not used in compound identification.
5.2.1 Differentiation of structural isomers
ACD/MS Fragmenter and SmartFormula3D helped in the differentiation of 111 structural
isomers belonging to an in-house toxicology database (II).  For 80% of the compounds studied
three characteristic fragments could be identified, and 82% of the fragments were identified by
both software tools. Fragment identification assisted in differentiation of 82% (91 compounds in
38 isomer groups) of the structural isomers. Ten isomer pairs, i.e. diastereomers or position
isomers, fragmented identically, and therefore mass fragmentation in silico did not benefit the
differentiation of these compounds. Eight of these pairs could be separated by proper
chromatography, however. Protriptyline and nortriptyline, as well as cis-3-methylfentanyl and
trans-3-methylfentanyl, remained inseparable both by chromatography and by fragmentation.
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Figure 3 MS/MS spectra and fragmentation schemes of structural isomers: 2C-H, etilefrine, HHMA, and
HMA, with the molecular formula C10H15NO2 corresponding to [M+H]+ at 182.1176. The proposed
fragmentation schemes are based on fragment identification in silico (II)
Figure 3 exemplifies differentiation of four phenethylamine-structured isomers with a
molecular formula of C10H15NO2 using in silico fragment identification. Both ACD/MS
Fragmenter and SmartFormula3D identified the product ions presented, except for the 2,5-
dimethoxyphenethylamine (2C-H) product ion with an exact mass of 105.0699 ([M+H-
C2H7NO2]+), which was proposed solely by SmartFormula3D. The structure of this fragment was
therefore not verified. All the fragments were identified within a mass error of ±1 mDa from the
exact monoisotopic mass. Product ions with exact masses of 150.0675 for 2C-H and 135.0679
for etilefrine resulted from loss of radical cations. Other fragmentation reactions were neutral
losses. Etilefrine and 3,4-dihydroxymethamphetamine (HHMA) did not differ in their
chromatographic retention times (¨tR 0.07 min), and thus in an actual toxicology case in which
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both compounds are positive, a sum spectra would be seen. However, characteristic fragments
would allow identification of both compounds even from the same spectrum.
Fragment prediction with ACD/MS Fragmenter helped in differentiation of metabolites with
an identical molecular formula (I).  The hydroxy and sulfoxy metabolites of QTP (M3 and M4),
as well as O-desalkyl-OH-QTP (M7) and O-desalkyl-QTP-sulfoxide (M8) (Table 6) share the
same molecular formula, and consequently could not be separated by TOFMS data only. The
spectra from these isomeric metabolites, obtained by ISCID analysis, showed compound-
characteristic fragments. The product ions formed after cleavage of the sulfoxy group ([M+H-
OS]+) from the sulfoxy metabolites unambiguously distinguished them from the hydroxy
metabolites.
2-DPMP metabolites formed via aromatic hydroxylation (M1) and hydroxylation at the
piperidine ring (M2) could be differentiated using ACD/MS Fragmenter (IV). A loss of water
was detected in the spectra of M2, which was not seen in the spectra of the aromatic
hydroxylated metabolite M1. A compound-characteristic fragment of M1 - a benzylphenol
structure (C13H11O at exact mass m/z 183.0804) - proved that the hydroxylation took place at the
aromatic part of the molecule.
The Į-PVP metabolites OH-propyl-Į-PVP (M2) and ǃ-OH-oxo-Į-PVP (M4) have the
molecular formula C15H21NO2 ([M+H]+ at  248.1645)  (IV). The product ions identified, formed
via  the  loss  of  the  hydroxypropyl  group  ([M+H-C3H7O]+)  from  M2,  and  fragmentation  of  the
pyrrolidinone ring ([M+H-C4H7NO]+) from M4, verified the different structures.
5.2.2 Metabolite structure identification
In silico fragment prediction was used for QTP (I), 2-DPMP, 3,4-DMMC, Į-PVP and MPA (IV)
metabolite structure identification without the respective PRSs. One to four characteristic
fragments were identified for 11 QTP metabolites from the ISCID data using ACD/MS
Fragmenter. The low intensity of the O-desalkyl-QTP-acid (M9) did not allow fragment
identification, and thus verification of the structure would require MS/MS analysis. Meteor
software suggested a sulfone structure, corresponding to the molecular formulae of OH-QTP-
sulfoxide (M11) and N-desalkyl-OH-QTP-sulfoxide (M12). This could be excluded as the
characteristic product ion from sulfoxy cleavage was identified.
The structures of the 2-DPMP, 3,4-DMMC, Į-PVP and MPA metabolites detected in the
human urine samples and in vitro experiments were confirmed by comparing the mass spectra
of the metabolites with the product ions identified for the parent compounds using ACD/MS
Fragmenter and SmartFormula3D (IV). The fragmentation of the metabolites mainly followed
the path of the parent compound. Fragment prediction was employed to determine the site of
the metabolic reaction in the molecule. Structural elucidation by the fragment prediction
software supported the identification of 11 previously unreported designer drug metabolites.
ACD/MS Fragmenter aided in, for example, identification of the novel metabolites Į-PVP-N-
butylic acid (M6) and Į-PVP-propanoic acid (M7). Product ions identified from the loss of acetic
acid and the loss of aminobutyric acid proved the structure of Į-PVP-N-butylic acid (M6), which
was formed by pyrrolidinone ring opening and oxidation. An oxidation reaction was found to
take place at the propyl side chain (M7), as the loss of propanoic acid was detected. The software
helped to differentiate between aromatic and aliphatic hydroxylations; however, the exact site of
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the hydroxylation could not be identified in the cases of the OH-DPMPs (M1 and M2), and OH-
methyl-DMMC (M4).
5.3 Liquid chromatographic retention prediction
The correlation between the experimental and the calculated tR in the PFP knowledge base was
satisfactory (r2=0.8533) (III). The prediction accuracy of the control knowledge base C18 was
practically the same (r2=0.8497). The C18 control knowledge base was created to confirm the
prediction capacity of ACD/ChromGenius, and the results were not used for compound
retention order determination. The mean and median absolute errors of the compounds in the
PFP knowledge base were 1.12 min, and 0.84 min, respectively, in a 20 min analysis time. Figure
4 presents the distribution of tR errors in the PFP knowledge base. For 17% of the compounds
the calculated tR differed  by  ±2%  from  the  experimental  value,  and  for  58%  the tR error was
within ±10%. The ACD/ChromGenius calculations were no higher or lower than the
experimental tR,  and  for  most  compounds  (57%)  the tR error  was  less  than  ±1.00  min.
Compounds that were structurally very distinctive, such as hydroxychloroquine (¨tR 6.10 min)
and amiodarone (¨tR 4.83 min), showed poor correlations between experimental and calculated
tR. Different drug compound categories showed variations in prediction accuracy. The
calculations were more precise for the structurally consistent groups phenethylamines, and tri-
and tetracyclic central nervous system (CNS) drugs than for opioids, which have greater
structural variety. Due to relatively large absolute tR errors, the results of ACD/ChromGenius
were useless for compound identification alone.
Figure 4 Distribution of tR errors in the PFP knowledge base (III)
Despite the large absolute errors in calculated tR, ACD/ChromGenius proved its feasibility in
predicting the compound elution order. The software calculated the correct retention order for
68%  of  the  structural  isomer  groups  in  the  PFP  knowledge  base.  The  retention  order  of  the
isomers was more correctly calculated for compounds with adequate prediction accuracy: eight
of the nine isomer groups with tri- and tetracyclic CNS drugs were correctly predicted.
36
Phenethylamine derivatives constitute potential isomeric NPSs [211], in which the
substituent and its position vary. The benefit of the ACD/ChromGenius software lies in the
retention order calculation for different phenethylamines. An example of a correctly predicted
elution order for five phenethylamine isomers: etilefrine, HHMA, 4-hydroxy-3-
methoxyamphetamine (HMA), 3,4-dimethoxyphenethylamine (DMPEA), and 2C-H, is
presented in Table 7. The predicted tR indicates the compound elution order compared with
other possible substances.
Table 7 Five isomeric phenethylamine derivatives in the PFP knowledge base: etilefrine, HHMA, HMA,
DMPEA, and 2C-H, with experimental and calculated tR, and their absolute errors (III).
5.4 Software tools applied to accurate mass data
Identification of the compounds by LC/TOFMS (I)  and  LC/QTOFMS  (II-IV)  was  based  on tR
repeatability, mass accuracy and isotopic pattern match value (SigmaFit). The mean mass
accuracy and the mean SigmaFit value were less than 1 mDa, and 30 mSigma, respectively, by
both TOFMS and QTOFMS instruments. The excellent mass accuracy with adequate instrument
resolution enabled the determination of molecular formulae for both parent compound and its
product ions. In silico fragment structure identification assisted the differentiation of isomeric
drug metabolites (I, IV) and the structural isomers from a toxicology database (II), as
compounds with identical elemental composition are inseparable from full-scan accurate mass
data only. Combining accurate mass data and fragment prediction facilitated the elucidation of
the structure of the metabolites (I, IV).
Both ACD/MS Fragmenter and SmartFormula3D enable exploitation of accurate mass data
in the interpretation of their fragment assignments. The exact mass information provided by
these software tools made it easy to distinguish between product ions formed via even and odd
electron cleavages. ACD/MS Fragmenter allowed an exact monoisotopic mass to be calculated
for the proposed fragments, which facilitated the selection of the respective product ion from the
experimental MS spectrum. The software also provides a visual inspection of the proposed
fragment structure, which simplifies determination of the correct product ion configuration.
ACD/MS Fragmenter was found to be useful with ISCID data as well, which demonstrates its
benefits over library spectra comparison. The list of predicted fragments, however, included
many potential false-positive predictions, and thus is not useful for mass fragmentation studies
alone without experimental data to compare with.
SmartFormula3D proved to be an effective tool for assigning possible product ions for the
parent compound from the TOFMS data. However, it does not offer any information about
fragment structure, and therefore, when the structure of an unknown compound needs to be
Formula Compound Experimental tR Calculated tR Absolute tR error
C10H15NO2 Etilefrine 1.82 2.35 0.53
[M+H]+ 182.1176 HHMA 1.87 2.91 1.04
HMA 3.34 3.61 0.27
DMPEA 5.08 5.18 0.10
2C-H 7.63 5.54 2.09
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determined, its usefulness is limited. The software would most likely benefit rapid identification
of compound-characteristic fragments from MS/MS data obtained by PRSs.
ACD/MS Fragmenter and SmartFormula3D showed some lack of robustness in their
performance, as they did not identify all the product ions seen in the spectra, and a few
dissimilarities were observed in their results. Therefore, the results from in silico fragment
assignment should always be checked carefully to confirm that the proposed structures are
logical. Nevertheless, the results of ACD/MS Fragmenter and SmartFormula3D support each
other’s fragment proposals.
The software gave information neither about the charge distribution nor the location of the
radical site in the proposed product ion. They did not estimate the probability or the ion
abundance of the proposed fragments. Identification of all the possible product ions seen in the
mass spectrum is necessary when studying metabolism of a new drug candidate where
determination of the detailed structure of each metabolite is crucial. However, in terms of
differentiating between regioisomers, identification of 1-3 compound-characteristic fragment
structures is sufficient. In drug metabolism studies with forensic toxicology cases, the aim is
usually to identify the main metabolites to be used as supporting information along with the
parent compound. In cases, where qualitative metabolite identification is pursued, ACD/MS
Fragmenter and SmartFormula3D provide valid structural information.
5.5 Preliminary compound identification
In silico tools  used  for  prediction  of  drug  metabolism  (I, IV), mass fragmentation (I, II, IV),
and chromatographic retention (III), combined with LC/accurate mass data, assisted with
compound identification. The software performed well in both studies carried out with PRSs as
well as in metabolite identification with authentic biological samples. The software solutions
employed in metabolite identification, MetaboliteDetect (I) and TargetAnalysis (IV), served as
rough screening tools.
The in vitro metabolism experiments using HLMs produced eight of the 12 most abundant in
vivo phase I designer drug metabolites detected in human urine (IV). For some of the
metabolites that showed probable stereoisomerism in vivo, such as metabolite ǃ-OH-oxo-Į-PVP
(M4), the in vitro incubations generated only one of the diastereomers. The incubations with
HLMs produced a few designer metabolites of minor abundance that were not detected in vivo.
Thus, when extrapolating the data from in vitro studies to be used in metabolite identification in
vivo, the differences in metabolism should be considered [15,38]. Despite these dissimilarities,
the in vitro experiments served as biological material to be used with in silico metabolism
studies when an authentic human urine sample is unavailable. To carry out an in vitro study,
however, requires PRSs for parent compounds.
Meteor software provided literature-based justification for the predicted metabolic reactions,
which made the interpretation of the results explicit. The prediction likelihood level was found
to be a useful indicator in estimating the probability of the metabolic reaction: all the
metabolites identified were formed via reactions at either probable or plausible level. The
inability of the software to predict some of the hydroxylation reactions, one of the major
metabolic routes for QTP and 2-DPMP, indicates a lack of sensitivity in its performance. Meteor
was able to predict the missing metabolic routes when less stringent likelihood level settings
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were used. This, however, resulted in a large number of false-positive predictions, which impairs
the usefulness of the results when the aim is to identify the main metabolic products. The
tendency towards overprediction and low prediction precision of Meteor has been reported
elsewhere as well [42]. The reason for the less successful predictions for 2-DPMP, compared
with other NPSs studied, might be that the Meteor knowledge base contains very few metabolic
reactions of structurally similar compounds. Therefore, metabolite predictions by Meteor for
structurally novel drug compounds should be reviewed critically. In addition, the prediction
results should always be compared with the published metabolic reactions of the structural
analogs, and completed with the missing metabolites, if possible.
Meteor was no more accurate in metabolite prediction than manual deduction based on the
metabolic reactions of the structural analogs. Nevertheless, the software served as a valuable
and time-saving tool for creating list of possible metabolites for toxicologically interesting drug
compounds. The molecular formulae presented and the exact monoisotopic masses of the
proposed metabolites were easily transferred into a spreadsheet form. This list of possible
metabolites can be exploited in an automated database search for accurate mass data. The
database used for routine urine drug screening could be subsequently complemented with the
tentatively identified metabolite formulae with the aim of facilitating drug identification in
authentic human urine samples.
MetaboliteDetect and TargetAnalysis software tools were utilized in metabolite
identification. MetaboliteDetect turned out to be unsuitable for screening metabolites in
complex biological samples such as urine. A pooled pseudo-reference urine sample was used
instead of a blank reference. Subtraction of the background ions from the test sample ions did
not clean up the chromatogram substantially because of the relatively difficult sample matrix of
post-mortem urine. The QTP urine samples also included several other toxicological findings
which interfered with metabolite identification. The identification capacity of MetaboliteDetect
software  varied  from  40%  to  100%  for  the  QTP  metabolites.  Manual  detection  proved  to  be
more accurate, as the variation in metabolite identification was between 80% and 100%. The
main reason for the poor identification capacity of MetaboliteDetect was that only a relative
intensity threshold could be selected as an identification parameter. Therefore, when the total
ion current was high, it missed even relatively abundant metabolites.
TargetAnalysis, which is designed for automated database searches, identified metabolites
reliably. However, it does not include any add-ons for higher-grade metabolite identification,
such as mass defect filtering or spectra comparison, and therefore is not the software of choice
for unknown metabolite detection. Even a relatively small-scale metabolite screening aiming to
find  the  main  phase  I  metabolites  of  four  drug  compounds  (IV) was time consuming, as the
creation of the list of possible metabolites predicted by Meteor could not be automated. For
metabolism studies with a considerable number of possible target compounds, such as those in
metabolomics, more advanced metabolite screening tools are necessary.
ACD/MS Fragmenter and SmartFormula3D software were found to be useful for fragment
structure determination. This was shown by identifying characteristic fragments for 111
compounds using PRSs (II). The study introduced a practical approach for preliminary
compound identification even without PRSs. This was demonstrated by identifying drug
metabolites for which no reference material was available (I, IV). Fragment prediction in silico
worked similarly by excluding the false metabolite structures. For some of the potential
39
metabolites Meteor software predicted several structures fitting the same molecular formula.
For example, eight structural isomers were predicted in silico for ǃ-OH-carboxy-DMMC (M6)
(C12H17NO2; [M+H]+ 224.1281) (IV). However, identification of the product ion, corresponding
to a methylbenzoic acid structure (C8H9O2; at exact mass m/z 137.0597), allowed elimination of
the proposed dihydroxy metabolites.
Prediction of the correct compound elution order provides valuable information for the
separation of structural isomers (III). Two isomer pairs: 2,5-dimethoxyamphetamine (2,5-
DMA) and 3,4-dimethoxyamphetamine (3,4-DMA) (C11H17NO2; [M+H]+ 196.1332), and 4-
isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4) and 4-propylthio-2,5-dimethoxy-
phenethylamine (2C-T-7) (C13H21NO2S; [M+H]+ 256.1366), had identical fragments, and thus
could not be separated by fragment prediction alone (II). However, successful retention order
prediction made it possible to differentiate between these isomers. The predicted tR, combined
with information produced by other in silico software tools employing accurate mass data,
completed the compound identification.
It was shown that the software employed in predicting metabolism and chromatographic
behavior was most accurate for compounds with a chemical structure similar to other
compounds in the database. QTP, a dibenzothiazepine derivative [207], has a tricyclic structure,
which is common to several drug compounds with pharmacological effects on the CNS [212].
Meteor software proposed correctly four of the five main metabolic reactions of QTP. For the 47
tri- and tetracyclic CNS drugs in the PFP knowledge base, the median absolute error of the
ACD/ChromGenius predictions was 0.62 min. Nine isomer groups included a tri- or a tetracyclic
compound, and the retention order was predicted correctly in eight cases. Retention order
prediction using ACD/ChromGenius also provided important information for identifying
designer drugs with a phenethylamine structure. The successful predictions related to
phenethylamines are of special interest to a forensic toxicologist, as NPSs are often chemical
modifications of amphetamines and cathinones: nineteen new designer drugs with a
phenethylamine structure were notified to the EU early-warning system in 2012 [3].
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6 GENERAL DISCUSSION
Computational systems that aid in the identification of small molecules have advanced and the
number of different methods has increased rapidly during recent years. Their role is becoming
increasingly important as improved analytical techniques offer a vast amount of data in a
shorter turn-around time. The bottleneck in studies of unknown compounds is the amount of
data that a researcher can handle, not the sample throughput time. There is therefore a pressing
need for validated and robust computational methods.
Computational approaches to predicting drug metabolism are common practice in the early
drug development process. The number of different in silico tools for metabolite prediction has
increased rapidly during the preparation of the present thesis, which demonstrates the growing
interest in this approach. Many of those in silico systems that predict ligand-enzyme
interactions are without doubt too complicated to implement in analytical toxicology practice.
However, in silico tools together with in vitro experiments provide useful information to
support in vivo metabolism studies [20]. Computational metabolite prediction was introduced
in forensic toxicology practice in this thesis. Meteor software provided sensitive metabolite
prediction, and allowed identification of new metabolites that were not previously detected in
vivo in rats. It is known that species differences, especially in CYP-related metabolism, can be
quite large [213,214]. Therefore, conclusions about the metabolic fate in humans should not be
based on animal tests alone.
Recently, in silico metabolite prediction has been applied to synthetic cannabinoids [215]. In
a preliminary study, the MetaSite software showed promising results by predicting the main in
vitro metabolites of the target compounds. Peters et al. [216] used a modified version of
MetaboLynx software to predict and identify steroid metabolites and their designer
modifications in spiked urine samples. The screening method proved successful; however, it was
not tested on authentic urine samples, in which the concentrations of the metabolites can be
very low. Nevertheless, in silico methods that predict metabolite structures would certainly be
useful for screening metabolites of toxicological interest in biological samples. The proposed
metabolic reactions can also complement the known metabolic reactions, even if the exact
predicted structures cannot be detected. Systems that can predict drug effects on metabolizing
enzymes, especially on CYP isozymes, could aid in toxicological risk assessment.
Predictive tools for drug metabolism studies have advanced considerably although there is
still much room for further development and enhancement [39]. It has been claimed that
computational methods cannot yet replace human expertise [20]. In the present thesis Meteor
software showed the potential to be beneficial in forensic toxicology practice. However,
conclusions about its feasibility with a wide variety of drug compounds would require further
studies. A comparative study of the performances of different in silico drug metabolism systems
for toxicologically relevant compounds would provide more reliable information about the
advantages of this type of software.
As controlled in vivo metabolism studies of NPSs on humans are out of the question, in vitro
experiments and in vivo animal studies have been employed with these compounds [38]. In vivo
animal studies require special facilities, and cannot be performed in the majority of analytical
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toxicology laboratories, which is why the use of in vitro metabolism studies has increased in
popularity [38]. Metabolite characterization studies using different in vitro systems have been
applied to compounds such as cathinones [99], synthetic cannabinoids [217], tryptamines [218]
and phenethylamines [219]. Another approach employing in vitro studies in a toxicology context
is to examine CYP-mediated metabolism. In these initial activity screening assays the goal is to
determine the main enzymes involved in the elimination of the drug, and investigate possible
drug-drug interactions and genetic variability in pharmacokinetics [220]. None of the current in
vitro experimental systems predict in vivo metabolite pattern perfectly; however, relatively
robust and reliable extrapolations regarding qualitative human metabolism can be made on the
basis of appropriate in vitro studies [20]. Furthermore, in vitro samples serve as a specimen for
screening in silico metabolites in cases where no authentic human urine sample is available.
In vitro metabolism studies are limited to compounds for which reference material is
available. Such studies have been used to produce metabolite standards to compensate for the
absence of PRSs [221-223]. However, the procedures involved require dozens of milligrams of
the parent compound to produce a reasonable amount of metabolites. In the case of novel
designer drugs or expensive standards, the method is impractical or even impossible.
MS instruments with high mass accuracy, moderate or high RP, and sufficient sensitivity
facilitate the identification and structural characterization of toxicological compounds and their
metabolites in complex biological matrixes [31,33,146]. Sophisticated computational systems
are indispensable for effective data processing, and numerous applications are available. The
identification of toxicologically relevant compounds has conventionally been based on
comparison with reference GC/EI spectra. Despite the recent advances in development of
universal MS/MS spectral libraries, there are doubts about their reliability and transferability
[187]. Compound identification by spectral library search does not enable identification of
unknown substances such as metabolites. MS/MS data for non-targeted compounds of low
abundance is also lost in data-dependent acquisition analysis. The novel fragmentation tree
approach [102,110-112] may aid in solving this limitation, but the further validation of these
software systems is required [110]. Screening against very large databases using orthogonal
filters for accurate mass and HRMS data has been used in determining the elemental
composition of unknowns [96,224-226]. The method was proposed as a systematic work flow
for untargeted screening, for instance in the environmental sciences [84]. Recently, the rapidly
growing open access compound and spectral databases have attracted criticism about the
reliability of their contents [227,228]. The authors highlight the responsibility of the analyst for
ensuring that the data are faultless and high of quality.
The above-mentioned approaches are particularly popular in the area of metabolomics,
where the aim is to identify and quantify all metabolites in a given biological context [229].
Nevertheless, these systems seem too laborious for routine use in forensic toxicology [146].
From the toxicology point of view, more useful computational tools for accurate mass data are
those that allow identification of the main metabolites of the target compound. Mass defect
filtering enables fast screening of possible metabolites, and this approach has helped in
identifying metabolites of synthetic cannabinoids in in vitro samples [217]. MetaboLynx
software has served in the identification of steroid metabolites in spiked urine samples [216].
However, with the exception of the present study, automated metabolite detection software
tools have not been applied to post-mortem cases. Post-mortem urine samples from forensic
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toxicology investigations are very heterogeneous in quality, as they often contain interfering
compounds such as other drugs and their metabolites, or substances formed in putrefaction
reactions. As found here, such software systems are probably better suited for in vitro
metabolism studies or for in vivo samples from controlled metabolism studies. The most
frequently used approach to screening metabolites from HR accurate mass MS data is to
generate a list of possible metabolites manually, and search for them in authentic biological
samples [31].
Accurate mass data alone does not allow the structure of an unknown compound to be
characterized with certainty. However, MS/MS analysis allows determination of the elemental
composition of the product ions, and can be used in structural characterization of the parent
compound. As shown in the present thesis, mass spectral interpretation tools and in silico
fragment prediction software assist in matching the product ions to the correct parent
compound structure. This provides enough information to establish the observed metabolic
reaction of a parent compound and to differentiate between structural isomers. Mass spectral
interpretation and structural determination of unknown compounds is without any doubt
possible without software assistance; however, it does enable spectral processing to be
performed within a reasonable time scale even for analysts with less experience. The software
used here worked well for a heterogeneous range of compounds, and can therefore be used
without prior knowledge of the fragmentation behavior of the substance. The combination of
accurate mass measurement and fragment prediction allows the fragment structure to be
determined. This provides a more universal identification approach for unknown compounds
than a spectral library comparison. An untargeted screening method for drugs of abuse and
antidepressant metabolites by SmileMS software worked well with unit resolution MS data,
where detection was based on known fragment structures recorded in the library [120,121].
However, the approach does not allow identification of structurally unique compounds that are
not included in the dataset. On the other hand, ISCID analysis does not produce pure spectra for
a suitable spectral library comparison. However, ACD/MS Fragmenter and SmartFormula3D
enabled characteristic fragment identification even from a mixed spectrum. These fragment
prediction software tools are useful in creating a database with qualifier ions for screening and
confirmation of targeted compounds in a single analytical run [176,182]. Accurate mass analysis
with ISCID or bbCID using data-independent acquisition also allows a retrospective fragmental
data investigation of unknown compounds without the need for reanalysis.
The predicted tR can  be  used  as  a  powerful  orthogonal  filter  to  cut  down  the  number  of
possible chemical structures [83,84,98,230], and it plays an important role in data mining
procedures such as in metabolomics [140]. Retention time prediction proved to be useful in the
differentiation of structural isomers, but the system suffered from a severe lack of robustness
and reliability. No comprehensive conclusions about the benefits of retention time prediction
with ACD/ChromGenius or other software tools in forensic toxicology can be drawn based on
this thesis, as the results have been achieved using an in-house database. The results for
ACD/ChromGenius need careful validation for each single LC method, which makes the use of
the software rather inflexible. In a recently introduced application, a QSRR method was used to
predict UHPLC tR of drug compounds to be used in toxicological drug screening [231]. However,
the dataset of 175 compounds in this study seems rather limited if tR is  to  be  predicted  for
structurally novel compounds. Currently, no commercial software with a user-friendly interface
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is  available  with  which  to  perform  reliable  and  robust  LC tR calculations for small molecules.
Computational methods for processing the data from MS analyses have advanced enormously
during the last decade. Whether similar progress will occur in the future in LC data processing
remains to be seen.
The predictive software systems used in this thesis had moderately user-friendly interfaces,
which made them easy to employ in routine laboratory work. The mathematical basis behind the
predictions of Meteor software was quite well explained by Lhasa Limited, which made the
evaluation of the results reliable. ACD/Labs did not provide the full algorithms for their
software ACD/MS Fragmenter and ACD/ChromGenius. This, especially in terms of retention
time prediction, made a comprehensive analysis of the software performance impossible. The
full algorithm in commercial predictive systems is rarely freely available, which makes the
comparison between different software tools difficult.
The in silico tools employed in the present thesis were from several manufacturers, and were
found beneficial more or less as independent systems. Therefore, most of the data entry,
transfer and processing had to be done manually. In many cases this was the most time
consuming part of the study. In order to operate as time-saving and work-enhancing tools, the
software should be platform-independent. Flexible data transfer between the MS instrument,
the data processing systems for compound identification, and the different predictive software
tools, would greatly improve the analysis and identification of small molecules.
Based on the findings in this thesis, a systematic workflow for metabolism studies employing
different in silico systems and accurate mass data is presented in Figure 5. The workflow
describes a procedure starting from prediction of the possible metabolites, followed by the
identification and structural elucidation of the metabolites in biological samples. In the present
thesis, the focus was on identification of phase I metabolites, although the suggested workflow
would function for investigation of phase II metabolites as well. In the final step, the proposed
metabolite formulae, along with the product ion data and possible retention time information
are added to the target drug screening database. The workflow demonstrated can be applied to
predictive software other than that employed in this thesis. This method helps in the
identification of the parent compound when an authentic urine sample turns up. The role of
metabolite prediction and fragment prediction software is central in the workflow presented, as
they definitely speed up the identification and structural verification of the proposed
metabolites. Retention order prediction may be useful in a case where isomeric metabolites
cannot be differentiated explicitly from each other based on their MS/MS spectra. The workflow
functions even if an authentic urine sample is not available. However, in such cases, the
metabolites should be considered as tentative propositions.
Careful selection of the most convenient software to be used in metabolism studies based on
the workflow presented here is necessary. The software tools chosen in the present thesis
functioned well individually; however, when combined they were too rigid for systematic large-
scale metabolism studies. A more advanced data processing tool for compound identification
and software compatible with the analysis data would have made metabolite characterization
more effective.
The metabolites found in these studies were detected using the present LC/TOFMS urine
drug screening method of our laboratory. Even more metabolites might have been detected with
a more selective and sensitive method validated separately for each of the compounds studied.
44
However, the results achieved here were directly applicable to the routine drug screening
method.
Figure 5 Systematic workflow for metabolism studies for toxicologically relevant compounds utilizing in
silico systems and accurate mass measurement
Because of the legal consequences, an unambiguous identification of substances is of high
priority in forensic and clinical toxicology. A false report may lead to incorrect convictions or to
a patient’s misdiagnosis, with the result that the laboratory may be perceived as unreliable
[232]. Laboratory guidelines and requirements for compound identification are available for
doping analysis [233] and forensic toxicology [234]. These regulations, however, cannot be
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directly applied to HR and accurate mass data, as their requirements for mass accuracy and
resolution (two decimal places and 10,000 FWHM, respectively) are not parallel with the
performance of modern HRMS instruments. The EU Council Directive for food safety control
[235] stipulates a minimum of four (4.0) identification points for animal and meat residue
LC/MS analysis. HRMS provides 2.0 points for a precursor ion and 2.5 points for a product ion.
In addition, a relative tR error  of  2.5%  is  allowed.  EU  Reference  Laboratories  for  Residues  of
Pesticides published a document (SANCO/12495/2011) [236] that includes a mass accuracy
tolerance of <5 ppm and accepts compound identification with two diagnostic product ions. Yet,
the document suggests ion ratio tolerances that are unsuitable for full-scan data acquisition
[237]. Rivier [238] has reviewed and summarized the guidelines for different LC/MS techniques
to be used in forensic toxicology and doping analysis ten years ago. Analytical techniques,
especially in the area of HRMS, have advanced, affording more informative data for compound
identification today. Up-to-date MS identification guidelines in forensic toxicology case work are
published by the Australian/New Zealand Specialist Advisory Group in Toxicology [239].
However, these criteria for compound identification strongly rely on the use of PRSs. Nielen et
al. [160] proposed an identification criterion for screening and confirmation analysis that
combines accurate mass (5 mDa) and mass resolution (RP 10,000-20,000 FWHM). They also
commented on the identification of unknowns, and suggested that the proposed structures
should be confirmed with either  NMR or  HRMS capable  of  RP 70,000 FWHM. Despite  this,
the present instructions related to compound identification by accurate mass do not take into
account isotopic pattern determination, which was found crucial for calculating the molecular
formula [88]. The current advanced methodologies in chromatography, i.e. UHPLC, provide
enhanced separation capacity, repeatability and stability, which might impose demands on new
tR criteria as well.
These criteria cannot be applied to compound identification as such when PRSs are not
available, and therefore the results should be treated as tentative. However, the reliable
characterization of novel compounds is important, as an increasing number of new designer
drugs is announced annually. The current in silico methods are not yet sufficiently validated to
produce robust data that could be regarded as an extra identification point. Nevertheless, the
present thesis clearly shows that computational methods do provide additional data to be used
in preliminary identification for toxicologically relevant compounds. The information achieved
using different in silico tools is straightforward to apply in accurate mass-based urine drug
screening.
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7 CONCLUSIONS
Computational methods for studying drug metabolism, mass fragmentation and
chromatographic behavior proved to be feasible in analytical toxicology practice. The software
was of particular benefit when applied to accurate mass data.
In silico prediction of drug metabolism with Meteor software was a rapid way to create a list
of possible metabolites to be screened from biological samples. The software was found most
accurate for compounds, such as phenethylamines or tricyclic CNS drugs, which were
structurally most similar to the compounds used to compile the Meteor knowledge base (I, IV).
The use of in silico metabolite prediction also enabled the identification of an unpublished
metabolic route and detection of unreported metabolites. Meteor software showed a tendency
towards overprediction, and therefore the results need to be verified against biological samples.
The in vitro experiments provide material for metabolite screening when no authentic urine
sample is available.
Fragmentation identification in silico aided the structural characterization of isomeric
compounds and drug metabolites (I, II, IV). The combination of two software solutions
ACD/MS Fragmenter and SmartFormula3D, which use a different approach in fragment
assignment, produced reliable information for structural elucidation. These software tools,
together with accurate mass fragmentation data, enabled determination of the product ion
structure. The method allows the identification of structurally novel compounds, such as
designer drug metabolites, that are not present in any compound or spectral database.
Retention time calculation can be used as additional information in differentiating between
structural isomers (III), which are inseparable by accurate mass determination alone. Within
the database used, the ACD/ChromGenius software was most accurate for drugs with a
phenethylamine structure. Therefore, the in silico tR prediction can provide valuable
information for the differentiation of novel designer drugs.
The software employed in the present thesis can be used to produce information for tentative
compound identification when no PRSs are available. The data obtained using these in silico
systems can further be applied to the toxicology database for accurate mass-based urine drug
screening to facilitate compound identification in authentic cases.
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Current in silico tools were evaluated for their ability to predict metabolism and mass spectral
fragmentation in the context of analytical toxicology practice. A metabolite prediction program
(Lhasa Meteor), a metabolite detection program (Bruker MetaboliteDetect), and a fragmentation
prediction program (ACD/MS Fragmenter) were used to assign phase I metabolites of the anti-
psychotic drug quetiapine in the liquid chromatography/time-of-ﬂight mass spectrometry (LC/
TOFMS) accurate mass data from ten autopsy urine samples. In the literature, the main metabolic
routes of quetiapine have been reported to be sulfoxidation, oxidation to the corresponding
carboxylic acid, N- and O-dealkylation and hydroxylation. Of the 14 metabolites predicted by
Meteor, eight were detected by LC/TOFMS in the urine samples with use of MetaboliteDetect
software and manual inspection. An additional ﬁve hydroxy derivatives were detected, but not
predicted by Meteor. The fragment structures provided by ACD/MS Fragmenter software conﬁrmed
the identiﬁcation of the metabolites. Mean mass accuracy and isotopic pattern match (SigmaFit)
values for the fragments were 2.40ppm (0.62mDa) and 0.010, respectively. ACD/MS Fragmenter, in
particular, allowedmetabolites with identicalmolecular formulae to be differentiatedwithout a need
to access the respective reference standards or reference spectra. This was well exempliﬁed with the
hydroxy/sulfoxy metabolites of quetiapine and their N- and O-dealkylated forms. The procedure
resulted in assigning 13 quetiapine metabolites in urine. The present approach is instrumental in
developing an extensive database containing exact monoisotopic masses and veriﬁed retention times
of drugs and their urinary metabolites for LC/TOFMS drug screening. Copyright # 2009 John
Wiley & Sons, Ltd.
There is growing interest today in the use of accurate mass
methods in various ﬁelds of small molecule analysis,
including pharmaceutical chemistry,1 drug metabolite
research,2 pesticide monitoring,3 and analytical toxicology.4
This is partly due to the fact that current liquid chromatog-
raphy/time-of-ﬂight mass spectrometry (LC/TOFMS)
instruments provide a robust and cost-effective means for
acquiring accurate masses in complex biological samples on
a routine basis. The advantages of modern LC/TOFMS
include high speed, good sensitivity, sufﬁcient resolution,
andmass accuracy similar to that of more expensive accurate
mass instruments.5
Our group has for several years been developing
automated LC/TOFMSmethods for toxicological urine drug
screening,6–8 street drug analysis,9 and doping control.10 We
have established a screening approach that involves accurate
mass measurement in a biological matrix combined with a
reverse search based on a large target database of exact
monoisotopic masses. Entries in the database, representing
the elemental formulae of reference substances and their
metabolites, are compared with the measured masses for
protonated molecules [MþH]þ. Dedicated software has been
developed to perform the automated data analysis. After
mass scale calibration of the data, extracted ion chromato-
grams (EICs) are created in a 0.002 m/zmass window for the
[MþH]þ ion of each molecular formula included in the
database. Peak detection and identiﬁcation criteria are
applied according to mass accuracy, isotopic pattern match
(SigmaFit), area and retention time, if available. Lastly, anMS
Excel-based result report is created.8
Poor accessibility of reference standards for new drugs,
designer drugs and metabolites hinders the analysis of these
compounds by conventional techniques, which essentially
rely on reference standards.9 In our LC/TOFMS method, the
current in-house database for toxicological urine screening
includes 830 masses comprising a wide variety of medicinal
and illicit substances, whereas retention time information
obtainedwith reference standards is available only for 50% of
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these compounds. Applying known urinary metabolic
patterns greatly facilitates substance identiﬁcation as drug
metabolites support the parent drug ﬁnding and as a number
of compounds are excreted solely as metabolites. Unfortu-
nately, sufﬁcient information on human urinary metabolites
does not always exist in the literature, neither for old nor new
drugs.
Another analytical challenge concerns compounds with
identical molecular formulae as these compounds cannot be
differentiated by accurate mass only in the absence of
reference standards. Collision-induced dissociation (CID),
performed either in-source (ISCID)3 or preferably in tandem
mass analyzers,11 would allow differentiation of most
unresolved combinations, but the interpretation of electro-
spray mass spectra requires signiﬁcant expertise, and
automated methods would reduce time and labour costs
for analytical toxicology laboratories. To meet these chal-
lenges, in silico tools have been made generally available for
predicting both drug metabolism in connection with MS
experiments and electrospray MS fragmentation.12,13
Generally, drug screening by the LC/TOFMS approach
described above is fairly straightforward. However, to fully
utilise the information-rich capability of the method, an
analyst should be able to assign undetected metabolites,
previously known or unknown, in the MS acquisition data
related to casework, and further, to include the spectral and
chromatographic data for these compounds in the target
database to aid identiﬁcation in other cases. Traditionally,
this has only been realisable in the basic research depart-
ments of universities and pharmaceutical companies, which
are capable of obtaining the appropriate reference standard
by synthesis.
The present study examines current representatives of
generally available software to assess their potential for
predicting metabolism and MS fragmentation in the context
of analytical toxicology practice. This includes identiﬁcation
of as many metabolites as possible without the correspond-
ing reference substances in order to usemetabolic patterns as
supporting information for the parent identiﬁcation, and to
exclude unidentiﬁed peaks from the raw data obtained. A
metabolite prediction program (Lhasa Meteor), a metabolite
detection program (Bruker MetaboliteDetect), and a frag-
mentation prediction program (ACD/MS Fragmenter) are
used to assign phase I metabolites of the antipsychotic drug
quetiapine in LC/TOFMS data from autopsy urine samples.
Quetiapine was selected as the study compound as it is a
common ﬁnding in forensic toxicology casework, it is
extensively metabolised,14 and detailed information about
the chromatographic behaviour of the metabolites is not
available in the literature.
EXPERIMENTAL
Materials
HPLC grade acetonitrile was purchased from Rathburn
(Walkerburn, UK) and b-glucuronidase from Roche (Mann-
heim, Germany). All the other solvents and reagents were of
analytical reagent grade from Merck (Darmstadt, Germany).
Water was puriﬁed with a DirectQ-3 instrument (Millipore,
Bedford, MA, USA). Isolute HCX-5 (130mg, 10mL) mixed-
mode solid-phase extraction (SPE) cartridges were from
Biotage (Hengoed, UK). The mixed-mode phase included
C-4 carbon chains combinedwith sulfonic acid functionalities.
Sample preparation
Urine samples were collected at autopsy, and sample
preparation was carried out according to the laboratory’s
routine procedures, as described earlier.7 Ten successive
cases containing quetiapine, based on the LC/TOFMS
results, were selected for this study.
Urine samples (1mL) were hydrolysed with b-glucuroni-
dase for 2 h in awater bath at 568C. Then, 10mL of dibenzepin
internal standard solution (10mg/mL in methanol) and 2mL
of pH 6 phosphate bufferwere added to the hydrolysed urine
sample. The SPE procedure was performed as follows. The
SPE cartridges were conditioned with 2mL of methanol,
followed by 2mL of water and 3mL of pH 6 phosphate
buffer. The sample was added, followed by washing with
1mL of pH 6 phosphate buffer and drying for 5min. The
cartridge was further washed with 1mL of 1M acetic acid
and again dried for 5min. The acidic/neutral fraction was
eluted with 3mL of ethyl acetate/hexane (25:75, v/v), and
the cartridge was dried for 2min. The cartridge was washed
with 1mL of methanol and dried for 2min. The basic fraction
was eluted with 3mL of freshly made ethyl acetate/
ammonia (98:2, v/v), 25% ammonia solution in water. The
combined efﬂuents were evaporated to dryness at 408C,
reconstituted with 150 mL of acetonitrile/0.1% formic acid
(1:9, v/v) and analysed by LC/TOFMS.
A pooled pseudo-reference urine sample to be used in
metabolism studies was prepared as follows. Ten autopsy
urine samples from ﬁve male and ﬁve female cases were
hydrolysed and pooled. Based on LC/TOFMS, the samples
were either drug-free or contained caffeine and/or nicotine
only. Two 1mL aliquots were prepared as described above.
The parallel samples were checked for an identical reference
proﬁle by LC/TOFMS, and only one of themwas used as the
reference sample.
Another ten samples not containing quetiapine were
analysed for the ions of the assigned quetiapine metabolites
in order to evaluate potential matrix effects, and all of the
samples proved to be free from interference.
Liquid chromatography/time-of-ﬂight mass
spectrometry
LC/TOFMS analysis was performed as described earlier,8
withminor modiﬁcations. The liquid chromatograph was a
1100 series instrument (Agilent Waldbronn, Germany)
including a vacuum degasser, autosampler, binary pump,
and column oven. Separation was performed in gradient
mode with a Luna C-18(2) 100 2mm (3mm) column and a
4 2mm pre-column at 408C (Phenomenex, Torrance, CA,
USA). Mobile phase components were 5mM ammonium
acetate in 0.1% formic acid and acetonitrile. The ﬂow ratewas
0.3mL/min. The proportion of acetonitrile was increased
from 10% to 40% at 10min, to 75% at 13.5min, to 80% at
16min, and held at 80% for 5min. The post-time was 6min
and the injection volume 10mL.
The mass analyser was a Bruker micrOTOF mass
spectrometer with an electrospray ionisation (ESI) source
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and a six-port divert valve (Bruker Daltonics, Bremen,
Germany). The instrument controls were performed with
HyStar 3.2 and micrOTOFcontrol 2.2 software (Bruker
Daltonics). The nominal resolution of the instrument was
10 000. The instrument was operated in positive ion mode
with m/z range of 50–800. The capillary voltage was 4500V,
the capillary exit was 85V, and skimmer 1 was 35V. The
nebuliser gas pressure was 1.6 bar, and the drying gas ﬂow
was 8 l/min. The drying temperature was 2008C. The spectra
average was set to 2, and the summation was 12 000,
corresponding to 0.6 s sample time. The transfer time was
40ms, and the hexapole RF was 45Vpp.
ISCID was used in the experiments with ACD/MS
Fragmenter software. The instrument parameters were as
described above, except for the capillary exit and skimmer 1,
which were set to 180 and 60V, respectively.
Software
Meteor 10.0.2 software by Lhasa Ltd. (Leeds, UK) is a
knowledge-based expert system for metabolism prediction.
In the prediction process, the software utilises structure-
metabolism rules stored in the knowledge base, with analysis
of the likelihood of a particular prediction based on global
lipophilicity-metabolism relations, and selection between
potentially competing biotransformations.15 The metabolic
reactions are reported with detailed route information, and
the predicted metabolites are categorised as plausible or
probable. Meteor was used in this study to predict quetiapine
metabolism. The default values of prediction parameters
were used, excluding phase II metabolites, as hydrolysed
urine samples were used in this study.
MetaboliteDetect 2.0 by Bruker Daltonics is a metabolite
detection program designed for use in metabolism studies
for which an authentic blank reference sample is available.
The software subtracts the blank reference sample data from the
data collected after drug exposure, referred to hereafter as
reference and sample, respectively. In an ideal case, the
subtraction produces a clean result chromatogram contain-
ing only a few peaks. Subsequently, the software lists the
molecular formulae generated for all peaks detected, the
difference between the measured and theoretical mass, and
the SigmaFit value. Information on both expected metab-
olites and other ﬁndings, classiﬁed as unexpected metab-
olites, is thus obtained. As the samples in this study were
collected at autopsies, authentic blank reference urine
samples were not available and therefore a pooled
pseudo-reference urine sample was used instead. The main
parameters used were as follows: Calculate Difference was
used at the Expose mode with a ratio of 5; Detect Masses
applied the EIC at the Simple Peak Detection mode; Noise PC
was 2; and Intensity Threshold was 30%.
ACD/MS Fragmenter 11.01 by Advanced Chemistry
Development (Toronto, Canada) is a new fragmentation
prediction program based on the established MS fragmenta-
tion rules from the literature. The software generates a tree-
structured presentation of the predicted fragments according
to the ionisation mode and the number of fragmentation
steps selected. When fragments detected in the experimental
data are selected from the tree, the software provides
detailed information on the routes of fragmentation and all
possible structure candidates for a speciﬁc mass. The exact
masses of the fragments are provided automatically. API
positive mode ionisation was selected for the prediction, and
the number of fragmentation steps was set to 5.
Study design
The study design is presented in Scheme 1.
RESULTS AND DISCUSSION
Prediction of metabolism by Meteor software
Meteor software predicted 14 metabolites of quetiapine
overall. All these were categorised as probable, and the
plausible ranking was given only to the minor moieties that
were cleaved. Of the 14 metabolites, eight were detected by
LC/TOFMS in the autopsy urine samples by using
MetaboliteDetect software and manual inspection. The main
reason for this difference was the fact that Meteor did not
predict any hydroxy metabolites of quetiapine. Instead,
Meteor suggested further oxidation of sulfoxides to sulfones.
In the literature, the main metabolic routes of quetiapine
have been reported to be sulfoxidation, oxidation to the
corresponding carboxylic acid, N- and O-dealkylation and
hydroxylation.16 Consequently, the hydroxy metabolites
were added manually to the list of metabolites used in the
further stages of the study (Table 1, Fig. 1). Four third-stage
Scheme 1. A generalised presentation of the study design.
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metabolites predicted by Meteor were not detected in the
samples, probably due to their low concentrations.
The known main metabolites, excluding hydroxylated
products, were included in the eight both predicted by
Meteor and detected in the samples. The ﬁve metabolites not
predicted by Meteor were all hydroxy derivatives. Several
papers have been published about quetiapine pharmacoki-
netics, and most of them mention that 11 metabolites have
Table 1. Quetiapine and 13 metabolites detected by the MetaboliteDetect software in ten autopsy urine samples. All average
values were calculated from absolute values
Compound Molecular formula [MþH]þ
RT
min
STDEV
min
Mass error
average
ppm
Mass error
average
mDa
Sigma
Fit average
Detected by
Metabolite
Detect
Detected
manually
Predicted
by Meteor
Quetiapine C21 H25 N3 O2 S 384.1740 11.29 0.03 1.86 0.72 0.007 100% 100%
M1 C17 H17 N3 S 296.1216 10.95 0.04 1.70 0.50 0.008 90% 100% yes
M2 C19 H21 N3 O S 340.1478 11.07 0.02 1.78 0.52 0.010 60% 100% yes
M3 peak 1 C21 H25 N3 O3 S 400.1689 8.68 0.03 2.15 0.96 0.010 80% 100% yes
M3 peak 2 C21 H25 N3 O3 S 400.1689 8.87 0.02 2.40 0.96 0.011 80% 100% yes
M4 C21 H25 N3 O3 S 400.1689 6.73 0.02 1.22 0.67 0.011 60% 100% no
M5 C21 H23 N3 O3 S 398.1533 11.80 0.01 1.65 0.66 0.018 70% 80% yes
M6 C17 H17 N3 O S 312.1165 4.64 0.09 1.67 0.52 0.010 100% 100% no
M7 peak 1 C17 H17 N3 O S 312.1165 8.42 0.05 1.24 0.39 0.010 100% 100% yes
M7 peak 2 C17 H17 N3 O S 312.1165 8.60 0.03 1.56 0.49 0.010 90% 100% yes
M8 C19 H21 N3 O2 S 356.1427 5.88 0.03 1.93 0.69 0.007 70% 90% no
M9 peak 1 C19 H21 N3 O2 S 356.1427 8.40 0.02 1.18 0.42 0.009 50% 100% yes
M9 peak 2 C19 H21 N3 O2 S 356.1427 8.61 0.04 1.36 0.48 0.014 40% 100% yes
M10 C19 H19 N3 O2 S 354.1271 7.76 0.01 2.23 0.79 0.004 40% 90% yes
M11 peak 1 C21 H23 N3 O4 S 414.1482 9.31 0.01 1.86 0.77 0.024 80% 80% yes
M11 peak 2 C21 H23 N3 O4 S 414.1482 9.49 0.01 1.38 0.57 0.021 70% 80% yes
M12 peak 1 C21 H25 N3 O4 S 416.1639 6.09 0.16 1.91 0.80 0.007 70% 100% no
M12 peak 2 C21 H25 N3 O4 S 416.1639 6.50 0.02 0.56 0.23 0.027 40% 90% no
M13 C17 H17 N3 O2 S 328.1114 5.17 0.04 2.21 0.67 0.006 90% 100% no
Figure 1. Structures of the 13 metabolites detected and identiﬁed in ten autopsy urine samples containing
quetiapine. The order of the metabolic reactions may differ from those presented.
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been described.16–19 However, detailed structures of these
metabolites have not been included in the papers nor in the
manufacturers’ prescription information.20
Compared to the manual reasoning of potential metabolic
routes and products, Meteor served as a valuable tool,
providing molecular structures and exact masses automati-
cally. The predictions made by Meteor were logical, and the
categorical distinction between plausible and probable
metabolic steps made the interpretation of the results
unambiguous. However, the inability of the software to
predict one of themainmetabolic routes can be considered as
a major drawback, and this suggests that predicting
metabolism without any previous information would be
much more challenging.
Detection of metabolites by MetaboliteDetect
software
The predicted and detected metabolites of quetiapine in ten
autopsy urine samples are indicated in Table 1, and the
corresponding structures are illustrated in Fig. 1. The use of
MetaboliteDetect software in this study differed from the
procedure suggested by the manufacturer, because authentic
Table 2. The molecular formulae, average mass accuracies and SigmaFit values of the observed fragments
Compound
Molecular
formula [MþH]þ RT
Fragment
no
Fragment molecular
formula protonated
[MþH]þ
theoretical
[MþH]þ
Measured
Mass error
average ppm
Mass error
average mDa
Sigma
average
Quetiapine C21H25N3O2S 384.1740 11.29 1 [C17H15N2S]þ 279.0950 279.0951 3.91 1.10 0.006
2 [C15H13N2S]þ 253.0794 253.0793 3.13 0.57 0.008
3 [C13H8NS]þ 210.0372 210.0370 2.60 0.55 0.019
M1 C17H17N3S 296.1216 10.95 1 [C17H15N2S]þ 279.0950 279.0947 1.79 0.77 0.009
2 [C15H13N2S]þ 253.0794 253.0783 2.31 0.56 0.012
3 [C13H8NS]þ 210.0372 210.0369 2.05 0.47 0.027
M2 C19H21N3OS 340.1478 11.07 1 [C17H15N2S]þ 279.0950 279.0945 2.76 0.50 0.008
2 [C15H13N2S]þ 253.0794 253.0790 2.22 0.58 0.007
3 [C13H8NS]þ 210.0372 210.0369 2.22 0.43 0.024
M3 peak 1 C21H25N3O3S 400.1689 8.68 1 [C21H26N3O2]þ 352.2020 352.2015 2.21 0.78 0.009
2 [C15H13N2OS]þ 269.0743 269.0738 2.29 0.62 0.005
3 [C17H18N3]þ 264.1495 264.1491 2.45 0.68 0.007
4 [C15H13N2]þ 221.1073 221.1071 2.18 0.48 0.006
M3 peak 2 8.87 1 [C21H26N3O2]þ 352.2020 352.2013 3.12 1.11 0.007
2 [C15H13N2OS]þ 269.0743 269.0739 2.45 0.66 0.004
3 [C17H18N3]þ 264.1495 264.1486 3.70 0.97 0.029
4 [C15H13N2]þ 221.1073 221.1071 2.28 0.51 0.004
M4 C21H25N3O3S 400.1689 6.73 1 [C17H15N2OS]þ 295.0900 295.0894 1.97 0.58 0.007
2 [C15H13N2OS]þ 269.0743 269.0738 1.90 0.51 0.008
3 [C8H16NO2]þ 158.1176 158.1167 3.86 0.62 0.035
M5 C21H23N3O3S 398.1533 11.80 1 [C17H18N3S]þ 296.1216 296.1211 3.06 0.91 0.019
2 [C17H15N2S]þ 279.0950 279.0946 2.76 0.77 0.007
3 [C15H13N2]þ 253.0794 253.0790 2.31 0.58 0.003
M6 C17H17N3OS 312.1165 4.64 1 [C15H13N2OS]þ 269.0743 269.0739 1.72 0.47 0.005
2 [C13H8NOS]þ 226.0321 226.0319 1.39 0.32 0.004
M7 peak 1 C17H17N3OS 312.1165 8.42 1 [C17H18N3]þ 264.1495 264.1492 2.29 0.61 0.008
2 [C15H13N2]þ 221.1073 221.1072 2.21 0.48 0.006
3 [C13H11N2]þ 195.0917 195.0911 3.34 0.65 0.004
M7 peak 2 8.60 1 [C17H18N3]þ 264.1495 264.1492 2.29 0.61 0.008
2 [C15H13N2]þ 221.1073 221.1071 1.93 0.43 0.006
3 [C13H11N2]þ 195.0917 195.0911 3.21 0.63 0.005
M8 C19H21N3O2S 356.1427 5.88 1 [C17H18N3O2S]þ 328.1114 328.1110 1.83 0.60 0.006
2 [C15H13N2OS]þ 269.0743 269.0741 1.71 0.46 0.005
M9 peak 1 C19H21N3O2S 356.1427 8.40 1 [C19H22N3O]þ 308.1757 308.1751 2.27 0.70 0.006
2 [C17H18N3]þ 264.1495 264.1492 2.35 0.62 0.007
3 [C13H11N2]þ 195.0917 195.0910 3.31 0.65 0.004
M9 peak 2 8.61 1 [C19H22N3O]þ 308.1757 308.1751 2.40 0.74 0.007
2 [C17H18N3]þ 264.1495 264.1491 2.34 0.61 0.008
3 [C13H11N2]þ 195.0917 195.0911 3.18 0.62 0.005
M10 C19H19N3O2S 354.1271 7.76 No identiﬁed fragments
M11 peak 1 C21H2N3O4S 414.1482 9.31 1 [C21H24N3O3]þ 366.1812 366.1810 2.07 0.75 0.023
2 [C15H13N2OS]þ 269.0743 269.0734 3.26 0.88 0.005
3 [C15H13N2]þ 221.1073 221.1069 2.23 0.49 0.003
M11 peak 2 9.49 1 [C21H24N3O3]þ 366.1812 366.1812 2.09 0.77 0.026
2 [C15H13N2OS]þ 269.0743 269.0738 2.21 0.59 0.006
3 [C15H13N2]þ 221.1073 221.1069 2.57 0.57 0.010
M12 peak 1 C21H25N3O4S 416.1639 6.03 1 [C21H26N3O3]þ 368.1969 368.1969 1.08 0.40 0.005
2 [C15H13N2O2S]þ 285.0692 285.0688 1.82 0.52 0.015
M12 peak 2 6.50 1 [C21H26N3O3]þ 368.1969 368.1969 1.28 0.47 0.004
2 [C15H13N2O2S]þ 285.0692 285.0693 1.89 0.54 0.034
M13 C17H17N3O2S 328.1114 5.17 1 [C17H18N3O]þ 280.1444 280.1438 2.24 0.63 0.008
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blank reference urine samples are not available in post-
mortem investigation. A pooled pseudo-reference was used
instead, resulting in a chromatogram that did not differmuch
from the sample chromatogram. This resulted in complicated
lists of unexpectedmetabolites, thus falling outside the scope
of this study. However, most of the metabolites predicted by
Meteor and the additional hydroxy metabolites (see above)
were detected by MetaboliteDetect. The software provided
information on retention time, mass accuracy, and isotopic
pattern match (SigmaFit) automatically. The use of the
pooled pseudo-reference sample was necessary for produ-
cing the chromatographic andmass spectral information on a
routine basis. In general, the EICs obtained were unambigu-
ous. As hydroxy and sulfoxy metabolites have identical
molecular formulae, they could not be differentiated by
accurate mass. Based on earlier experience with the
chromatographic behaviour of metabolites, we hypothesised
that the early eluting peak was the hydroxy metabolite. In
addition, all of the sulfoxy metabolites gave a double peak,
most likely due to sulfoxide stereochemistry.
Finding the most suitable settings in MetaboliteDetect for
optimal results was laborious, and even then some of the
metabolites readily detected by manual inspection were
missed by the program (Table 1). This was due to the ﬁxed
nature of some of the parameters, in particular, the Mass
Spectrum Intensity Threshold of the Detect Masses parameter.
This threshold could only be selected as a relative value as a
percentage of the base peak. In such instances, where a lot of
compounds are co-eluting, even a relatively abundant ion
could be rejected due to the relative cut-off. For instance, in
the case of the O-dealkyl quetiapine sulfoxide (M9)
metabolite, the N-dealkyl quetiapine sulfoxide (M7) co-
eluted. The abundance of the N-dealkyl metabolite ions was
always much higher, and consequently the relatively
abundant O-dealkyl metabolite ions were not detected,
because their abundanceswere lower than 30% of the former.
This could have been ﬁxed by lowering the value to 5–10%,
but doing so resulted in very long and complex results lists;
hence the selected 30% was a compromise between
detectability and ease of interpretation. An option to select
between absolute and relative threshold values would be a
desirable addition to the software.
The detection capability of MetaboliteDetect varied from
40% to 100% in the ten urine samples, being better than 70%
in 13 of the 18 metabolite peaks detected. Therefore,
MetaboliteDetect worked well as a coarse search tool for
Figure 2. Mass spectra of the two quetiapine metabolites having identical molecular formula. The upper spectrum shows the
characteristic fragment ions for the sulfoxide metabolite, corresponding to theoretical masses 352.2020, 264.1495 and
221.1073. The protonated molecule is circled.
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ﬁnding metabolites, but it cannot replace manual inspection
if more detailed information is required. Hakala and co-
workers had similar experience with Waters Metabolynx
software.21
Identiﬁcation of metabolites by accurate mass
and prediction of fragmentation by ACD/MS
Fragmenter software
The approach of substance identiﬁcation by accurate mass
measurement methods combined with isotopic pattern
matching has been discussed earlier.8 Table 1 shows that
the previously established identiﬁcation criteria, based on
reproducible retention time ( 0.2min), mass accuracy below
5ppm, and isotopic pattern match (SigmaFit) below 0.03,
were clearly achieved in this study. The mean standard
deviation of retention time was 0.03min, the mean mass
accuracy was 1.68 ppm (0.62mDa), and the mean SigmaFit
value was 0.012.
The fragmentation pattern produced by ACD/MS Frag-
menter, typically containing 150–200 suggested fragments,
may be too complicated to interpret without experimental
data. However, when the fragments generated in the ISCID
experiment were selected from the fragment list provided by
ACD/MS Fragmenter, the program generated concise
information on the following: routes to the speciﬁc fragment,
molecular structure and accurate mass of the protonated
species, and information on neutral loss. The fragments
detected and their suggestedmolecular formulae are listed in
Table 2. Mean mass accuracy and SigmaFit values for the
fragments were 2.40 ppm (0.62mDa) and 0.010, respectively.
The fragment structures provided by ACD/MS Fragmenter
conﬁrmed the metabolites predicted by Meteor. Overall,
ACD/MS Fragmenter was found to be an easy-to-use tool for
solving fragmentation patterns of quetiapine metabolites.
Metabolites M7 and M9 produced a mixed spectrum due
to co-elution. These compounds were sulfoxy metabolites
with two fragments in common, representing the cleavage of
the sulfoxy (M7, M9) and N-alkyl group (M9) (m/z 264.1495)
and further N-dealkylation (m/z 195.0917). This did not
interfere with identiﬁcation, as the molecular formulae of the
precursor ions were different, but no conclusions could be
made about the intensities of the fragments. Furthermore, ion
m/z 195.0917 was not predicted by ACD/MS Fragmenter for
M7, and therefore the source of the ion could not be
conﬁrmed. This example illustrates the limitations of the
instrument, as only ISCID data were available, and tandem
mass spectrometric (MS/MS) capabilities would be prefer-
able for ideal interpretation of the data.
ACD/MS Fragmenter was found to be advantageous in
differentiating compounds with identical molecular formulae.
For the ions m/z 312.1165, 356.1427, and 400.1689, EICs with
three separate peaks were obtained, representing the
hydroxy/sulfoxy metabolites of quetiapine and their N-
and O-dealkylated forms (metabolites M3, M4, M6, M7, M8,
andM9, Fig. 1). The structural elucidation procedures for M3
and M4 are described in detail in the following. The average
retention times (RT) obtained form/z 400.1689were 6.73, 8.68,
and 8.87min (Table 1). The two later eluting peaks had
identical fragmentation, suggesting an identical structure
(sulfoxy stereochemistry). The peak at RT 6.73min had a
distinctly different fragmentation pattern, as shown in Fig. 2.
Analysed by ACD/MS Fragmenter, the fragments were
readily identiﬁed and connected to speciﬁc structures, as
shown in Fig. 3. Ion m/z 352.2020 resulted from cleavage of a
sulfoxy group referring unambiguously to M3. Ion m/z
264.1495 resulted from cleavage of sulfoxy and N-dealkyl
groups of M3. The fragments detected with the hydroxy
metabolite were also possible for the sulfoxy metabolite, but
they were of low abundance, as the sulfoxy cleavage
appeared to dominate the fragmentation. No explicit
conclusions about the site of hydroxylation could be made,
except that it occurred at the tricyclic part of the molecule.
According to the literature, hydroxylation of quetiapine
takes place at position 7 of the aromatic ring (Fig. 3).14 Hence,
the peak with RT 6.73min was assigned asM4, and the peaks
with RTs 8.68 and 8.87min as stereoisomers of M3. The
fragmentation schemes of all identiﬁed compounds are
available as Supporting Information in the online version of
this article.
The presence of sulfone metabolites could be excluded, as
both of the metabolites M12 and M13, predicted as sulfones
by Meteor, had the characteristic fragment from sulfoxy
cleavage. For most of the compounds, at least two
characteristic fragments were observed repeatedly. For
M10 no characteristic fragments could be found, as the peak
was a minor one. For M13 only one fragment, resulting from
sulfoxy cleavage, could be assigned. Two distinct fragments
Figure 3. The fragmentation schemes of sulfoxy and hydroxy
metabolites of quetiapine (M3 and M4 in the text and Tables 1
and 2) provided by the ACD/MS Fragmenter software.
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detected in experimental data for M3, M7 and M11 were not
predicted by ACD/MS Fragmenter. These were combi-
nations of sulfoxy and alkyl cleavages (ionsm/z 221.1073 and
195.0917). The ions were abundant and the cleavages were
logical, and they were thus evaluated as possible (see Figs. 2
and 3). Figure 4 shows a representative total ion chromato-
gram and a set of EICs with all 13 metabolites identiﬁed.
Accurate mass-based screening by LC/TOFMS
in analytical toxicology
In analytical toxicology, there is a trend underway to move
from triple quadrupole mass spectrometry towards accurate
mass alternatives.22 In addition to our own contributions,
several other monitoring methods based on LC/TOFMS
have been recently published.23–25 In an interesting exper-
imental approach, a very large target database (a subset of
the PubChem Compound database containing approxi-
mately 50 500 compounds) was tested, but this application
is still far from being routine.26 Some authors applied CID or
ISCID fragmentation to screen for pesticides3 and drugs,11
using corresponding target databases supplemented with
fragment ions. These studies utilised reference standards to
establish the fragment ions, but did not concentrate on
structural elucidation of unknown compounds.
Within drug discovery, metabolic predictions are now an
essential part of research.27 Very recently, Tiller et al.,28
Figure 4. The total ion chromatogram of an autopsy urine sample containing quetiapine (upper), and the set of extracted ion
chromatograms showing the 13 detected and identiﬁed metabolites (lower).
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utilising MetaboLynx software for predicting metabolism,
highlighted the role of current accurate mass MS/MS
technology as a ‘ﬁrst-line’ high-throughput technique for
the detection and characterisation of drugmetabolites. Yet, in
the ﬁeld of analytical toxicology, prediction software has
been unexplored as of to date. Our present study is
pioneering in its use of in silico tools together with accurate
mass measurement for predicting metabolism and MS
fragmentation in the context of drug screening practice.
ACD/MS Fragmenter software allowed a problem to be
solved that has been much discussed in connection with LC/
TOFMS:29 how to differentiate drugs and metabolites with
identical molecular formulae when the respective reference
standards or reference spectra are unavailable.
CONCLUSIONS
The aim of the present studywas to evaluate the feasibility of
current in silico methods in predicting, detecting and
identifying drug metabolites in the context of toxicological
urine drug screening by LC/TOFMS when the respective
reference standards are unavailable. The results showed that
by applying readily available software to the antipsychotic
drug quetiapine, it was possible to assign 13 metabolites in
ten quetiapine-positive autopsy urine samples. In particular,
the differentiation of metabolites with identical molecular
formulae in ISCID experiments by ACD/MS Fragmenter
software provided a new powerful instrument for substance
identiﬁcation without reference standards. For the experi-
enced user, the whole procedure of predicting metabolites,
assigning the corresponding ions in the LC/TOFMS
acquisition data, and adding the spectral and retention time
data into the target database, is a task that only takes a few
days. Consequently, building up an extensive toxicology
database containing exact monoisotopic masses of proto-
nated molecules and veriﬁed retention times, with a
comprehensive coverage of urinary drug metabolites, is a
reasonable approach to be carried out in-house or on an
interlaboratory basis.
SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of this article.
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Differentiation of structural isomers in a target
drug database by LC/Q-TOFMS
using fragmentation prediction
Elli Tyrkko¨,∗ Anna Pelander and Ilkka Ojanpera¨
Isomers cannot be differentiated from each other solely based on accurate mass measurement of the compound. A liquid
chromatography/quadrupole time-of-ﬂight mass spectrometry (LC/Q-TOFMS) method was used to systematically fragment
a large group of different isomers. Two software programs were used to characterize in silico mass fragmentation of
compounds in order to identify characteristic fragments. The software programs employed were ACD/MS Fragmenter (ACD
Labs Toronto, Canada), which uses general fragmentation rules to generate fragments based on the structure of a compound,
andSmartFormula3D (BrukerDaltonics),whichassigns fragments fromamass spectraandcalculates themolecular formulae for
the ions using accurate mass data. From an in-house toxicology database of 874 drug substances, 48 isomer groups comprising
111 compounds, forwhich a reference standardwas available,were found. Theproduct ion spectrawereprocessedwith the two
softwareprogramsand1–3 fragmentswere identiﬁed for each compound. In 82%of the cases, the fragment couldbe identiﬁed
with both software programs. Only 10 isomer pairs could not be differentiated fromeach other based on their fragments. These
compounds were either diastereomers or position isomers undergoing identical fragmentation. Accurate mass data could be
utilized with both software programs for structural elucidation of the fragments. Mean mass accuracy and isotopic pattern
match values (SigmaFit; BrukerDaltonics Bremen,Germany)were 0.9mDaand24.6mSigma, respectively. The study introduces
a practical approach for preliminary compound identiﬁcation in a large target database by LC/Q-TOFMS without necessarily
possessing reference standards. Copyright c© 2010 John Wiley & Sons, Ltd.
Keywords: structural isomers; drug; liquid chromatography/quadrupole time-of-ﬂight mass spectrometry (LC/Q-TOFMS); mass
fragmentation in silico; accurate mass
Introduction
Analytical techniques exploiting accurate mass measurement
have become common in the pharmaceutical industry and drug
metabolism studies,[1] as well as in analytical toxicology[2] and
doping analysis[3] using large target databases. Current liq-
uid chromatograpy/time-of-ﬂight mass spectrometry (LC/TOFMS)
instruments are fast, sensitive, and cost-effective in routine lab-
oratory analysis.[4] They provide mass accuracy comparable to
more expensive instruments together with moderately high mass
resolution, which facilitates the determination of the elemental
composition of small molecules.
An analytical challengewith accurate mass-based identiﬁcation
is the differentiation of isomers from each other, as these
compounds cannot be differentiated solely based on accurate
mass data, although in most cases they can be separated by
means of LC. Further structural information can be produced with
MS techniques by fragmenting the molecule and identifying the
compound characteristic fragments.[5] Several large libraries of
electron ionization (EI) reference mass spectra are available for
use with gas chromatography-mass spectrometry (GC-MS),[6–8]
which makes tentative identiﬁcation of library compounds fast
and convenient. Interpretation of the mass spectra acquired from
electrospray ionization (ESI) LC/MS is more challenging, since
less fragmentation occurs, and thus less structural information is
achieved compared to EI with GC/MS.[9] ESI-MS fragment spectra
tend to vary in ion intensities with different instruments,[5,9] and
although reference mass spectral libraries for ESI-MS exist, it is
not straightforward to exploit the data between different mass
analyzers and laboratories without careful standardization of the
conditions for compound identiﬁcation.[10,11]
Both commercially available and in-house built software has
been developed to predict in silico mass spectral fragmentation in
MS analyses. In some programs, such as ACD/MS Fragmenter[12,13]
or Mass Frontier,[14,15] the fragment prediction is mainly based
on general rules of fragmentation reactions. Non-commercial soft-
ware that simulates fragmentationand formsa reconstructedmass
spectrum based on fragmentation rules includes MASSIS[16] and
MASSIMO.[17] The following two software programs for fragment
prediction do not rely on the general rules of mass fragmentation,
but take into account optimal bond energies in order to predict
the most stable fragments and estimate by a validated algorithm
the probability of the predicted fragment. Fragment iDentiﬁcator
(FiD)[18] uses scoring functions to rank competing fragmentation
pathways of a molecule that can explain the mass peaks observed
in the product ion (MS/MS) spectrum. The algorithm calculates
the dissociation energies of the cleaved bonds and estimates
the energetic favorability of the alternative fragments. Another
recently published algorithm, Density Functional Theory (DFT),[19]
calculates the thermodynamically most stable position for the
∗ Correspondence to: Elli Tyrkko¨, Department of Forensic Medicine, PO Box 40,
FI-00014 University of Helsinki, Finland. E-mail: elli.tyrkko@helsinki.ﬁ
Department of Forensic Medicine, PO Box 40, FI-00014 University of Helsinki,
Finland
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protonation in a molecule. This information can be utilized in the
prediction of the cleavage site of the molecule.
Mass fragmentation prediction with ACD/MS Fragmenter
was successfully used in our previous study[20] for quetiapine
metabolism and differentiation of the structurally isomeric
metabolites. In that study, in-source collision-induced dissociation
(ISCID) with LC/TOFMS was used to produce the fragments,
and structural elucidation of the metabolites was done without
reference standards. In ISCID analysis, sample background or
other co-eluting analytes can interfere with the identiﬁcation
of compound characteristic ions. In the present study, a hybrid
quadrupole TOFMS instrument (Q-TOFMS) is used for systematic,
reference-standard-based analysis of a large number of different
isomeric drugs with the purpose of producing compound
characteristic fragments and differentiating the isomers from
each other. Two software programs are used to specify mass
fragmentation of the compounds in silico: one predicting
the possible fragments based on the molecular structure of
the compound (ACD/MS Fragmenter), and another assigning
fragments from mass spectra acquired by MS/MS analysis and
calculating the molecular formulae for the ions based on accurate
mass measurement (SmartFormula3D).
Experimental Section
Materials
All solvents and reagents were of analytical grade from Merck
(Darmstadt, Germany), except the HPLC-grade methanol, which
was purchased from Rathburn (Walkerburn, UK). Water was
puriﬁed with a Millipore DirectQ-3 instrument (Bedford, MA, USA).
The selected 111 standards were from several different suppliers.
Sample preparation
Isomeric compounds were searched from an LC/TOFMS in-house
toxicology database of 874 substances, for which 462 reference
standards were at hand, and 111 compounds were found from
these standards. The compounds constituted 48 isomer groups
with 2–4 compounds each, with m/z ranging from 150.1277 to
387.1559. Sixteen reference standard mixtures were prepared,
containing 6–7 of the selected compounds of 1 μg/mL in 0.1%
formic acid and methanol (9 : 1). Compounds in the same mixture
were known to separate chromatographically.
Liquid chromatography/quadrupole time-of-ﬂight mass
spectrometry
The liquid chromatograph was an Agilent 1200 series instrument
(Waldbronn,Germany) includingavacuumdegasser, autosampler,
binary pump, and column oven. Chromatographic separation was
performed in gradient mode at 40 ◦C with Phenomenex Luna
PFP(2) 100 × 2 mm (3 μm) column and a PFP 4 × 2.0 mm pre-
column (Torrance, CA, USA). Mobile phase components were
2 mM ammonium acetate in 0.1% formic acid and methanol and
the ﬂow rate was 0.3 mL/min. The proportion of methanol was
increased from 10% to 40% over 5 min, to 75% at 13.50 min, to
80% at 16 min and held at 80% for 4 min. The post-timewas 8 min,
comprising a total run timeof 28 min per sample, and the injection
volume was 10 μL.
The mass analyzer was a Bruker Daltonics micrOTOF-Q mass
spectrometer (Bremen, Germany)with an orthogonal electrospray
ionization source and a six-port divert valve. The instrument was
operated in positive ion mode with m/z range of 50–800. The
nominal resolution of the instrument was 10 000 (FWHM). The
nebulizer gas pressure was 1.6 bar and the drying gas ﬂow
8.0 L/min. The drying temperature was 200 ◦C. The capillary
voltage of the ion source was set at 4500 V and the end
plate offset at −500 V. The quadrupole collision energy in MS
mode was 6.0 eV and the collision cell radio-frequency 100.0
Vpp. The quadrupole transfer time was 60.0 μs and pre-pulse
storage time 8.0 μs. The spectra rolling average was set at 2
and spectra time 0.6 s. Instrument calibration was performed
externally with sodium formate solution, consisting of 10 mM
sodium hydroxide in isopropanol and 0.2% formic acid (1 : 1, v/v).
Ten sodium formate cluster ions, (Na(NaCOOH)1–10) m/z values
between 90.9766 and 702.8635, were selected for calibrating the
instrument. Post-run internal mass scale calibration of individual
sampleswas performedby injecting the calibrant at the beginning
and at the end of each sample run. The calibrator ions in
the post-run internal mass scale calibration were the same,
excluding the ion m/z 702.8635, as used in the instrument
calibration.
Mass fragmentation was performed in AutoMS(n) mode. When
the intensityof thepeak crosses the threshold level, the instrument
measures every other spectrum in MS/MS mode and the alternate
spectrum in MS mode. If several ions overlap, the instrument
changes the ion for fragmentation after ﬁve spectra (3 s). The
collision energy varies depending on the mass of the ion: light
molecules are fragmented with less collision energy than heavier
ones. Three different AutoMS(n) methods were created: general,
high-collision energy and low-collision energy. In the general
method, the collision energy for ions between 100 and 600
m/z varied linearly from 17 to 48 eV; in high-collision energy,
from 22 to 56 eV; and in low-collision energy, from 12 to 36 eV.
The absolute intensity threshold level in AutoMS(n) analysis was
set at 30 000 cnts. All 16 mixtures were analyzed by the three
methods to ﬁnd out the optimal fragmentation energy for each
compound.
Software
DataAnalysis 4.0 software by Bruker Daltonics (Bremen, Germany)
was used for post-run internal mass spectrum calibration and
further processing of the data acquired in the analyses. An
automatic compoundﬁnding functionofDataAnalysis,AutoMS(n),
was used for fast identiﬁcation of the compounds in the total ion
current (TIC) chromatograms. Parameters for AutoMS(n) were
determined: the intensity threshold was set at 2500 cnts and the
maximum number of compounds to be identiﬁed was 250.
A mass spectra processing tool of DataAnalysis, SmartFor-
mula3D, was used for calculating molecular formulae for possible
fragments and precursor ions based on their accurate masses
and isotope distribution matches, mSigma values. The elements
included in the calculations were C, H, N, O, Cl and S. SigmaFit
algorithm provides a numerical comparison of theoretical and
measured isotopic patterns and can be utilized as an identiﬁcation
tool in addition to accuratemass determination. The calculation of
SigmaFit value includes generation of the theoretical isotope pat-
tern for the assumed protonated molecule,[21] and calculation of a
match factor based on the deviations of the signal intensities.[22]
The lower themSigma value, the better the isotopicmatch. Smart-
Formula3D includesanalgorithmthatestimateswhethera formula
for a product ion is a subset of a formula for the precursor ion. It
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Figure 1. Mass spectra and fragmentation schemes of MDMA and BDB ([M+H]+ = 194.1176, C11H15NO2). Results of SmartFormula3D identiﬁcation are
presented in tables automatically formed by the software. The identiﬁed characteristic fragments, corresponding to theoretical masses of m/z 163.0754,
135.0441 and 133.0648 forMDMA; andm/z 177.0910, 147.0804 and 135.0441 for BDB, are circled in the spectra. Possible structures for fragments provided
by ACD/MS Fragmenter and SmartFormula3D are represented with arrows.
calculates a formula for theneutral or radical loss anddetermines if
it ﬁts with the observedmass difference for precursor and product
ions. Product ions that cannot be related to the precursor ion are
omitted; conversely, precursor ions that cannot be composed of
any of the product ions are excluded. The precursor and product
ion spectra of each compoundwere processedwith the SmartFor-
mula3Dprogram. Themass tolerance for the precursor ionwas set
at 4 mDa and the isotopic pattern match value at 50 mSigma, and
for product ions, 5 mDa and 100 mSigma, respectively. Electron
conﬁguration was set even for precursor ions and both even and
odd for product ions. SmartFormula3D gives the sum formula,
mass error, isotopic pattern match and electron conﬁguration of
the precursor and product ions in a chart (Figure 1), which can
automatically be transferred to a spreadsheet.
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ACD/MS Fragmenter 11.01 from Advanced Chemistry Develop-
ment (Toronto, Canada) is a rule-based fragmentation prediction
software. The program generates a fragmentation scheme for
the drawn molecular structure using fragmentation rules of mass
spectrometry known in the literature, as well as the selected ion-
ization mode and the number of fragmentation steps. ACD/MS
Fragmenter predicts both even and odd electron fragments, and
forms a tree-model of all the possible fragments. The software
provides information about the routes of fragmentation and all
possible structures for a speciﬁc mass as well as the exact masses
of the fragments. Experimental spectra of each compound were
compared to the predicted fragment schemes, and the detected
fragments were selected from the tree. The program parame-
ters used in this study were API positive mode ionization, and
the number of fragmentation steps was ﬁve. The fragmenta-
tion reactions were selected to include hetero and homolytic
cleavage, neutral losses and hydrogen rearrangements. Other
parameters of ACD/MS Fragmenter were left at their default
values.
Results and Discussion
The results of SmartFormula3D and ACD/MS Fragmenter for
each compound were compared and compound characteristic
fragments were identiﬁed based on the information achieved
from the programs. The most abundant and isomer speciﬁc
fragment ions in a mass spectrum were selected for each parent
compound. Table 1 shows all of the 111 compounds studied,
belonging to 48 isomer groups, and the fragmentation data.
For each compound, 1–3 fragments were identiﬁed, adding
up to 305 fragments. In 80% of the cases the total number
of identiﬁed fragments was three. For six compounds, only
one fragment could be identiﬁed, due to poor fragmentation
(e.g. ropivacaine and metolazone) or because neither of the
programs predicted the observed fragments (e.g. chlorcyclizine).
Ten isomer pairs could not be differentiated from each other
based on fragmentation; however, eight of these pairs could
be differentiated with proper chromatographic separation. The
compounds, which had similar fragmentation, were either
diastereomers (e.g. ephedrine and pseudoephedrine, [M+H]+ =
166.1226; Table 1, isomer group 2), or position isomers (e.g. 2C-
T-4 and 2C-T-7, [M+H]+ = 256.1366; Table 1, isomer group 21),
where the position of the fragmenting side chain or substituent
did not affect the fragments formed in the MSn analysis. The
differences in spectra intensities were not used as an identiﬁcation
parameter in this research, because neither of the software
predicted the ion abundances. Two isomer pairs, protriptyline
and nortriptyline ([M+H]+ = 264.1747; Table 1, isomer group
23), as well as cis-3-methylfentanyl and trans-3-methylfentanyl
([M+H]+ = 351.2431; Table 1, isomer group 46), could be
differentiated from each other neither by chromatography nor
by their fragmentation.
From the 305 identiﬁed fragments, ACD/MS Fragmenter
predicted 89% and SmartFormula3D 93%, while in 82% of cases
the identiﬁed fragmentwas predicted by both programs. Only 7%
of the fragments were identiﬁed solely by ACD/MS Fragmenter
and 11% by SmartFormula3D. Of the identiﬁed fragments, 89%
were formed by even electron neutral losses and 11% by odd
electron radical losses. The structure of the identiﬁed fragment
could not be determined based on SmartFormula3D results alone,
because the program does not give structural information, only
the sum formula. The validity of the fragment identiﬁcation based
on SmartFormula3D evaluation was ensured with mass accuracy
and isotopic pattern match. The reason why ACD/MS Fragmenter
and SmartFormula3D did not predict the same fragments in
all cases remained unclear. The aim of this study was not to
identify all fragments formed in the analysis, but to ﬁnd the
characteristic fragments in order to differentiate isomers from
each other.
Both programs exploit accurate mass data in their prediction,
which was the key feature in the identiﬁcation of the compound
characteristic fragments. The mean mass accuracy was 0.9 mDa
and themean SigmaFit value 24.6, as calculated from the absolute
values of theprecursor and fragment ions. Several research articles
about the relationshipbetweenmass accuracy and ion abundance
with Q-TOFMS instrument have been published.[23,24] Both mass
accuracy and isotopic pattern match values are dependent on
the ion abundance and show reduced match values when ion
abundance is very low (<1000) or high (>1 × 106). The same
feature was seen in the present study and was taken into
account when identifying precursor ions and fragments with
SmartFormula3D. In some occasions the identiﬁcation parameters
had to be extended as high as 250 mSigma (ketobemidone,
hydrocodone and milnacipran) to enable the identiﬁcation of the
parent compound or an obvious fragment structure predicted by
the ACD/MS Fragmenter. A poor SigmaFit value of fragments did
not always arise from high or low ion abundance. An extensively
fragmenting molecule can have fragments differing only 2 Da
from each other, resulting in the overlap of the isotopes, which
may cause errors in isotopic pattern match measurement. That
is why a good mass accuracy could be achieved, although the
SigmaFit value did not fulﬁll the identiﬁcation criteria (Table 1),
and thus SigmaFit values higher than 200 were left out of the
calculations.
Differentiation of isomers is presented here in detail by
three examples of different isomer groups: MDMA and BDB;
histapyrrodine, imipramine andnortrimipramine; and cocaine and
scopolamine (Figures 1–3).
Methylenedioxymethamphetamine (MDMA, Ecstacy) and 1,3-
benzodioxolylbutanamine (BDB), sharing a molecular formula of
C11H15NO2 and [M+H]+ 194.1176, are structurally very similar
compounds (Figure 1, isomer group 8 in Table 1). The only
difference in their structure is the position of one methyl
group. MDMA and BDB are chromatographically well-separated
(Rt 7.18 min and 8.38 min, respectively), and their individual
mass spectra are visually dissimilar. Both molecules undergo
fragmentation of the amine group, which leads to fragments
m/z 163.0754 for MDMA ([M+H]+ - CH5N) and m/z 177.0910 for
BDB ([M+H]+ - H3N). The fragments m/z 133.0648 for MDMA
and m/z 147.0804 for BDB are formed as a summation of the
cleavage of amino group and the breakage of themethylenedioxy
ring. MDMA and BDB share one common fragment, m/z 135.0441,
which forms in the cleavage of the aliphatic side chain ([M+H]+
- C3H9N). SmartFormula3D did not identify the ion m/z 135.0441
with the selected software parameters to be cleaved from MDMA,
although the mass accuracy and isotopic pattern match were
within the identiﬁcation criteria (Figure 1, Table 1) for that ion. The
fragmentation reaction, from which the fragment m/z 135.0441
would be formed, is in congruence with the reactions of other
compounds with similar structure, e.g. BDB, MDDMA, MDEA and
MBDB, for which SmartFormula3D identiﬁed the fragment m/z
135.0441 correctly. All other fragments were predicted by both
software programs and they were even electron neutral losses.
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Histapyrrodine, imipramine andnortrimipramine share amolec-
ular formula of C19H24N2 and [M+H]+ 281.2012 (Figure 2, isomer
group 32 in Table 1). Imipramine and nortrimipramine are struc-
tural isomerswith the same tricyclicmolecule skeleton.Histapyrro-
dine is structurally different from these two compounds. All three
compounds were chromatographically separated, and the re-
tention times were 12.81 min for histapyrrodine, 13.99 min for
imipramine, and 14.48 min for nortrimipramine. The mass spec-
trum of histapyrrodine was obviously different from the spectra of
imipramine and nortrimipramine, which for their part were visu-
ally quite similar. The fragment m/z 210.1277 of histapyrrodine is
formed by the pyrrolidine ring fragmentation ([M+H]+ - C4H9N),
the fragmentm/z 132.0808 is formed after the benzene ring cleav-
age from the former ([M+H]+ - C10H15N), and the fragment m/z
98.0964 is a methylaminobenzene residue (C6H12N). All the frag-
ments detected for histapyrrodine were compound characteristic,
so its differentiation from the other two structural isomers was
undisputable. Imipramine and nortrimipramine could be differen-
tiated from each other based on the fragment ions m/z 236.1434
of imipramine and m/z 250.1590 of nortrimipramine, which are
formed in the cleavage of the amino group. The fragment ionsm/z
208.1125, m/z 196.1121 and m/z 86.0964 are detected for both
compounds; however, the ion m/z 196.1121 of imipramine is very
low in intensity. The three fragment ions identiﬁed for imipramine
and nortrimipramine were all built up in the fragmentation of
the alkyl side chain. The identiﬁed fragments of histapyrrodine,
imipramineandnortrimipraminewereevenelectronneutral losses
and were predicted by both ACD/MS Fragmenter and SmartFor-
mula3D, except fragmentm/z 250.1590 of nortrimipramine, which
was only predicted by ACD/MS Fragmenter. The fragmentation
reaction, which builds up the fragment m/z 250.1590, is logical
and consistent with the known reactions for amines. The mass
accuracy and isotopic pattern match for the ion were −0.2 mDa
and 3.4 mSigma, respectively, and thus fulﬁll the identiﬁcation
criteria (Table 1).
Cocaine and scopolamine, which share molecular formula
C17H21NO4 and [M+H]+ 304.1543, are plant alkaloids that include
a tropane ring in their structure[18] (Figure 3, isomer group 42
in Table 1). The retention times were 9.58 min for cocaine and
6.00 min for scopolamine. The MSn spectra of cocaine and
scopolamine are compound characteristic and can easily be
differentiated from each other. The three fragments identiﬁed
for cocaine and scopolamine are formed in the fragmentation of
the ester bonds, or the carbon atom next to the ester bond. The
fragments identiﬁed for cocainewere m/z 182.1176,m/z 150.0913
and m/z 105.0335, which were formed by fragmentation of
C7H6O2, C8H10O3 and C10H17NO3, respectively. The characteristic
fragments of scopolamine were m/z 156.1019, m/z 138.0913
and m/z 121.0648. These fragments were formed in cleavage
of C9H8O2, C9H10NO3 and C9H13NO3, respectively. The fragments
identiﬁed for cocaine and scopolaminewere even electron neutral
losses, predicted and identiﬁed by both ACD/MS Fragmenter and
SmartFormula3D.
The number of fragments per compound predicted by ACD/MS
Fragmenter ranged from 34 to 232, and SmartFormula3D
suggested 1–4 different formulae for the precursor ions and
2–15 possible formulae as product ions relatable to the precursor
ion, respectively. The long list of possible fragments of ACD/MS
Fragmenter, with many potentially false positive predictions,
might be difﬁcult to use on its own for structural elucidation
without comparison with experimental data. Also the fact that the
software did not predict the same fragments in all cases shows
some lack of robustness. That is why care should be taken when
interpreting mass spectral data with these software programs.
However, with accurate mass data and good chromatographic
separation, the reliability of the software is superior compared to
nominal mass data.
The programs used in this study give neither exact knowledge
about thechargedistributionandthe locationof the radical sitenor
approximations of theprobability and abundanceof thepredicted
fragment. These features have given rise to criticism,[18,19] and
consequently software has been developed that take into account
the thermodynamic and stability aspects as well as the probability
rates of the predicted fragments. Identiﬁcation and structural
elucidation of all detected fragments might be crucial when
studyingdrugmetabolismwhere the structure of themetabolite is
unknown and needs to be identiﬁed based on its fragments. In the
present study, an adequate approach was to identify compound
characteristic fragments in order to differentiate the structural
isomers.
The present study was carried out using pure standards,
and the compounds in the same mixture were known to be
chromatographically separated. This arrangement does not quite
correspond to authentic samples, where isomers with retention
times close to each other can co-elute. Such a pair is for example
etilefrine and HHMA, with a retention time difference of only
0.07 min (Table 1; isomer group 7). In this case, the MS/MS
spectrum would be a combination of both of these compounds.
However, etilefrine and HHMA have compound characteristic
fragments, and hence, if fragment ions of HHMA are seen with
the fragment ions of etilefrine in the same spectrum, it can be
concluded that both compounds are in the sample.
The structural elucidation with tandem mass spectrometry has
been used, for example, in drug metabolism research,[26] analysis
of impurities in pharmaceuticals[27] and technical chemicals[28]
as well as in detection of environmental toxins.[29] Several stud-
ies concerning differentiation of structural isomers with MS/MS
techniques have been published, but these works deal with the
differentiation of two or three compounds. For instance, stud-
ies have been published about differentiation of MDEA and
MBDB;methamphetamine and phentermine;[30] hydromorphone,
morphine and norcodeine;[31] clobazam and temazepam;[32]
as well as metolazone and indapamide.[33] Tramadol and
O-desmethyl venlafaxin sharing amolecular formula of C16H25NO2
and [M+H]+ 264.1958, have been reported to undergo similar
fragmentation,[34] yielding only a single fragment of m/z 58. In our
study, tramadol and O-desmethyl venlafaxine were differentiated
based on O-desmethyl venlafaxine’s characteristic fragment, m/z
133.0648. Similar results have been reported about isomers that
couldnotbedistinguishedbasedon their fragments, including the
compounds studied in the present work (MDEA and MDDMA,[35]
and ephedrine and pseudoephedrine[36]).
To date, software for in silico fragment prediction has mostly
been used for structural elucidation of drug metabolites[15,37,38]
where the compound structures are unknown or just approxi-
mated and the identiﬁcation and structural determination of all
observed fragments in the mass spectra is crucial. There have
been no publications on differentiation of structural isomers by
MS/MS spectra and identiﬁcation of the characteristic fragments
with fragment prediction software, except our previous study of
quetiapine.[20] The advantage of this method – combining accu-
ratemass and fragmentprediction inorder toelucidate compound
structure – over identiﬁcation by spectral library comparison lies
in the fragment structure determination it enables.
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Figure 2. Mass spectra and fragmentation schemes of histapyrrodine, imipramine and nortrimipramine ([M+H]+ = 281.2012, C19H24N2).
Conclusion
Poor accessibility of reference standards has hindered substance
identiﬁcation within drug screening, especially for new drugs,
designer drugs, and metabolites. Formula-based identiﬁcation
against a target database of exactmonoisotopicmasses is a partial
remedy, but even this approach fails with isomeric compounds.
The aim of the present study was to differentiate all isomers found
in a comprehensive target database, based on LC/Q-TOFMS prod-
uct ion spectra of the reference standards available, and to identify
thecompoundcharacteristic fragments. The results from48 isomer
groups demonstrated an indisputable advantage of the predictive
software in assigning relevant mass fragments to structural iso-
mers and in deﬁning themolecular formulae of the fragments. The
two software programs proved to be valuable for interpretation of
experimentalaccuratemassdata.However,oneshouldbeawareof
the differences in the performance of each software program and
the possibility of false positive predictions. The use of fragmenta-
tionpredictionallowsa targetdatabase tobebuilt up that contains
the exact monoisotopic masses of both precursor and the most
www.drugtestinganalysis.com Copyright c© 2010 John Wiley & Sons, Ltd. Drug Test. Analysis 2010, 2, 259–270
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Figure 3. Mass spectra and fragmentation schemes of cocaine and scopolamine ([M+H]+ = 304.1543, C17H21NO4).
characteristic fragment ions, even for those compounds for which
a reference standard cannot be readily obtained. Compound char-
acterization in a biological sample can be carried out using these
two fragment prediction software programs, as accurate mass
data enables the elucidation of fragment structures. This, in turn,
makes a rapid tentative identiﬁcation of a range of compounds
feasible in pharmaceutical, toxicology, and forensic contexts.
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a  b  s t r a  c t
A  liquid  chromatography  (LC) retention  time  prediction  software,  ACD/ChromGenius,  was employed
to  calculate  retention  times for  structural  isomers, which  cannot  be differentiated  by  accurate  mass
measurement  techniques  alone. For 486  drug  compounds  included  in an in-house database  for  urine
drug  screening  by  liquid chromatography/quadrupole  time-of-ﬂight  mass  spectrometry (LC/Q-TOFMS),
a  retention  time  knowledge  base  was created  with  the  software. ACD/ChromGenius  calculated  retention
times for  compounds  based on the  drawn  molecular  structure and  given chromatographic  parameters.
The  ability  of the  software  for  compound identiﬁcation  was evaluated  by  calculating  the  retention  order  of
the 118  isomers,  in  50 isomer  groups  of 2–5  compounds  each, included in the  database. ACD/ChromGenius
predicted  the  correct  elution order  for  68% (34)  of isomer  groups.  Of  the  16 groups  for  which  the
isomer  elution order was incorrectly  calculated,  two were  diastereomer  pairs  and  thus difﬁcult  to dis-
tinguish  using  the  software. Correlation  between  the  calculated  and  experimental  retention  times in the
knowledge  base tested was moderate,  r2 = 0.8533. The mean  and  median absolute  errors  were  1.12 min,
and  0.84 min, respectively, and  the  standard deviation was 1.04  min.  The  information  generated by
ACD/ChromGenius,  together  with  other  in silico  methods  employing  accurate  mass  data,  makes the iden-
tiﬁcation  of substances  more  reliable.  This  study  demonstrates  an approach for  tentatively  identifying
compounds  in a  large target  database  without  a need  for  primary  reference  standards.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Liquid chromatography (LC) is a separation method that is
increasingly important and widely used in  the pharmaceutical
industry as well as in doping analysis and clinical and forensic tox-
icology. LC techniques have developed and improved signiﬁcantly
during the last decade: New ultra-high performance instruments
provide efﬁciency, sensitivity, and higher resolution. Reversed-
phase LC, especially coupled with mass spectrometry (MS), is  a fast,
robust, and reliable analytical technique in  routine analysis [1–3].
A  wide variety of in silico tools are available for the analyst
to  facilitate and speed up the analytical processes and com-
pound identiﬁcation. For example, computer software may  aid
in  the study of drug metabolism [4] and toxicity [5],  in metabo-
lite  identiﬁcation [6],  in  mass fragmentation prediction [7], and in
optimization of sample preparation [8] or chromatographic sep-
aration [9].  Commercial software for chromatographic method
development, optimization, and validation [10–13] include DryLab
(Molnár-Institute for Applied Chromatography, Berlin, Germany)
∗ Corresponding author at: P.O. Box 40, FI-00014, University of Helsinki, Finland.
Tel.: +358 50 3175574; fax: +358 9  19127518.
E-mail address: elli.tyrkko@helsinki.ﬁ (E. Tyrkkö).
[14] and ChromSword (ChromSword, Riga, Latvia) [15].  The DryLab
software is  based on experimental data and simple calculations, like
the linear solvent strength model. ChromSword, a more advanced
software, combines the chemical structure of compounds with
chromatographic data. These software, however, have predicted
retention times for compounds only in  simple isocratic or linear
gradient separations with a  small number of analytes [9,10].
More extensive information about retention phenomena can
be obtained from quantitative structure–retention relationship
(QSRR) models [16–18]. The aim of these models is  to  discover the
relation  between the molecular descriptors – calculated from the
chemical structure – and retention. QSRR models describe chro-
matographic retention in single chromatographic systems. QSRR
analyses can identify the most useful structural descriptors in a
molecule, detect the molecular mechanism of retention of a  given
compound, compare the separation mechanisms of various chro-
matography columns, calculate the physicochemical properties
of  the analytes, and estimate biological activity of xenobiotics.
QSRR models have been used for predicting the retention times
of  drug compounds in order to determine their retention behaviors
[19–21]; however, for identiﬁcation purposes they have only been
applied to peptides [22–25].
Despite the advantages of QSRR models, they have not yet
become part of routine LC method development or of compound
0003-2670/$ – see  front matter ©  2012 Elsevier B.V. All rights reserved.
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identiﬁcation. A crucial challenge is  to select the most informa-
tive molecular descriptors from a large number of possibilities [16];
Dragon software (Talete, Milano, Italy) [26], for example, calculates
almost 5000 molecular descriptors. The evaluation of prediction
performance is an important and critical phase in  model valida-
tion  [18].  The use of QSRR also requires personnel conversant with
computational modeling.
The lack of reference standards for new drugs, metabo-
lites, and designer drugs forces the analyst to ﬁnd alternative
methods for tentative compound identiﬁcation. Our in-house
toxicology database for urine drug screening by liquid chromatog-
raphy/quadrupole time-of-ﬂight mass spectrometry (LC/Q-TOFMS)
includes the molecular formulae of  almost 900 substances (legal
and  illegal drug compounds and their metabolites), while retention
time data obtained by  reference standards is available for 486.
High resolution mass spectrometry (HRMS) instruments for sys-
tematic  toxicological analysis in clinical and forensic toxicology
laboratories have become more common [3,27] since accurate mass
data  enables the determination of elemental analyte composition.
Differentiation of structural isomers is  not possible by accurate
mass measurement alone, which is why good chromatographic
separation is necessary.
Here we used an in silico method to  determine the reten-
tion order of 118 isomers comprising 50 isomer groups of 2–5
compounds. We  created a retention time knowledge base of the
486  compounds included in our LC/Q-TOFMS in-house toxicol-
ogy  database with ACD/ChromGenius software (ACD/Labs, Toronto,
Canada) [28].  This software uses a self-created knowledge base of
structures and experimental retention times as a  basis to  predict,
using  built-in physicochemical prediction algorithms, retention
times  and chromatograms for new compounds. Another knowl-
edge base of 458 compounds that were analyzed under different
chromatographic conditions was created to test if the knowledge
bases  would yield similar prediction accuracies. The two knowl-
edge bases included 454 compounds in common. The aim of the
study was to evaluate the ability of the software to  predict reten-
tion  times for structural isomers as an additional tool for identifying
compounds in  LC/Q-TOFMS urine drug screening.
2.  Materials and methods
2.1. Chemicals and reagents
All the solvents and reagents were of analytical grade (Merck,
Darmstadt, Germany), except high performance liquid chro-
matography (HPLC)-grade methanol (T.J. Baker, Deventer, The
Netherlands) and acetonitrile (Rathburn, Walkerburn, UK). Water
was puriﬁed with a Millipore DirectQ-3 instrument (Bedford, MA,
USA). The standards were from several different suppliers.
2.2. Liquid chromatography/quadrupole time-of-ﬂight mass
spectrometry
The  liquid chromatograph was an Agilent 1200 series instru-
ment (Waldbronn, Germany) with a  vacuum degasser, binary
pump,  autosampler and column oven. Reference standard mixtures
(1  g mL−1 in 0.1% formic acid and methanol or acetonitrile, 9:1)
of  the compounds in  the in-house toxicology databases were ana-
lyzed by two chromatographic methods. In the ﬁrst method, a Luna
PFP(2) (pentaﬂuorophenyl) 100 mm × 2 mm (3 m) column and a
PFP  4 mm × 2 mm  pre-column (Phenomenex, Torrance, CA, USA)
were  used in gradient mode at 40 ◦C. The mobile phase components
were 2  mM  ammonium acetate in 0.1% formic acid, and methanol.
The  injection volume was 5 L, and the ﬂow rate 0.3 mL min−1.  The
proportion of methanol was increased from 10% to 40% at 5  min, to
75% at 13.50 min, to 80% at 16 min  and held 4 min  at 80%. The hold-
up  time of the PFP column was 0.75 min. The analysis time was
20  min, and the post-time 8 min. In the other method, the separa-
tion  was performed in  gradient mode at 40 ◦C with a Luna C-18(2)
100  mm × 2 mm (3 m)  column and a  4 mm × 2 mm  pre-column
(Phenomenex, Torrance, CA, USA). The mobile phase consisted of
5  mM  ammonium acetate in 0.1% formic acid and acetonitrile. The
ﬂow rate was 0.3 mL min−1,  and the injection volume was 10 L.
The amount of the organic phase was  increased from 10% to 40% at
10  min, to  75% at 13.50 min, to 80% at 16 min  and held for 5 min, for
a  total analysis time of 21 min, and the post-time was  6 min. The
C-18 column hold-up time was 0.70 min.
The mass analyzer was a Bruker Daltonics micrOTOF-Q mass
spectrometer (Bremen, Germany) with an orthogonal electrospray
ionization source. The nominal resolution of the instrument was
10,000 (FWHM). The instrument was  operated in  positive ion mode
with an m/z range of 50–800. The nebulizer gas pressure was
1.6 bar, the drying gas ﬂow 8.0 L min−1,  and the drying gas tem-
perature was 200 ◦C. The capillary voltage was 4500 V, and the
end  plate offset was set at −500 V. The quadrupole ion energy was
3.0  eV, and the collision cell radio frequency was  100.00 Vpp. The
quadrupole transfer time was 60.0 s and pre-pulse storage time
8.0  s. The spectra rate was  1.7 Hz, and the spectra rolling average
were set at 2.  External instrument calibration was performed with
sodium formate solution, comprised of 10 mM sodium hydroxide
in  isopropanol and 0.2% formic acid (1:1, v/v). The calibration was
completed with ten sodium formate cluster ions, with exact masses
between 90.9766 and 702.8635. Post-run internal mass calibration
for  each sample was  performed by injecting the calibrant at the
beginning and at the end of the run.
2.3.  Software
Post-run internal mass spectrum calibration and processing
of the sample data was  performed with DataAnalysis 4.0 soft-
ware (Bruker Daltonics, Bremen, Germany). The retention times
of  the compounds were recorded in the in-house toxicology
database. Two  retention time knowledge bases were created
from the in-house databases: PFP (including 486 compounds)
and C18 (458 compounds, respectively), by ACD/ChromGenius
12.00 software from Advanced Chemistry Development (Toronto,
Canada). The chemical structure of each compound was drawn
with  ACD/ChemSketch, and the structure was added to the knowl-
edge base with the experimental retention time (min) and peak
width at half maximum (min), as  well as the chromatographic
conditions. ACD/ChromGenius software predicted retention times
for  compounds using chemical structures and calculated physic-
ochemical properties. It  calculated the retention time for each
compound by comparing the structure to the most similar com-
pounds in  the knowledge base, which were selected by a speciﬁed
algorithm. It looked for the chemically most similar structures, and
searched for the physical properties of these structures that most
closely correlated with the retention time. A  prediction equation
for  each compound, relating retention time to physical properties,
was  generated: The calculated retention time was a sum of the most
correlated properties, for which a  speciﬁc coefﬁcient was  deter-
mined based on experimental results. The software estimated the
prediction accuracy of the knowledge base by performing a  leave-
one-out study for each compound. The software parameters used
for calculating physicochemical parameters included log D, log P,
polar surface area, molecule volume and weight, molar refractiv-
ity,  as well as the number of hydrogen donors and acceptors. The
retention time calculations for the compounds in the knowledge
base were performed using 30 of the most similar compounds
obtained by Dice coefﬁcient similarity search and linear regression.
Reversed phase mode was selected as the chromatographic system.
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Fig. 1. Correlation between experimental and calculated retention times (tR) of  (A) 486 compounds in the PFP knowledge base (r2 = 0.8533) and (B) 454 compounds in the
C18 knowledge base (r2 =  0.8497).
The parameters of ACD/ChromGenius also included the software
default values. The calculated retention times of the compounds in
the  PFP and C18 knowledge bases were compared to the true exper-
imental values. ACD/ChromGenius also calculated the retention
factor  (k) for the compounds. This would have been the param-
eter  of choice, if the method was transferred to  another column
system, however, to clarify the comparison between experimental
and calculated retention times, the absolute values were chosen for
this  study. The predicted retention order of the 118 isomers in the
PFP knowledge base was compared to experimentally determined
data.  The C18 knowledge base was employed for comparing the
prediction accuracies between the two chromatographic methods,
not  for isomer retention order determination.
3.  Results and discussion
The correlation between the calculated and experimental reten-
tion times of the 486 compounds in the PFP knowledge base
is  shown in  Fig. 1A. The prediction accuracy of the C18 knowl-
edge base of 458 compounds (Fig. 1B) was virtually equal to the
PFP  knowledge base. A statistical comparison between PFP and
C18  knowledge bases is  presented in Table 1. The C18 knowl-
edge base was created to  test if the ACD/ChromGenius software
was able to  predict retention times with equal accuracy in two
common chromatographic systems. The prediction accuracy of the
PFP  knowledge base turned out to be  slightly more precise, which
might result from the 6% (28 compounds) size difference of the
two  knowledge bases, as the prediction accuracy increases with
knowledge base size and diversity [28].
As can be observed from the distribution of retention time errors
in  the PFP knowledge base (Fig. 2), most of the compounds fall
in  a range of error of ±1.00 min. The absolute error between the
Table 1
Comparison of  the PFP and C18 knowledge bases.
PFP knowledge base C18 knowledge base
r2 0.8533 0.8497
Mean absolute errora 1.12  1.26
Median absolute errora 0.84 0.95
Standard deviationa 1.04 1.19
RMSEa,b 1.53  1.74
Minimum absolute errora 0.01 0.00
Maximum absolute errora 6.10 8.97
a Minutes.
b Root mean square error.
calculated and experimental retention time was less than 0.50 min
for  33% (162), less than 1.00 min  for 57% (279), and less than
2.00 min  for 84% (407) of compounds. The calculated retention time
value  was higher than the experimental in  48% (232 compounds);
thus,  no tendency for the predicted values being higher or lower
than the experimental retention times was  observed. The minimum
and maximum errors were −6.10 min, and 5.00 min, respectively.
Guidelines for compound identiﬁcation criteria by LC reten-
tion  time are available. The technical document for identiﬁcation
criteria  for qualitative assays in  doping analysis by the World Anti-
Doping Agency (WADA) states that the HPLC retention time of the
compound and the reference standard should not  differ by more
than 2% or ±0.1 min  in  the same analysis [29]. According to the
Society of Toxicological and Forensic Chemistry guidelines, a  toler-
ance for relative retention time repeatability of 5% is acceptable as
one  criterion for positive compound identiﬁcation [30].  Here, the
retention times calculated by ACD/ChromGenius differed by ±2%
for  17% (82), by ±5% for 35% (171) and by ±10% for 58% (280) of the
compounds in the PFP knowledge base. Since the absolute errors
between the calculated and experimental retention times were rel-
atively  large, the results of ACD/ChromGenius alone are invalid for
compound identiﬁcation.
Fig. 2. Distribution of retention time (tR) errors for 486 compounds in the PFP
knowledge base.
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The prediction accuracy was somewhat poorer for early elut-
ing  (experimental retention time, tR ≤ 9.00 min; 153 compounds),
more polar analytes, for which the average absolute retention time
error in the PFP knowledge base was 1.29 min. For substances elut-
ing  after 9.00 min  (333 compounds), the error was 1.04 min. The
error  between the experimental and calculated retention time was
large  for compounds that share very few similar physicochemi-
cal  properties with other compounds, such as hydroxychloroquine
(tR 6.10 min), minoxidil (5.00 min), amiodarone (4.83 min), and
clonidine (4.10 min). Variation in  prediction accuracy was also
observed between different drug compound categories. The aver-
age absolute error was 0.78 min  (median 0.64 min) for the 50
phenethylamines, and 0.88 min  (median 0.62 min) for the 47 tri-
and  tetracyclic central nervous system drugs, while the error was
1.01 min  (median 0.73 min) for the 45 opioids. This may  due to
the  greater variety in  chemical structure and retention behavior
between opiates and synthetic opioids. The prediction accuracy in
the  C18 knowledge base varied similarly.
Why  the software yielded such poor results for some of the com-
pounds remains unclear. Increasing the size of the knowledge base
might improve prediction accuracy as well as the precision of the
calculated retention times, since the number of structurally similar
compounds would rise. The rather complex chromatographic con-
ditions used in  this study, including non-linear gradient and PFP
column, represent a  real-life analytical separation. Our approach
of  employing a retention time prediction software for determina-
tion  of compound elution order is  novel, as commercial retention
time  prediction software are generally employed for HPLC method
development, not for compound identiﬁcation. Comparison to  pre-
vious published studies on retention time predictions [9,10,19–21]
is  disparate, since the chromatographic conditions and the diver-
sity  of the database in this study are widely different from those in
previous studies.
ACD/Labs does not provide the full algorithm for retention
time  calculation, and consequently the present evaluation of the
prediction performance of ACD/ChromGenius software relies on
examination of retention time errors. A critical study of the
algorithm and how it relates physicochemical properties to  the cal-
culated retention time would possibly help analyzing the errors in
the  individual calculated retention times. Unfortunately, commer-
cial  software, developed by non-academic communities, are rarely
transparent by their algorithms. This is why the results obtained by
these  software should be regarded with a  critical aspect.
Despite the rather large absolute errors between the exper-
imental  and calculated retention times, the ACD/ChromGenius
software proved to  be useful in predicting the compound elu-
tion order. It calculated the right isomer elution order for 68%
(34) of groups. The results of the 50 isomer groups with exper-
imental and calculated retention times, as well as the absolute
retention time errors, are presented in Table 2. Of those 16 groups
for  which the software was unable to calculate the isomer elution
order  correctly, two were diastereomer pairs: ephedrine and pseu-
doephedrine (Table 2; group 4; [M+H]+ 166.12264; C10H15NO),
as  well as quinine and quinidine (group 46; [M+H]+ 325.19105;
C20H24N2O2), which differ only in  their three-dimensional ori-
entation. Apparently, the differentiation of stereoisomers was
extremely challenging for the software. Two diastereomer pairs,
E-  and Z-10-hydroxyamitriptyline, as well as E- and Z-10-
hydroxynortriptyline, were left out of the isomer differentiation
because the ACD/ChromGenius software could not distinguish
between them.
In two groups, anabasine and nicotine (group 3;
[M+H]+ 163.12298; C10H14N2), and the 2-,  3-, and 4-
ﬂuoromethamphetamines (group 5; [M+H]+ 168.11830;
C10H14NF), the experimental retention time difference between the
isomers was less than 0.20 min, which also made the differentiation
demanding for the software. The calculated retention times for
the  three ﬂuoromethamphetamines were within 0.06 min, which
would have been inadequate for chromatographic separation of
the  isomers, although the retention order was correct.
In  six cases of the groups with a  falsely predicted retention
order,  the error did not extend to all of the isomers of the group.
For example, in group 20 ([M+H]+ 247.18049; C15H22N2O), the
retention order was  predicted correctly for 3-methylnorfentanyl,
5-MeO-MIPT and mepivacaine, but the large retention time error
of  milnacipran, 4.35 min, made the isomer group unresolved. Mil-
nacipran is structurally different from other compounds in  the PFP
knowledge base, which led to poor retention time  calculation. The
same was observed in  group 34 ([M+H]+ 278.19033; C20H23N),
where the poor prediction accuracy of EDDP, tR 2.87 min, induced
an  incorrect calculation of the retention order, though the order
was  correctly predicted for amitriptyline and maprotiline. Thirteen
of  the 50 isomer groups included one or more opioids, for which
the prediction accuracy was quite poor in  the PFP knowledge base.
The presence of a  single compound for which retention time cal-
culation is difﬁcult can obscure the exact retention order in  the
isomer group. Thus a critical perspective should be adopted when
interpreting the results and using the predicted retention times
generated by ACD/ChromGenius for compound identiﬁcation.
The retention order of the isomers was  more likely to be cor-
rectly calculated if the prediction accuracy of a  compound was
adequate. Of the nine isomer groups that included tri- and tetra-
cyclic central nervous system drugs (23, 26, 28, 30, 34,  35, 36,
41, and 50), the retention order was correctly predicted in eight
cases. The retention order was  also correct in groups where a tri-
or  tetracyclic compound was an isomer with a  structurally dif-
ferent  compound, such as mirtazapine with antazoline (group 28;
[M+H]+ 266.16517; C17H19N3), as well as in groups where two tri-
or  tetracyclic compounds form an isomer pair, e.g. chlorcyclizine
and norclomipramine (41; [M+H]+ 301.14660; C18H21N2Cl). The
incorrect order in  one group (34) was due to the poor prediction
accuracy of EDDP, as is  explained in more detail in  the previous
paragraph.
Correct prediction of the substance elution order gives valu-
able  information for the separation of isomeric compounds. New
designer  drugs are often different phenethylamine derivates [31],
which vary by substituent and substituent position. These com-
pounds are potential structural isomers to  each other, as in group
10  (Table 2): 2-CH, DMPEA, etilefrine, HHMA and HMA  ([M+H]+
182.11756; C10H15NO2). The separation of these ﬁve isomers
by  predicting the right elution order demonstrates the value of
ACD/ChromGenius software. A similar situation in  a  biological sam-
ple  would be very unlikely, but the software predictions provide
an  indication of the compound retention time compared to other
possible  substances.
In  our previous study [7] we employed a  software for mass frag-
mentation prediction in order to differentiate isomers. Two  isomer
pairs,  also included in this study, 2,5-DMA and 3,4-DMA (group
12;  [M+H]+ 196.13321; C11H17NO2) as well as 2C-T-4 and 2C-T-7
(group  24; [M+H]+ 256.13658; C13H21NO2S), could not then be sep-
arated by fragmentation prediction alone, since they had identical
fragments. In the present study, however, these isomer pairs were
successfully separated by retention order prediction. In a  situation
where an unidentiﬁed compound is  known to be a  phenethylamine
analog, retention time prediction offers signiﬁcant information.
The  retention time data generated by ACD/ChromGenius combined
with data produced by other prediction software, together with
accurate  mass data, can complete the identiﬁcation of a  substance.
It  has been shown elsewhere that HRMS enables non-targeted
screening or  screening against very large databases. To attain the
correct chemical structure, all possible structures for a determined
molecular formula are ﬁrst ﬁltered by different heuristic rules [32].
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Table 2
Molecular formulae, experimental and calculated retention times, and absolute retention time errors of 118 structural isomers in the PFP knowledge base listed by  increasing
molecular mass of  precursor ions. Isomer groups with  correctly calculated retention order are italicized.
Mass [M+H]+ Molecular formula Compound Retention time
(expa)
Retention time
(calcb)
Retention time
error (absc)
1 150.12773 C10H15N Metamphetamine 5.96 5.54  0.42
150.12773 C10H15N Phentermine 7.04 6.64  0.40
2 161.10733 C10H12N2 Anatabine 1.28 3.30 2.02
161.10733 C10H12N2 Tryptamine 5.94 6.82  0.88
3 163.12298 C10H14N2 Anabasine 1.43 3.22  1.79
163.12298 C10H14N2 Nicotine 1.25 3.90 2.65
4 166.12264 C10H15NO Ephedrined 3.37 3.58  0.21
166.12264 C10H15NO Paramethoxyamphetamine (PMA) 6.87 6.29  0.58
166.12264 C10H15NO Pseudoephedrined 3.82 3.53  0.29
5 168.11830 C10H14NF 2-Fluoromethamphetamine 6.66 5.83  0.83
168.11830 C10H14NF 3-Fluoromethamphetamine 6.85 5.80 1.05
168.11830 C10H14NF 4-Fluoromethamphetamine 7.04 5.78  1.26
6 178.12264 C11H15NO 4-Methylmethcathinone (4-MMC) 7.48 6.03 1.45
178.12264 C11H15NO Ethylcathinone 5.56 6.50 0.94
178.12264 C11H15NO Phenmetrazine 5.81 5.77  0.04
7 180.10191 C10H13NO2 3,4-Methylenedioxyamphetamine (MDA) 6.40 6.72  0.32
180.10191 C10H13NO2 Phenacetin 11.75  11.77 0.02
8 180.13829 C11H17NO Methoxyphenamine 8.19 6.73  1.46
180.13829 C11H17NO Methylephedrine 4.16 5.74  1.58
180.13829 C11H17NO Mexiletine 9.59 8.48  1.11
180.13829 C11H17NO Paramethoxymethamphetamine (PMMA) 7.39 6.83  0.56
9 181.07200 C7H8N4O2 Theobromine 5.47 6.90 1.43
181.07200 C7H8N4O2 Theophylline 7.27 7.90 0.63
10 182.11756 C10H15NO2 2,5-Dimethoxyphenethylamine (2C-H) 7.63 5.54  2.09
182.11756 C10H15NO2 3,4-Dimethoxyphenethylamine (DMPEA) 5.08 5.18  0.10
182.11756 C10H15NO2 Etilefrine 1.82 2.35  0.53
182.11756 C10H15NO2 3,4-Dihydroxymethamphetamine (HHMA) 1.87 2.91  1.04
182.11756 C10H15NO2 4-Hydroxy-3-methoxyamphetamine (HMA) 3.34 3.61  0.27
11 194.11756 C11H15NO2 4-Methoxymethcathinone (4-MeOMC) 6.89 6.21  0.68
194.11756 C11H15NO2 1,3-Benzodioxolylbutanamine (BDB) 8.18 8.76  0.58
194.11756 C11H15NO2 Methylenedioxymethamphetamine (MDMA) 6.96 6.75  0.21
12 196.13321 C11H17NO2 2,5-Dimethoxyamphetamine (2,5-DMA) 8.63 7.28  1.35
196.13321 C11H17NO2 3,4-Dimethoxyamphetamine (3,4-DMA) 6.81 6.95  0.14
196.13321 C11H17NO2 4-Hydroxy-3-methoxymethamphetamine (HMMA) 3.75 5.02 1.27
13 205.13354 C12H16N2O 5-Methoxy-˛-methyltryptamine (5-MeO-AMT) 8.38 8.01 0.37
205.13354 C12H16N2O Psilocin 5.07 6.49  1.42
14 208.13321 C12H17NO2 N-Methyl-1,3-benzodioxolylbutanamine (MBDB) 8.45 8.47  0.02
208.13321 C12H17NO2 3,4-Methylenedioxy-N,N-dimethylamphetamine (MDDMA) 7.17 7.90 0.73
208.13321 C12H17NO2 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 7.85 7.89  0.04
15 210.14886 C12H19NO2 2,5-Dimethoxy-4-ethylphenethylamine (2C-E) 11.19 10.03 1.17
210.14886 C12H19NO2 4-Methyl-2,5-dimethoxyamphetamine (DOM) 10.50  9.16  1.34
16 226.14377 C12H19NO3 3,4,5-Trimethoxyamphetamine 7.56 6.58  0.98
226.14377 C12H19NO3 Terbutaline 3.82 4.77  0.95
17 236.16451 C14H21NO2 Dinortramadol 8.91 7.82  1.09
236.16451 C14H21NO2 O-desmethylnortramadol 6.66 7.07 0.41
18 237.15975 C13H20N2O2 Procaine 4.18 8.65  4.47
237.15975 C13H20N2O2 Dropropizine 4.53 5.61  1.08
19 245.20123 C16H24N2 N,N-Dibutyltryptamine (DPT) 10.62 12.36 1.74
245.20123 C16H24N2 Xylometazoline 12.83 12.23 0.60
20 247.18049 C15H22N2O 3-Methylnorfentanyl 9.03 8.32  0.71
247.18049 C15H22N2O N-isopropyl-5-methoxy-N-methyltryptamine (5-MeO-MIPT) 9.16 9.08 0.08
247.18049 C15H22N2O Mepivacaine 7.65 7.79  0.14
247.18049 C15H22N2O Milnacipran 10.29 5.94  4.35
E. Tyrkkö et al. /  Analytica Chimica Acta 720 (2012) 142– 148 147
Table 2 (Continued)
Mass [M+H]+ Molecular formula Compound Retention time
(expa)
Retention time
(calcb)
Retention time
error (absc)
21 248.16451 C15H21NO2 Ketobemidone 7.39  8.00 0.61
248.16451 C15H21NO2 Pethidine 9.49  9.01 0.48
22 250.18016 C15H23NO2 Alprenolol 11.85 11.79 0.06
250.18016 C15H23NO2 Nortramadol 9.17  8.98 0.19
250.18016 C15H23NO2 O-desmethyltramadol 6.48  8.56 2.08
23 253.13658 C15H12N2O2 Oxcarbazepine 12.48 11.91 0.58
253.13658 C15H12N2O2 Phenytoin 13.08 13.05 0.03
24 256.13658 C13H21NO2S  4-Isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4) 11.91 11.95 0.04
256.13658 C13H21NO2S  4-Propylthio-2,5-dimethoxyphenethylamine (2C-T-7) 12.35 13.41 1.06
25 256.16959 C17H21NO Diphenhydramine 11.57 11.12 0.45
256.16959 C17H21NO Nororphenadrine 12.57 11.55 1.02
26 264.17468 C19H21N Nortriptyline 13.81  13.56 0.25
264.17468 C19H21N Protriptyline 13.67 13.22 0.45
27 264.19581 C16H25NO2 Norvenlafaxine 10.30 9.74 0.56
264.19581 C16H25NO2 O-desmethylvenlafaxine 8.00 9.34 1.34
264.19581 C16H25NO2 Tramadol 8.94  9.80 0.86
28 266.16517 C17H19N3 Antazoline 11.02 12.36 1.34
266.16517 C17H19N3 Mirtazapine 9.07 10.07 1.00
29 267.17032 C14H22N2O3 Atenolol 3.99  4.77 0.78
267.17032 C14H22N2O3 Practolol 5.53  5.64 0.11
30 267.18558 C18H22N2 Cyclizine 11.91 10.38 1.53
267.18558 C18H22N2 Desipramine 13.57 12.92 0.66
31 268.16959 C18H21NO Azacyclonol 10.54 10.46 0.08
268.16959 C18H21NO Pipradrol 9.92  10.85 0.93
32 275.21179 C17H26N2O N,N-diisopropyl-5-methoxytryptamine (5-MeO-DIPT) 10.45 10.90 0.45
275.21179 C17H26N2O Ropivacaine 9.58  10.58 1.00
33 276.15942 C16H21NO3 Homatropine 6.11  7.87 1.76
276.15942 C16H21NO3 Methylenedioxypyrovalerone (MDPV) 9.73  9.57 0.16
34 278.19033 C20H23N Amitriptyline 13.75 13.30 0.45
278.19033 C20H23N EDDP (methadone metabolite) 11.62 14.49 2.87
278.19033 C20H23N Maprotiline 13.29 12.82 0.47
35 281.20123 C19H24N2 Histapyrrodine 12.45 12.43 0.02
281.20123 C19H24N2 Imipramine 13.51 13.68 0.17
281.20123 C19H24N2 Nortrimipramine 14.04 13.73 0.31
36 285.14200 C17H20N2S Promazine 13.39 12.77 0.62
285.14200 C17H20N2S Promethazine 12.82 12.73 0.09
37 286.14377 C17H19NO3 Hydromorphone 2.83  4.20 1.37
286.14377 C17H19NO3 Morphine 1.92  2.56 0.64
286.14377 C17H19NO3 Norcodeine 4.48  3.82 0.66
38 287.05818 C15H11N2O2Cl  Demoxepam 13.13 11.73 1.40
287.05818 C15H11N2O2Cl  Oxazepam 14.43 13.55 0.88
39 300.15942 C18H21NO3 Codeine 5.02 4.94 0.08
300.15942 C18H21NO3 Hydrocodone 6.51  6.02 0.49
40 301.07383 C16H13N2O2Cl  Clobazam 14.69 13.85 0.84
301.07383 C16H13N2O2Cl  Temazepam 15.21 14.36 0.85
41 301.14660 C18H21N2Cl Chlorcyclizine 13.63 11.73 1.91
301.14660 C18H21N2Cl Norclomipramine 15.00 13.36 1.64
42 302.13868 C17H19NO4 Oxymorphone 2.36  4.38 2.02
302.13868 C17H19NO4 Noroxycodone 6.05 4.29 1.76
43 302.17507 C18H23NO3 Dihydrocodeine 4.95  5.63 0.68
302.17507 C18H23NO3 Isoxsuprine 10.12 10.02 0.10
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44 304.15434 C17H21NO4 Cocaine 9.45  10.61 1.16
304.15434 C17H21NO4 Scopolamine 5.79  6.06 0.27
45 314.17507 C19H23NO3 Ethylmorphine 7.21  6.32 0.89
314.17507 C19H23NO3 Reboxetine 12.22 11.44 0.78
46 325.19105 C20H24N2O2 Quinidined 9.38  8.45 0.93
325.19105 C20H24N2O2 Quinined 9.68  8.42 1.26
47 328.15433 C19H21NO4 6-Monoacethylmorphine (6-MAM) 6.63  5.91 0.72
328.15433 C19H21NO4 Naloxone 5.36  6.14 0.78
48 366.06737 C16H16N3O3SCl Indapamide 13.40 15.09 1.69
366.06737 C16H16N3O3SCl Metolazone 12.64 13.74 1.10
49 377.20710 C20H28N2O5 Enalapril 12.25 11.86 0.39
377.20710 C20H28N2O5 Remifentanil 9.83  10.16 0.33
50 387.15593 C21H26N2OS2 Mesoridazone 12.15 13.24 1.09
387.15593 C21H26N2OS2 Thioridazine-5-sulfoxide 12.45 14.61 2.16
a Experimental, min.
b Calculated, min.
c Absolute value, min.
d Diastereomers.
The predicted retention time can be  used as a powerful orthogo-
nal  ﬁlter to  cut down the number of possible chemical structures
[33–36].  Hence, retention time prediction plays an important role
also in data mining procedures, such as in  the metabolomics con-
text  [37].
4. Conclusion
We have demonstrated a  novel approach for differentiation of
structural isomers in a large target database by liquid chromatog-
raphy retention order prediction. For the ﬁrst time, retention time
prediction software has been employed to help identify for small
molecules. The results showed that, despite the rather large abso-
lute  errors between the calculated and experimental retention
times, the software turned out to be  a  feasible predictor of the
correct retention order of most compounds. The predictions were
particularly adequate for structurally similar compounds, such as
phenethylamine derivates. While insufﬁcient for compound iden-
tiﬁcation on its own, ACD/ChromGenius does nevertheless bring
valuable information by determining retention orders, and thus
making the identiﬁcation of unknown compounds more reliable,
even when primary reference standards are unavailable. Molecular
formula determination by accurate mass measurement is an out-
standing method for reliable compound identiﬁcation; however,
it  requires further assistance in order to  distinguish isomers. The
software  used in the present study provided additional data that
can  be utilized in  the context of clinical and forensic toxicology
drug screenings in  order to tentatively characterize compounds in
biological samples.
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Abstract Human phase I metabolism of four designer drugs,
2-desoxypipradrol (2-DPMP), 3,4-dimethylmethcathinone
(3,4-DMMC), α-pyrrolidinovalerophenone (α-PVP), and
methiopropamine (MPA), was studied using in silico and
in vitro metabolite prediction. The metabolites were identified
in drug abusers’ urine samples using liquid chromatography/
quadrupole-time-of-flight mass spectrometry (LC/Q-TOF/
MS). The aim of the study was to evaluate the ability of the
in silico and in vitro methods to generate the main urinary
metabolites found in vivo. Meteor 14.0.0 software (Lhasa
Limited) was used for in silico metabolite prediction, and
in vitro metabolites were produced in human liver microsomes
(HLMs). 2-DPMP was metabolized by hydroxylation, dehy-
drogenation, and oxidation, resulting in six phase I metabolites.
Six metabolites were identified for 3,4-DMMC formed via N-
demethylation, reduction, hydroxylation, and oxidation reac-
tions. α-PVP was found to undergo reduction, hydroxylation,
dehydrogenation, and oxidation reactions, as well as degrada-
tion of the pyrrolidine ring, and seven phase I metabolites were
identified. For MPA, the nor-MPA metabolite was detected.
Meteor software predicted the main human urinary phase I
metabolites of 3,4-DMMC, α-PVP, and MPA and two of the
four main metabolites of 2-DPMP. It assisted in the identifica-
tion of the previously unreported metabolic reactions for α-
PVP. Eight of the 12 most abundant in vivo phase I metabolites
were detected in the in vitro HLM experiments. In vitro tests
serve as material for exploitation of in silico data when an
authentic urine sample is not available. In silico and in vitro
designer drug metabolism studies with LC/Q-TOF/MS
produced sufficient metabolic information to support identifi-
cation of the parent compound in vivo.
Keywords 2-Desoxypipradrol . 3,4-Dimethylmethcathinone .
α-Pyrrolidinovalerophenone .Methiopropamine .Metabolite
prediction . Liquid chromatography/quadrupole-time-of-flight
mass spectrometry
Introduction
An increasing number of new designer drugs arrive annually
on the illicit drug market. Between 2005 and 2012, 237 new
psychoactive compounds were reported through the early
warning system in Europe, and a record number of 73 new
substances were notified in 2012 [1, 2]. Analytical laborato-
ries in the fields of forensic and clinical toxicology, as well as
customs and criminal investigation, need to tackle this chal-
lenge and develop methods for compound identification, even
if a certified reference standard is not always available.
In terms of toxicological risk assessment and analytical
method development aspect, the knowledge about designer
drug metabolism is highly substantial [3–5]. The metabolism
of designer drugs is commonly studied in animals, especially
rats [3, 5]. In vitro experiments in metabolism studies have
become popular among forensic and clinical toxicology re-
search groups [6] and in doping control laboratories [7–10]
during recent years. Drug incubation with human liver micro-
somes (HLMs), S9 fraction, or hepatocytes is an established
ethical and cost-effective method in studies of the metabolism
of new designer drugs and psychoactive compounds [6]. Their
main application to date has been in enzyme kinetics.
High-resolution mass spectrometry (HRMS) applications
are today widely employed in drug metabolism studies [11,
12]. Modern quadrupole-time-of-flight (Q-TOF) instruments
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provide high mass resolution and accuracy on a routine
basis. Q-TOF instruments operate at high data acquisition
speed, and their full-range data acquisition enables retro-
spective data mining. Q-TOF mass analyzers are frequently
used in drug metabolism research in substance identification
and in confirmation of nominal mass MS data [11, 13].
Software solutions play a key role in systematic drug metab-
olism studies by HRMS, and most of the MS manufacturers
provide software tools such as MetaboLynx (Waters,
Milford, MA, USA) and MetWorks (Thermo Scientific,
Waltham, MA, USA) to detect products of common meta-
bolic pathways [14]. Mass defect filtering (e.g., MassLynx,
Waters) [15] and MS/MS spectra comparison (e.g.,
SmileMS, GeneBio, Geneva, Switzerland) [16] software en-
able nontargeted metabolite screening and have served in the
identification of drugs of abuse metabolites. Several software
tools for metabolite prediction of xenobiotics are commercially
available, three being MetaSite (Molecular Discovery Ltd,
Middlesex, UK), MetaDrug (Thomson Reuters, NY, USA),
and Meteor (Lhasa Limited, Leeds, UK). Drug metabolite pre-
diction in silico is widely used to study the biotransformation of
pharmaceuticals [17–21]. Prediction using commercial or self-
coded software has not become common in studies of designer
drugs or other toxicologically interesting compounds, however.
Here, we studied the metabolism of four structurally
different designer drugs: 2-desoxypipradrol (2-DPMP,
Daisy), 3,4-dimethylmethcathinone (3,4-DMMC), α-
pyrrolidinovalerophenone (α-PVP), and methiopropamine
(MPA). At the moment, only 2-DPMP is classified as a
controlled drug of abuse in Finland, which makes the other
compounds attractive among drug users, as the penalties are
less severe than those for drug offenses. Methiopropamine and
α-PVP are classified as pharmaceutical compounds, whereas
3,4-DMMC is not yet subject to any legislation and is cate-
gorized as a research chemical. 2-DPMP is a phencyclidine-
derived compound, and its metabolism has not previously
been reported. For the pyrrolidinophenone analog α-PVP, 12
phase I metabolites in rats have been reported [22]. These
include hydroxylation, dehydrogenation, ring opening and
oxidation reactions, and degradation of the pyrrolidine ring
to the corresponding primary amine. These metabolites have
not been confirmed from authentic human urine samples. The
main human urinary phase Imetabolites of theβ-keto-structured
cathinone 3,4-DMMC have recently been reported by Shima
et al. [23]. They identified three metabolites, formed after N-
demethylation and reduction of the β-ketone, using synthesized
standards. In a recent metabolism study of the thiophene deriv-
ative of methamphetamine MPA, a nor-metabolite was detected
in human urine [24].
We identified the main human urinary phase I metabolites
of the designer drugs studied using in silico and in vitro
methods for metabolite prediction. The aim was to produce
sufficient metabolic information for urine drug screening to
support the identification of the parent compound. In our
previous study, the metabolite prediction software Meteor
was found to be useful in assigning metabolites to quetiapine
[20]. Here, the ability of the Meteor software to predict the
metabolism of designer drugs was evaluated by comparing the
results between in silico predictions and our own predictions
based on knownmetabolic reactions of structural analogs. The
in vitro metabolism of 2-DPMP, 3,4-DMMC, α-PVP, and
MPAwas studied using HLMs to support the in vivo metab-
olite findings and to test whether the HLM experiments pro-
duced the main phase I metabolites. Several authentic human
urine samples, which had tested positive for the designer
drugs studied, were analyzed using liquid chromatography
(LC)/Q-TOF/MS, and the metabolites were characterized
from their MS/MS spectra without reference standards.
Experimental
Materials
Methanol (LC-MS grade) and isopropanol (analytical grade)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Other reagents (analytical grade) were fromMerck (Darmstadt,
Germany). Water was purified with a MilliQ Integral5
instrument (Millipore, Billerica, MA, USA). α-PVP (HCl)
was obtained from Toronto Research Chemicals (Toronto,
Canada), tramadol (HCl) from Nycomed Christiaens
(Brussels, Belgium), and dibenzepin (HCl) of pharmaceutical
purity from Sandoz (Holzkirchen, Germany). 2-DPMP, 3,4-
DMMC, and MPAwere obtained from material seized by the
Finnish National Bureau of Investigation or from the Finnish
Customs. The purity of the substances was determined by LC-
chemiluminescence nitrogen detection [25] with a linear
gradient separation. The purity of 2-DPMP was 50.7 %,
3,4-DMMC 85.0%, andMPA 97.6%, as their hydrochlorides
(measurement uncertainty 6.5 %, unpublished data). The
unpurified seized drug material (0.1 mM in 0.1 % formic
acid + methanol) was analyzed by the LC/Q-TOF/MS method
before the in vitro incubations to exclude possible contaminat-
ing active ingredients. No such substances were found, which
would interfere with the metabolic reactions. Thus, the impu-
rity was presumed to be from inactive excipients. HLMs (BD
UltraPool™ HLM 150) and NADPH regenerating system
solutions A (26 mM NADP+, 66 mM glucose-6-phosphate
and 66 mM MgCl2 in H2O) and B (40 U/mL glucose-6-
phosphate dehydrogenase in 5 mM sodium citrate) were
supplied by BD Biosciences (Woburn, MA, USA). β-
glucuronidase was obtained from Roche (Mannheim,
Germany). Mixed-mode solid phase extraction (SPE) car-
tridges with strong cation exchange and hydrophobic interac-
tions (Isolute HCX-5, 130 mg, 10 mL) were provided by
Biotage (Uppsala, Sweden).
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Urine samples were either collected at autopsy or they
were clinical toxicology cases investigated at our laboratory.
The urine samples tested positive for one or more of the
designer drugs studied in our routine drug screening by LC-
TOF/MS [26]. The positive findings were confirmed and
quantified by gas chromatography-MS [27]. Ten 2-DPMP
cases (concentrations in urine between 0.29 and 42 mg/L),
two 3,4-DMMC cases (0.53 and 1.4 mg/L), eight α-PVP
cases (0.08–13 mg/L), and three MPA cases (0.52–19 mg/L)
were studied. The urine samples contained several other tox-
icological findings, including prescription drugs and illicit
drugs and their metabolites, as well as alcohol, caffeine, and
nicotine. The maximum number of positive findings was 22,
and the average and median were 10 and 9, respectively. The
predicted metabolites were checked against the in-house tox-
icology database to exclude potential false-positive findings
resulting from other compounds.
Urine sample preparation
Urine samples (1 mL) were hydrolyzed overnight (15 h) at
37 °C, with β-glucuronidase. Solid phase extraction [26] was
used for sample preparation. The samples were reconstituted
with 150 μL methanol/0.1 % formic acid (1:9 v/v). The meth-
anol used for washing the SPE cartridge between neutral and
basic extractions was evaporated and reconstituted likewise
and analyzed by LC/Q-TOF/MS method to find out if any of
the most polar metabolites were lost in sample preparation.
In vitro metabolism studies
Phase I metabolism in vitro of the four designer drugs, 2-DPMP,
3,4-DMMC, α-PVP, and MPA, was studied using HLMs. The
reactionmixture consisted of 1.3mMNADP+, 3.3mMglucose-
6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase,
and 3.3 mM magnesium chloride, in 100 mM phosphate buffer
at pH 7.4. The final reactionmixture volumewas 100μL,where
the drug concentration was 100 μM and the protein concentra-
tion was 2.0 mg/mL. The reaction was initiated by addition of
the microsomes, and the incubation time was 4 h at 37 °C. The
reaction was terminated with 100 μL of ice-cold methanol. The
samples were centrifuged (16,000 rpm, 25,000 g-units, 10 min),
and the supernatant was stored at −80 °C until analysis. Test
samples were prepared in triplicate. In addition to the test
samples, a blank sample without the drug, biological control
samples without either HLMs or NADPH regenerating solu-
tions, and a chemical control sample without both HLMs and
NADPH were prepared to determine any interference resulting
frommatrix compounds and spontaneously formed metabolites.
A standard control sample with a compound of known in vitro
metabolism, tramadol, was also included in the test set. The
presence of the main in vitro phase I metabolites of tramadol
[28] confirmed the incubation conditions.
In silico metabolite prediction
The metabolism of the designer drugs was predicted using
Meteor 14.0.0 software (Lhasa Limited, Leeds, UK). Meteor
predicts the metabolism of xenobiotics using a rule-based
expert system [29]. First, substructures of a query compound
labile towards a biotransformation reaction are checked in
the knowledge base. Second, an absolute reasoning algo-
rithm evaluates the possibility of that reaction taking place
on five likelihood levels: probable, plausible, equivocal,
doubted, and improbable [30]. Last, relative reasoning ranks
concomitant metabolic reactions to remove the more improb-
able transformations. The following prediction parameters
were used here: metabolism was outlined to include phase I
reactions, the maximum number of metabolic steps was set at
four, and the maximum number of predicted metabolites was
400. Absolute reasoning likelihood included probable and
plausible levels for 3,4-DMMC and α-PVP and was expand-
ed to cover equivocal level for 2-DPMP and MPA. Relative
reasoning level was set at one, and mammals were selected
as species. Absolute reasoning was set at a higher likelihood
level for 3,4-DMMC and α-PVP because at the equivocal
level, Meteor predicted over 200 metabolites for these com-
pounds, which was thought to include an excessive number
of false-positive predictions. After processing, duplicate me-
tabolites and metabolites with a molecular mass lower than
100 were removed from the results, as they were thought
most likely to be false-positive predictions. A database with
the molecular formulae of both the origin compound and the
predicted metabolites for each designer drug was created in
Excel 2003 (Microsoft, Redmond, WA, USA).
Metabolite prediction based on published analogous
reactions
The metabolism of the compounds studied was also
predicted from the published metabolic reactions of their
structural analogs in order to test the ability of the Meteor
software to predict designer drug metabolism. The metabo-
lism of 2-DPMP was deduced from the metabolism of
phencyclidine-derived designer drugs [3]. Phencyclidines are
known to undergo N-dealkylation, which in this case was
thought to result in opening of the piperidine ring, and further
oxidation of the primary alcohol. Those metabolites pre-
dicted after β-keto-structured cathinones, especially 4-
methylmethcathinone (4-MMC, mephedrone) [3, 31],
were added to the list of published metabolites of 3,4-
DMMC [23]. The metabolites of α-PVP were taken from the
study of Sauer et al. [22] in rats, supplemented with the metab-
olism of other pyrrolidinophenone-derived designer drugs [3,
5]. The MPA metabolites were based both on the published
normetabolite [24] and as predicted by methamphetamine [32],
as well as thiophene-structured compounds [33]. Metabolic
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reactions were thought to be overlapping, even though this
resulted in unreported metabolites. An Excel-based metabolite
database of each designer drug was created as above.
Liquid chromatography/quadrupole-time-of-flight-mass
spectrometry
The liquid chromatograph was a Waters Acquity Ultra
Performance instrument (Milford, MA, USA) including a high-
pressure mixing binary-gradient pump with a six-channel sol-
vent degasser, a sample manager, and a thermostated column
manager. A Luna PFP(2) column (pentafluorophenyl,
100×2 mm, 3 μm) and a PFP pre-column (4×2 mm, from
Phenomenex, Torrance, CA, USA) were used for separation in
a gradient mode at 40 °C. The mobile phase components were
2 mM ammonium acetate in 0.1 % formic acid and methanol.
The flow rate was 0.3 mL/min, and the pre-run time was 5 min.
The gradient started at 5 % of methanol and was increased to
40% in 5min, to 75% in 13.50min, to 80% in 16min, and held
at 80 % for 2 min. A partial loop with needle overfill mode was
used for injection, and the volume was 3 μL for the urine
samples and 7.5 μL for the HLM incubation samples.
Themass spectrometer was a Bruker Daltonics micrOTOF-
Q instrument (Bremen, Germany) with an orthogonal
electrospray ionization source. The nominal resolution of the
instrument was 10,000 FWHM. It was operated in a positive
ion mode over a m/z range of 50–800. The drying gas flow
was 8.0 mL/min, temperature was 200 °C, and the nebulizer
gas pressure was 1.6 bar. The capillary voltage of the ion
source was set at 4,500 V and the end plate offset at −500 V.
In MS mode, the quadrupole ion energy was 5.0 eV, the
collision cell radiofrequency 150.0 Vpp, the quadrupole trans-
fer time 60.0 μs, and pre-pulse storage time 8.0 μs. The
spectra time was 0.6 s and the spectra rolling average was
set at 2. An external instrument calibration with sodium
formate solution (10 mM NaOH in isopropanol and 0.2 %
formic acid, 1:1 v/v) was performed using ten cluster ions
(Na(NaCOOH)1–10), m/z values from 90.9766 to 702.8635.
The same calibrant was injected at the beginning and end of
each sample run for post-run internal mass scale calibration.
AutoMS(n) methods were built for each designer drug for
mass fragmentation. In the AutoMS(n) system, the instru-
ment alternates MS and MS/MS modes in each spectrum.
The selection of the precursor ion was based on a preselected
mass list and an intensity threshold of 500 counts. If none of
the ions from the list were detected, the most abundant ion
was fragmented. A precursor ion list of the metabolites de-
tected in the screening mode was constructed for each drug. A
smart exclusion technique was used to reduce background
noise, and an active exclusion mode allowed the rejection of
the precursor ion after three spectra. The voltages for frag-
mentation were optimized by flow injection of a mixture of
the compounds studied (1 μg/mL in methanol) and using an
auto-optimization function. The collision energy was 20–
40 eV for ions between m/z 100 and 500, and the energy
varied from 80 to 120 % of the set value using collision
sweeping. Ion source and transfer parameters were as in the
screening mode. Spectra time was shortened to 0.5 s.
Data analysis
DataAnalysis 4.1 (Bruker Daltonics, Bremen, Germany) was
employed to process the analysis data. An automatic data-
base search function was created for each designer drug in
TargetAnalysis 1.2 (Bruker Daltonics, Bremen, Germany) to
find the predicted metabolites. This reverse database search
reported hits from the LC/Q-TOF/MS acquisition data within
the selected identification criteria: peak area counts of 2,000,
a mass tolerance of ±3 mDa, and an isotopic pattern match,
mSigma, threshold of 200. The script has been described in
more detail by Ojanperä et al. [34].
Rule-based fragmentation prediction software, MS/
Fragmenter 12.01 (Advanced Chemistry Development,
ACD/Labs, Toronto, Canada), was used to identify and aid
in structural determination of the designer drugs and their
metabolites. This software was used in our previous studies
[20, 35] and is described in more detail in these papers. The
function “atmospheric pressure positive ion protonation”
was selected as the ionization type, and the number of
fragmentation steps was set at five. Other fragmentation
parameters outlined aromatic bond cleavage, ring formation,
resonance reaction, hydride shift, heterolytic and homolytic
cleavages, hydrogen rearrangements, and neutral losses. For
some product ions unidentified by the MS/Fragmenter, a
DataAnalysis built-in tool for MS spectra interpretation,
SmartFormula3D [36], was used to provide additional infor-
mation in structural determination of the metabolites.
Results and discussion
Table 1 shows the reactions used by the Meteor software for
metabolite prediction, the pathways collected from the pub-
lished analogous reactions, as well as the total number of
predicted metabolites, with prediction likelihood levels for
each compound.
The identified human urinary metabolites of the designer
drugs studied are listed in Table 2 and described below in
detail. The structures of the metabolites detected in the human
urine samples and in vitro experiments were confirmed by
comparing the mass spectra of the metabolites with the prod-
uct ions identified for the parent compounds in MS/MS spec-
tra using MS/Fragmenter and SmartFormula3D. Fragment
prediction for eachmetabolite was also performed, to determine
the site of the metabolic reaction in the molecule and also to
differentiate between possible structural isomers. In the analysis
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of the wash methanol (see “Urine sample preparation”), no
designer drug metabolites other than those seen in the urine
samples were detected.
2-DPMP
2-DPMP (at m/z 252.1747) was found to undergo extensive
oxidative metabolism, including aromatic hydroxylation, hy-
droxylation at the piperidine ring, and oxidation after ring
opening. Dehydrogenated hydroxy metabolites were also
found, resulting in six identified phase I metabolites in total.
The proposed phase I metabolism of 2-DPMP is presented in
Fig. 1a. Several characteristic product ions could be identified
with the MS/Fragmenter for 2-DPMP and these are presented
in detail in Fig. 2a. Product ions at m/z 193.1012, 181.1012,
167.0855, and 91.0542, or their modifications formed in
metabolic reactions, could be detected from the MS/MS spec-
tra of the metabolites, making the identification reliable.
Six peaks fitting the exact mass of m/z 268.1696,
corresponding to a hydroxylated metabolite, were ob-
served in the total ion chromatograms of the urine sam-
ples. The site of the hydroxylation reaction was conclud-
ed to take place at both aromatic (M1) and piperidine
(M2) rings, which could be differentiated by their char-
acteristic product ion spectra. Product ions (exact masses)
at m/z 197.0961 (C14H13O) and 183.0804 (C13H11O),
formed by the addition of a hydroxyl group to the
corresponding 2-DPMP product ions (Fig. 2a), indicate
Table 1 List of biotransformation reactions (in alphabetical order) applied to designer drug metabolite prediction based on Meteor software and the
analogous reactions found in the literature
2-DPMP 3,4-DMMC α-PVP MPA
Meteor (n=42) Meteor (n=69) Meteor (n=15) Meteor (n=21)
pro: n=5; pla: n=14;
equ: n=23
pro: n=9; pla: n=60 pro: n=1; pla: n=14 pla: n=14; equ: n=7
β-Oxidation of carboxylic
acids (pla)
5-Hydroxyl. of 1,2,4-subst.
benzenes (pla)
Hydroxylation of alkyl
methylene (pla)
Benzylic hydroxylation (pla)
Decarboxylation (equ) Hydroxylation of aromatic
methyl (pro)
Hydroxylation of terminal
methyl (pla)
Decarboxylation (equ)
Hydrolysis of cyclic
carboxyamides (equ)
Hydroxylation of terminal
methyl (pla)
Lactams from aza-alicyclic
comp. (pla)
Hydroxylation of terminal
methyl (pla)
Hydroxylation of aromatic
methine (equ)
Oxidation of primary
alcohols (pla)
Oxidation of primary
alcohols (pla)
N-hydroxylation of secondary
amines (equ)
Lactams from aza-alicyclic
comp. (pla)
Oxidation of secondary
alcohols (pla)
Oxidation of secondary
alcohols (pla)
Oxidation of primary alcohols
(pla)
N-hydroxyl. of secondary
amines (equ)
Oxidative N-demethylation
(pro)
Oxidative N-dealkylation
(pro)
Oxidation of secondary
alcohols (pla)
Oxidation of primary
alcohols (pro)
Reduction of aliphatic
ketones (pla)
Reduction of aliphatic
ketones (pla)
Oxidative deamination (equ)
Oxidation of secondary
alcohols (pro)
Oxidative N-demethylation
(pla)
Oxidative deamination (equ) Reduction of aliphatic
ketones (pla)
Oxidative N-dealkylation (pla)
Para-hydroxylation of
benzenes (pla)
Reduction of aliphatic
ketones (pla)
Published analogous
reactions (n=14)
Published analogous
reactions (n=11)
Published analogous
reactions (n=23)
Published analogous
reactions (n=13)
Dehydrogenation Hydroxylation Degradation of
pyrrolidine ring
Hydroxylation
Hydroxylation N-demethylation Dehydrogenation N-demethylation
N-dealkylation→ ring
opening
Oxidation Hydroxylation Sulfoxidation
Oxidation Reduction Ring opening + oxidation
Total number of predicted metabolites and their likelihood levels are in brackets. True identified metabolic reactions are presented in bold
pro probable likelihood level, pla plausible likelihood level, equ equivocal likelihood level
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aromatic hydroxylation. The product ion spectra from the
M1 peaks were identical; thus, differentiation of the
compounds was not possible, nor could the exact site
of the hydroxylation be determined. Metabolite M1 was
detected in HLM experiments only at trace levels.
In addition to the corresponding product ions of 2-DPMP,
the loss of water was detected in the spectra of metabolites
M2 hydroxylated at the piperidine ring. Metabolites M2
were present in relatively high abundance in the urine sam-
ples, signifying that hydroxylation at the piperidine ring is
the main phase I metabolism route of 2-DPMP. These peaks
are possibly a mixture of regioisomers and conformational
isomers, forming sum spectra, as the peaks were not fully
separated at their baseline. The metabolite M2 eluting at
Table 2 Phase I metabolites identified for 2-DPMP, 3,4-DMMC, α-PVP, and MPA in authentic human urine samples. Identification criteria
were ±3 mDa for mass error, mSigma threshold of 200, and peak area counts of 2,000
Metabolite found in
human urine in vivo
Metabolic reaction Formula Rt (min) [M+H]+ (m/z) Found
in vitro
Found
in silico
Deduced from
analogous
reactions
2-DPMP C18H21NO 7.10 252.1747
M1a Hydroxylation (aromatic) C18H21NO 5.06 268.1696 X X
6.30
M2a Hydroxylation
(aliphatic, i.e., piperidine ring)
C18H21NO 5.86 268.1696 X
6.09
6.50 X
8.68 X
M3a Hydroxylation (aliphatic) +
dehydrogenation
C18H19NO 12.11 266.1539 X X X
M4a 2 × hydroxylation (aliphatic) +
1 × dehydrogenation
C18H19NO2 10.46 282.1489 X
10.83
M5 3 × hydroxylation (aliphatic
and aromatic) + 1 ×
dehydrogenation
C18H19NO3 8.34 298.1438 X
M6 2 × hydroxylation (aromatic) +
ring opening + oxidation
C18H21NO4 9.97 316.1543 X
3,4-DMMC C12H17NO 5.89 192.1383
M1a N-demethylation C11H15NO 5.51 178.1226 X X X
M2a Reduction C12H19NO 5.45 194.1539 X X X
M3a Reduction + N-demethylation C11H17NO 4.88 180.1383 X X
5.06
M4a Hydroxylation C12H17NO2 3.18 208.1332 X X X
3.67 X
M5 N-demethylation + hydroxylation C11H15NO2 5.88 194.1176 X X
M6 Reduction + hydroxylation +
oxidation
C12H17NO3 4.68 224.1281 X X X
α-PVP C15H21NO 5.70 232.1696
M1a Reduction C15H23NO 5.84 234.1852 X X
M2 Hydroxylation C15H21NO2 5.35 248.1645 X X X
M3a Hydroxylation + dehydrogenation C15H19NO2 12.02 246.1489 X X X
M4a Reduction + hydroxylation +
dehydrogenation
C15H21NO2 8.90 248.1645 X
9.95 X
M5 Degradation of pyrrolidine ring C11H15NO 4.95 178.1226 X X
M6 Hydroxylation + dehydrogenation +
ring opening + oxidation
C15H21NO3 5.97 264.1594 X X
6.67
M7 Hydroxylation + oxidation C15H19NO3 10.42 262.1438 X
MPA C8H13NS 3.13 156.0841
M1a N-demethylation C7H11NS 2.79 142.0685 X X X
a Abundant metabolites in human urine
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αc
b
a
d
Fig. 1 Proposed phase I metabolism of 2-DPMP, 3,4-DMMC, α-PVP, and MPA in humans. Metabolite M5 of 3,4-DMMC (dashed arrow) was
identified solely by exact mass and isotopic pattern comparison
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8.68 min was a minor urinary metabolite, but it was present
in the HLM samples in rather high abundance. The Meteor
software did not predict hydroxylation at carbon atoms in the
piperidine ring under the chosen reasoning constraints.
However, the α-carbinolamine structure is expressed as a
reaction intermediate in the lactam (metabolite M3) forma-
tion. In the absence of an intermolecular hydrogen bonding
stabilization, this structure is generally not observed in vivo.
Because of the relative reasoning filter applied, biotransfor-
mations expressing hydroxylation at the alicyclic carbon
atoms are discarded. With a lower filter, these metabolites
would also have been observed. N-hydroxylation at the
piperidine nitrogen was predicted for 2-DPMP by Meteor
(Table 1) at equivocal likelihood level. N-hydroxylated sec-
ondary aliphatic amines may react further to produce more
complex compounds [37], which means that these metabo-
lites could not be detected in human urine. The presence of
this metabolite is therefore rather doubtful.
2-DPMP M2 metabolites were found to undergo dehydro-
genation (M3 at m/z 266.1539) to a corresponding lactam or
ketone. In the HLM samples, three peaks showing [M+H]+ at
m/z 266.1539 at 11.00, 11.47, and 12.11 min were observed.
Traces of these two first eluting compounds were also present
in the urine samples, and thus, reliably interpretable MS/MS
spectra could not be produced to confirm the structures.
The 2-DPMP metabolite M4 (at m/z 282.1489) was detect-
ed in rather high abundance. It was formed via two hydroxyl-
ation reactions at the piperidine ring, one of the hydroxyl
groups subsequently undergoing dehydrogenation. The meta-
bolic reactions of M4 were found to take place only at the
piperidine ring, as the product ion at m/z 167.0855 indicated
the aromatic rings were not hydroxylated. The loss of H2O (at
m/z 264.1383), followed by the loss of CO (at m/z 236.1434)
and NH3 (at m/z 219.1168), confirmed this presumption. A
minor peak of M4, detected at 10.46 min, indicates possible
isomerism of this metabolite. Metabolite M5 (at m/z
298.1438) was formed via aromatic hydroxylation of M4.
Characteristic product ions for aromatic hydroxylated com-
pounds (see M1 above) were detected for metabolite M5. In
addition, product ions formed via loss of H2O, CO, and NH3
could be seen, similar to M4, at 15.9949 atomic mass units
and higherm/z values. This shows a difference of one hydrox-
yl group between M4 and M5, located outside the piperidine
ring system. M4 and M5 were not detected in in vitro exper-
iments nor were they predicted by the Meteor software.
2-DPMP was found to undergo oxidative N-
dealkylation resulting in ring opening of the piperidine
structure and oxidation of the primary alcohol to a
carboxylic acid. Metabolite M6 (at m/z 316.1543) was
found to comprise the previous structure and in addition
was twice hydroxylated at the aromatic rings. Product
ions [M+H–NH3]
+ at m/z 299.1278 and [M+H–NH3–
CO2H2]
+ at m/z 253.1223, and those identical to other
aromatic hydroxy metabolites, specified this structure.
Meteor suggested an oxidative N-dealkylation reaction,
followed by oxidation of the primary alcohol.
Nevertheless, the formation of M6 was not predicted
by the software, as the likelihood of sequential hydrox-
ylation reactions in the two aromatic rings is assigned
as doubted.
Great individual variation in metabolite abundances
was noticed between the 2-DPMP cases studied, which
makes the determination of the main metabolites diffi-
cult. Metabolites M1 and M2 were identified in nine
cases out of ten, indicating hydroxy metabolites would
be the primary phase I human metabolites. Metabolites
M3–M6 were thought to be minor 2-DPMP metabolites,
as the intensities of the compounds were in some cases
quite low. The number of other toxicological findings in
the urine cases studied was up to 15. Possible drug–
drug interactions may have an influence on the meta-
bolic ratios. The urine concentrations of 2-DPMP itself
varied greatly as well, and thus, care should be taken
when concluding the quantity of the metabolites.
3,4-DMMC
Six metabolites could be identified for 3,4-DMMC in human
autopsy urine cases (Table 2). They included the recently
reported [23] N-demethylated (M1) and reduced metabolites
(M2) and the combination of the reactions (M3). Hydroxylated
(M4 and M5) and further oxidated (M6) metabolites were
detected and identified here as well. Compounds M4 and M6
have previously been reported as putative metabolites, as the
identification was based on nominal mass MS/MS data and
relative retention times [23]. All metabolites identified here
were predicted by the Meteor software. The proposed metabo-
lism of 3,4-DMMC is presented in Fig. 1b.
In the MS/MS spectrum of 3,4-DMMC (atm/z 192.1383),
two main peaks formed after fragmentation of the ketone
group (at m/z 174.1277), together with further loss of a
methyl radical (at m/z 159.1043), were detected (Fig. 2b).
Fragmentation of the metabolites mainly followed the path
of 3,4-DMMC. An additional loss of water was detected in
the MS/MS spectra of hydroxylated and oxidated metabo-
lites. Other characteristic product ions, identified for the me-
tabolites using the MS/Fragmenter, are presented with an
asterisk (*) in Fig. 2b.
Two peaks were identified for metabolite M3 (at m/z
180.1383), formed via N-demethylation and reduction reac-
tions (Table 2). The product ion spectra of these compounds
were identical, indicating the formation of diastereomers [23].
Fig. 2 Proposed fragmentation schemes identified using fragment pre-
diction for 2-DPMP, 3,4-DMMC, α-PVP, andMPA and the correspond-
ing MS/MS spectra. Product ions denoted with an asterisk (*) were
detected in metabolite MS/MS spectra
b
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Racemization of the reduced metabolite M2 could not be
shown in the analysis of the urine and in vitro samples.
However, confirmation of the possible isomerism of M2
would require further analysis under different separation con-
ditions, e.g., with a chiral column.
Two peaks for the hydroxylated metabolite M4 (at m/z
208.1332) were detected in urine and HLM samples
(Table 2). Previous studies [23, 29] indicate that the hydrox-
ylation takes place at the aromatic methyl group. In addition to
this, Meteor predicted hydroxylations at terminal methyl
groups of the side chain (Table 1). The MS/MS spectra of
the hydroxy metabolites were identical in both ion quality and
abundance, possibly indicating that the hydroxylation reaction
takes place at either of the aromatic methyl groups. The
prediction likelihood also applies to the aromatic methyl hy-
droxylation (Table 1). However, hydroxylation of the aliphatic
methyl group could not be excluded.
A previously unreported metabolite of 3,4-DMMC, metab-
olite M5, resulted from N-demethylation and hydroxylation
(atm/z 194.1176). It eluted at the same time as 3,4-DMMC (at
m/z 192.1383); thus, a characteristic MS/MS spectrum of M5
could not be produced, as the separation mass window in the
quadrupole had to be wide enough to utilize the isotopic
pattern match comparison in the compound identification in
MS/MS analysis. The identification of M5 is based on accu-
rate mass measurement only, and further studies should be
carried out to confirm its existence.
Metabolite M6 (at m/z 244.1281) was produced via reduc-
tion of the ketone group, followed by hydroxylation and
oxidation of the aromatic methyl group. The most abundant
product ion in its spectrum at m/z 174.0913 corresponded to
the structure C11H12NO ([M+H–H4O2–CH2]
+). Detection of
an ion at m/z 137.0597 (product ion at m/z 105.0699+O2,
Fig. 2b.) showed that the position of the carboxylic acid group
was in the xylyl methyl. MetaboliteM6was confirmed in only
one of the urine samples and was detected in vitro only as
trace levels, which would indicate it is a minor metabolite of
3,4-DMMC.
α-PVP
α-PVP (at m/z 232.1696) was metabolized extensively, as
seven phase I metabolites were detected in the human urine
samples (Table 2). The proposed metabolism is presented in
Fig. 1c. Characteristic product ions were identified using
fragment prediction (Fig. 2c). α-PVP was found to metabo-
lize by hydroxylation at the propyl side chain (M2 at m/z
248.1645), hydroxylation followed by dehydrogenation at
the pyrrolidine ring to form a lactam structure (M3 at m/z
246.1489), and degradation of the pyrrolidine ring to a pri-
mary amine (M5 at m/z 178.1226). These metabolites were
previously identified in rat urine [22] and were found here in
the HLM samples as well. For the hydroxy-α-PVP (M2), the
product ion at m/z 189.1148 ([M+H–C3H7O]
+·) showed that
the hydroxylation takes place at the propyl side chain.
Metabolite M3 showed a characteristic product ion of a γ-
lactam structure at m/z 86.0600 (C4H8NO). For metabolite
M5, product ions corresponding to the loss of water (at m/z
160.1121) followed by the loss of a propyl side chain (at m/z
118.0651) were identified.
Metabolite M1 (at m/z 234.1852), formed by reduction of
the ketone structure to a corresponding alcohol, was the most
abundant metabolite of α-PVP in both human urine and
in vitro experiments. Loss of water, followed by pyrrolidine
ring loss, or propyl side chain loss as a radical cation was
identified as an indication of the hydroxylated structure. This
metabolic reaction has not previously been reported for α-
PVP [22]. Here, it was predicted by the Meteor software.
Metabolite M4 (at m/z 248.1645) was found to be derived
through a combination of reduction (M1) and lactam forma-
tion (M3) reactions. Metabolite M4, which has two chiral
atoms, was expressed as potential diastereomers [38, 39], at
8.90 and 9.95 min, with identical MS/MS spectra. The struc-
ture of M4was verified by identification of product ions atm/z
230.1539 from the loss of water and the loss of the lactam ring
at m/z 145.1012.
Metabolite M6 (at m/z 264.1594) was formed from metab-
olite M3 by oxidation after pyrrolidine ring opening. Product
ions from the loss of water, the loss of acetic acid, and the loss
of aminobutyric acid were identified, demonstrating the pro-
posed structure. Two peaks of M6 with identical MS/MS
spectra and ion abundances were detected (Table 2), indicat-
ing the possible formation of enantiomers. In the HLM in-
cubations, only one form of this metabolite was produced, as
only the first eluting compound was observed.
Hydroxylation followed by oxidation at the propyl side
chain produced metabolite M7 (at m/z 262.1438). This pro-
posed structure was based on the detection of benzaldehyde and
a loss of propanoic acid from the parent compound. Oxidation
of the propyl side chain was not identified for α-PVP in rat
urine [22] nor was it reported for other pyrrolidinophenone
derivatives [38–44]. Metabolite M7 was predicted by Meteor,
but not seen in the in vitro tests.
An additional metabolite of α-PVP, formed via reduction
and hydroxylation (at m/z 250.1802), was detected in HLM
incubations, but was not present in human urine samples,
however.
Four of the seven metabolites identified here for α-PVP
were new metabolites, and two of them formed via an
unreported metabolic reaction, i.e., reduction of the β-ketone
and oxidation of the propyl side chain. Three out of the ten
phase I metabolites of α-PVP detected in rat urine [22] were
identified here. For the pyrrolidinophenone derivatives stud-
ied in rats, reduced metabolites have only been reported as
minor metabolites for α-pyrrolidinopropiophenone, PPP [38],
4′-methyl-α-pyrrolidinohexanophenone, MPHP [39], and 4′-
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methyl-α-pyrrolidinobutyrophenone, MPBP [43]. Here, the
reduced metabolite M1 was found to be as the most abundant
metabolite in all eight human urine samples studied. The fact
that reduction of the ketone group was not detected in rats may
be because of differences between species in the dominant
metabolic reactions [45, 46].Metabolites formed via reduction
of the oxo group in humans have been reported for β-keto-
structured cathinones [31, 47, 48], however. Based on the
findings in this study, reduction of the ketone should be taken
into consideration in the identification of human urinary
metabolites of pyrrolidinophenone derivatives.
Sauer et al. [22] proposed that the urine screening proce-
dure used for α-PVP, which is metabolized to a great extent
in rats, should be based on its metabolites. Although α-PVP
also undergoes significant metabolism in humans, the drug
itself was the most abundant finding in all urine samples
analyzed. Thus, identification of the metabolites in conjunc-
tion with α-PVP in human urine makes identification of this
compound substantially more reliable.
MPA
In the analysis of three urine cases that tested positive for MPA
(at m/z 156.0841), the N-demethylated metabolite nor-MPA
(M1 at m/z 142.0685) was identified (Fig. 1d and Table 2).
The product ions identified were identical for MPA and nor-
MPA (Fig. 2d). Traces of MPA hydroxy metabolites could
also be seen in the in vitro experiments; however, they could
not be identified in human urine. The results are in concor-
dance with the recent paper by Welter et al. [24], who stated
that MPA metabolized to only a minor extent, as only one
phase I metabolite, nor-MPA, was detected in human urine.
Feasibility of in silico and in vitro experiments
in identification of metabolites in vivo
The likelihood level of a metabolic reaction calculated by
Meteor was found to be a reasonable indicator of the probability
of the prediction. All the reactions identified were either at a
probable or plausible level. Four of the five probable reactions,
oxidation of primary alcohol, hydroxylation of aromatic methyl,
and oxidative N-demethylation or N-dealkylation (Table 1),
were found to occur. The predictions proved to be most suc-
cessful for the phenethylamine-structured designer drugs:
Meteor predicted all the identified metabolites of 3,4-DMMC
and MPA, as well as five of the seven metabolites of α-PVP. It
improved the identification of the previously unreported meta-
bolic reactions for α-PVP: reduction of the ketone group and
oxidation of the propyl side chain, resulting in detection of three
new metabolites. The Meteor prediction results were less suc-
cessful for 2-DPMP, as only two of the six metabolites identified
had been proposed. One of the most abundant metabolites of 2-
DPMP, M2, was predicted only as an intermediate in the
formation of a lactam structure. It is likely that Meteor finds
only a few metabolic reactions from its knowledge base for
compounds structurally similar to 2-DPMP, as most of
the predictions were created at the equivocal likelihood
level. This would explain the low prediction sensitivity
[17]. The unpredicted metabolites would probably be achiev-
able by widening the Meteor processing settings. This would,
however, also produce a great number of false-positive pre-
dictions. The Meteor software has shown a tendency towards
overprediction [17], as also discovered in this study. Thus, the
relevance of metabolites predicted at a likelihood level lower
than “plausible” is at least questionable when the aim is to
identify the main urinary metabolites.
In silico metabolite prediction has not previously been ap-
plied to designer drugs, and one of the goals in this study was to
evaluate the applicability of the Meteor software in this area.
Based on the findings in this study, Meteor is a suitable tool for
predicting the main human phase I metabolites for amphet-
amine analogs and phenethylamine analogs. For phencyclidine
compounds, or structurally completely novel designer drugs,
the prediction results need to be viewed more critically. It is
necessary to evaluate the suitability of in silico prediction for
each designer drug class individually. The software predictions
should always be compared with biological material, in vivo or
in vitro samples, to screen for the true-positive metabolites.
Drug metabolism prediction based on published analo-
gous reactions is time consuming and, in the case of struc-
turally new compounds, sometimes uncertain. Although me-
tabolite prediction in silico did not prove here to be better
than our own judgment based on the metabolic reactions of
structural analogs, it definitely speeds up the creation of the
list of possible metabolites to be used in an automated
database search for Q-TOF/MS data.
Eight of the 12 most abundant phase I metabolites of the
four designer drugs studied in human urine could be detected
in the in vitro HLM experiments. A few designer metabolites
detected in the HLM samples in minor abundance were not
seen in human urine. Thus, the difference between in vitro and
in vivo metabolism [6] should be taken into consideration
when extrapolating the metabolic data from in vitro experi-
ments to identification of metabolites in vivo. Although
in vitro tests do not absolutely predict human in vivo metab-
olism [6], they definitely serve as material for exploitation of
in silico data when an authentic urine sample is not available.
The results can be extrapolated for qualitative drug screening
analysis in toxicology to support a positive finding of a parent
compound. However, to perform in vitro metabolite experi-
ments on designer drugs requires the availability of reference
standards for the parent drugs, which limits the usage of the
procedure for rare compounds.
The metabolites proposed for the designer drugs studied
here do not necessarily cover all the possible phase I metab-
olites of the compounds. Drug–drug interactions may also
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have an influence on the metabolite ratios. A comprehensive
designer drug metabolism study on forensic cases is demand-
ing, as information about the possible intake of the drug, or the
time since intake, is rarely available. The benefits of in silico
predictions are in qualitative metabolite identification which
was the main objective of this study.
Conclusion
Applying in silico and in vitro experiments to support identi-
fication of designer drug metabolites in drug abusers’ urine
samples by LC/Q-TOF/MS was both effective and straightfor-
ward. The LC/Q-TOF/MS instrumentation used provided suf-
ficient sensitivity for identification of designer drug metabo-
lites in a complex biological matrix that also contained a great
number of prescription drugs and street drugs. Compound
identification with the automated reverse database search
method was feasible, even though the metabolite peaks were
partly overlapping. Structural characterization of fragments by
accurate mass data, assisted by the MS/MS data interpretation
tool MS/Fragmenter, served well in the differentiation between
structural isomers. Eleven previously unreported metabolites
for the four designer drugs studied, 2-DPMP, 3,4-DMMC,
α-PVP, and MPA, were identified here. Six metabolites, in-
cluding hydroxylated and further dehydrogenated and oxidated
compounds, were detected for 2-DPMP, for which the metab-
olism has not been published earlier. The hydroxy-N-desmethyl
metabolite was a new product found in this study for 3,4-
DMMC. Four of the α-PVP metabolites found here, formed
via reduction of the β-ketone and oxidation reactions, were not
detected in the earlier metabolism studies in rats. The in silico
metabolite predictionmethod proved to be a rapid way to create
a list of possible metabolites for a novel designer drug, which
can further be screened from in vitro incubation samples to
identify the true-positive metabolites. These tentatively identi-
fied metabolite formulas could then be added to the database
used for routine urine drug screening, in order to facilitate
designer drug identification in authentic urine samples.
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